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PREFACE
The Occupational Safety and Health Act of 1970 emphasizes the need for 
standards to protect the health and provide for the safety of workers 
occupationally exposed to an ever-increasing number.of potential hazards. The 
National Institute for Occupational Safety and Health (NIOSH) evaluates all 
available research data and criteria and recommends standards for occupational 
exposure. The Secretary of Labor will weigh these recommendations along with 
other considerations, such as feasibility and means of implementation, in 
promulgating regulatory standards.
NIOSH will periodically review the recommended standards to ensure 
continuing protection of workers and will make successive reports as new 
research and epidemiologic studies are completed and as sampling and 
analytical methods are developed.
The contributions to this document on antimony by NIOSH staff, other 
Federal agencies or departments, the review consultants, the reviewers 
selected by the American Industrial Hygiene Association and the American 
Medical Association, and Robert B. O'Connor, M.D., NIOSH consultant in 
occupational medicine, are gratefully acknowledged.
The views and conclusions expressed in this document, together with the 
recommendations for a standard, are those of NIOSH. They are not necessarily 
those of the consultants, the reviewers selected by professional societies, or 
other Federal agencies. However, all comments, whether or not incorporated, 
were considered carefully and were sent with the criteria document to the 
Occupational Safety and Health Administration for consideration in setting the 
standard. The review consultants and the Federal agencies which received the 
document for review appear on pages v, vi, and vii.
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The Division of Criteria Documentation and Standards 
Development (DCDSD), National Institute for Occupational 
Safety and Health, had primary responsibility for 
development of the criteria and recommended standard for 
antimony. Allan S. Susten, Ph.D., served as criteria 
manager during the initial development and Barbara L. 
Wilkes during the final development of this criteria 
document. The DCDSD review was provided by Douglas L. 
Smith, Ph.D. (Chairman), Paul E. Caplan, and Keith H. 
Jacobson, Ph.D., with Carl Zenz, M.D.
Personnel from other NIOSH divisions who assisted in 
developing the basic information for this document were 
Harry M. Donaldson (Division of Surveillance, Hazard 
Evaluation, and Field Studies); David H. Groth, M.D., 
and Harry B. Plotnick, Ph.D. (Division of Biomedical and 
Behavioral Science); Peter M. Eller, Ph.D., James A. 
Gideon, R. DeLon Hull, and William F. Todd (Division of 
Physical Sciences and Engineering).
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I. RECOMMENDATIONS FOR AN ANTIMONY STANDARD
NIOSH recommends that employee exposure to antimony and its compounds in 
the workplace be controlled by compliance with the following sections. The 
recommended standard is designed to protect the health and provide for the 
safety of employees for up to a 10-hour workshift, AO-hour workweek, over a 
working lifetime. Compliance with all sections of the recommended standard 
should prevent adverse effects of antimony or antimony compounds on the health 
of employees and provide for their safety. The standard is measurable by 
techniques that are reproducible and available to industry and government 
agencies. Sufficient technology exists to permit compliance with the 
recommended standard. Although NIOSH considers the workplace environmental 
limit to be safe based on current information, employers should regard it as 
the upper boundary of exposure and make every effort to maintain exposure as 
low as is technically feasible. The criteria and recommended standard will be 
reviewed and revised as necessary,
"Antimony" refers to elemental antimony and all antimony compounds except 
the gas stibine (SbH3). Stibine is excluded from the standard because it 
evolves as a byproduct of operations involving other sources of antimony. The 
"action level" is defined as one-half the appropriate recommended time- 
weighted average (TWA) concentration limit. "Occupational exposure to 
antimony" is defined as exposure to antimony at a concentration greater than 
one-half the recommended environmental limit. Exposures to airborne antimony 
concentrations equal to or less than one-half the TWA workplace environmental 
limit, as determined in accordance with Section 8(a), will require adherence 
to all sections of the recommended standard except Sections 2(b), 4(c), 8(b),
and the monitoring provisions of 8(c). If exposure to other chemicals occurs 
(for example, from contamination of antimony with arsenic or free silica), 
provisions of any applicable standards for the other chemicals shall also be 
followed.
The recommended environmental limit is based on data which indicate that 
exposure to antimony may cause cardiac and respiratory changes and irritation 
of the skin and mucous membranes. Compliance with the following sections 
should provide worker protection from these hazards. Some data on antimony 
workers raise the possibilities of reproductive and carcinogenic effects; 
however, these hazards ascribed to antimony have not been confirmed.
Section 1 - Environmental (Workplace Air)
(a) Concentrations
Exposure to antimony shall be controlled so that employees are not exposed 
to antimony at a concentration greater than 0.5 milligram per cubic meter of 
air (0.5 mg/cu m), determined as a time-weighted average concentration limit 
for up to a 10-hour workshift in a AO-hour workweek.
(b) Sampling and Analysis
Environmental samples shall be collected and analyzed for antimony as 
described in Appendices I and II or by any methods at least equivalent in 
accuracy, precision, and sensitivity.
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Section 2 - Medical
Medical surveillance as outlined below shall be made available to workers 
subject to exposure to antimony.
(a) Preplacement examinations shall include at least:
(1) Comprehensive medical and work histories, with special emphasis 
directed to skin, respiratory, cardiac, and reproductive systems.
(2) Comprehensive physical examinations, with particular attention 
to the skin, mucoua membranes, and pulmonary and cardiac systems.
(3) Clinical tests including a 14- x 17-inch posterio-anterior chest 
roentgenogram, electrocardiogram, and pulmonary function tests including 
forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1),
(4) A judgment of the employee's ability to use positive and 
negative pressure respirators.
(b) Periodic examinations shall be made available at least annually. 
These examinations shall include at least:
(1) Interim medical and work histories.
(2) A physical examination and tests as outlined in paragraphs
(a)(2) and (a)(3) of this section.
(c) During or after examinations, applicants or employees having medical 
conditions such as dermatitis or pulmonary disease that would be directly or 
indirectly aggravated by exposure to antimony shall be counseled on the 
increased risk of impairment of their health from working with these 
materials. In addition, employees shall be advised that one report has
indicated possible hazards to reproduction in both humans and animals due to
antimony exposure.
(d) Pertinent medical records shall be maintained for all employees 
exposed to antimony and shall be kept for at least 30 years after the last 
work-related exposure to antimony. Records of environmental exposures 
applicable to an employee shall be included in that employee's medical
records. These records and copies, if requested, shall be made available to
the designated medical representatives of the Secretary of Health, Education, 
and Welfare, of the Secretary of Labor, of the employer, and of the employee 
or former employee.
Section 3 - Labeling and Posting
All warning signs shall be printed both in English and in the predominant 
language of non-English-reading workers. Workers unable to read the labels 
and signs provided shall receive information regarding hazardous areas and 
shall be informed of the Instructions printed on labels and signs.
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(a) Labeling
Containers of antimony compounds shall carry labels that bear the trade 
names of the products, the chemical name(s) of the compound(s) contained 
therein, and information on the effects of the particular product(s) on human 
health. The trade names and pertinent information shall be arranged as in the 
following examples.
For Antimony Oxides and Sulfides:
TRADE NAME 
(CHEMICAL NAME)
MAY BE HARMFUL IF INHALED OR SWALLOWED 
MAY CAUSE SKIN AND RESPIRATORY TRACT IRRITATION
Do not get in eyes, on skin, on clothing. 
Avoid breathing dust, fume, vapor.
For Antimony Halides:
TRADE NAME 
(CHEMICAL NAME)
DANGER 
CAUSES SEVERE BURNS 
VAPOR HAZARDOUS
Do not get in eyes, on skin, on clothing.
Do not breathe vapor.
Keep container closed.
Immediately flush with copious amounts of water and remove 
contaminated clothing. For eyes, get medical attention. 
Wash contaminated clothing before reuse.
(b) Posting
Readily visible signs containing information on the effects of antimony on 
human health shall be posted in work areas and at entrances to work areas or 
building enclosures where antimony is present. Warnings shall follow these 
examples :
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For Antimony Oxides and Sulfides:
TRADE NAME 
(CHEMICAL NAME)
MAY BE HARMFUL IF INHALED OR SWALLOWED 
MAY CAUSE SKIN AND RESPIRATORY TRACT IRRITATION
Avoid breathing or swallowing dust.
Work with adequate ventilation.
Wash hands thoroughly after handling, and before eating or smoking. 
Keep skin clean to avoid irritation.
For Antimony Halides:
TRADE NAME 
(CHEMICAL NAME)
DANGER
SEVERE INHALATION, SKIN, AND EYE HAZARD 
CAUSES BURNS 
DO NOT BREATHE DUST, FUME, OR VAPOR 
DO NOT GET IN EYES, ON SKIN, OR ON CLOTHING
In case of contact, immediately flush skin or eyes with copious 
amounts of water and remove contaminated clothing. For eyes, get 
medical attention. Wash clothing before reuse.
Section 4 - Personal Protective Clothing and Equipment
(a) Protective Clothing
(1) Work and protective clothing appropriate for the work situation 
shall be provided by the employer. This may include underwear, cloth or 
calfskin gloves, coveralls or long-sleeved shirts and trousers, and head and 
neck protection. When antimony halides are being processed in a manner that 
may result in skin contact, gloves with gauntlets and aprons made of rubber or 
other material resistant to penetration by antimony halides shall be used. 
The employer shall ensure that appropriate clothing is worn by every employee.
(2) The employer shall ensure that a change of clothing is 
immediately available to any employee whose clothes become grossly 
contaminated or lose their protective quality.
(3) If protective clothing becomes grossly contaminated, or in the 
case of halides, if the resistant material is penetrated, this clothing must 
be removed immediately and not be reworn until the antimony compound is 
removed.
(4) Protective clothing shall be changed at least daily at the end 
of the shift.
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(5) Contaminated clothing must be stored in closed containers until 
washed or discarded.
(6) The employer shall inform persons involved in laundering or 
handling the contaminated clothing of the hazardous properties of the 
contaminant.
(b) Eye and Face Protection
(1) Chemical safety goggles meeting the requirements listed in 29 
CFR 1910.133 and ANSI Z87.1-1968 shall be provided by the employer and shall 
be worn during any operation in which there is a reasonable possibility of 
antimony entering the eyes.
(2) Where antimony halides may contact the eyes, employers shall 
provide an eye wash fountain or other source of water within the immediate 
work area for flushing the eyes in an emergency.
(c) Respiratory Protection
(1) Engineering controls shall be used when needed to keep 
concentrations of airborne antimony at or below the environmental limit. 
Compliance with this standard by the use of respirators is permitted only
during installation and testing of engineering controls, during performance of 
nonroutine maintenance or repair, or during emergencies.
(2) When a respirator is permitted, it shall be selected and used in 
accordance with the following requirements:
(A) The employer shall establish and enforce a respiratory 
protective program meeting the requirements of 29 CFR 1910.134.
(B) The employer shall provide respirators in accordance with
Table 1-1 and shall ensure that, when needed, employees use the respirators 
provided. The respiratory protective devices provided shall be those approved 
by NIOSH and the Mine Safety and Health Administration (MSHA). Initial
selection and assignment of negative pressure respirators shall be made on the 
basis of qualitative or quantitative facepiece fit tests. The employer shall 
ensure that respirators are properly cleaned, maintained, and stored when not 
in use.
(3) Respirators specified for use in higher airborne concentrations 
of antimony may be used in atmospheres of lower concentrations.
(4) The employer shall ensure that employees are properly instructed 
in the use of respirators assigned to them and in ways to test for leakage, 
proper fit, and proper operation.
(d) The employer shall perform a routine periodic check of all personal
protective equipment to maintain it in a safe state of repair and shall store 
it properly to prevent damage by heat, degrading chemicals, or other harmful 
agents.
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TABLE 1-1
RESPIRATOR SELECTION GUIDE FOR PROTECTION AGAINST ANTIMONY
Dust
Concentration Respirator Type Approved Under 30 CFR 11
Less than or 
equal to 5 mg/cu m
Less than or 
equal to 25 mg/cu m
Less than or 
equal to 500 mg/cu m
Greater than 500 mg/ 
cu m
(1) Half-mask respirator with replaceable high 
efficiency filter(s)*
(2) Type C supplied-air respirator, demand type 
(negative pressure) with half-mask facepiece**
(1) Full facepiece respirator with replaceable 
high efficiency filter(s)
(2) Type C supplied-air respirator, demand type 
(negative pressure) with full facepiece
(3) Self-contained breathing apparatus in demand 
mode (negative pressure) with full facepiece
Powered air-purifying (positive pressure) 
respirator with high efficiency filter(s)
(1) Self-contained breathing apparatus with 
positive pressure in full facepiece
(2) Combination supplied-air respirator, pressure 
demand type with auxiliary self-contained 
air supply
For antimony halides!
No concentration 
limit
(1) Self-contained breathing apparatus with 
positive pressure in full facepiece
(2) Combination supplied-air respirator, pressure 
demand type with auxiliary self-contained 
air supply
*A high-efficiency filter is a filter having an efficiency of at least 99.97% 
against 0.3 tm dioctyl phthalate.
**If eye irritation occurs with half-mask, a full facepiece respirator 
should be worn.
Section 5 - Informing Employees of Hazards from Antimony
(a) All new and current employees working with antimony shall be informed 
of the hazards, relevant signs and symptoms of overexposure, appropriate 
emergency procedures (including first aid), and proper conditions and 
precautions concerning safe use and handling of the hazardous material(s). 
Employees shall be informed, preferably by medical personnel, that antimony 
can irritate the skin and mucous membranes, cause respiratory and cardiac 
changes, and possibly cause reproductive problems.
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(b) The employer shall institute a continuing education program, 
conducted by persons qualified by experience or training, to ensure that all 
employees have current knowledge of job hazards, preventive sanitation and 
work practices, proper maintenance and cleanup methods, and proper use of 
personal protective equipment. The instructional program shall include a 
description of the general nature of the environmental and medical 
surveillance procedures and of the advantage to the employee of participating 
in these surveillance procedures. Educational programs for employees engaged 
in maintenance and repair shall include instruction on those work situations 
in which they will be exposed to antimony.
(c) Instructional material in written or published form shall be kept on 
file at each establishment or department where employees are exposed to 
antimony. Each employee shall be informed of the availability of the required 
information, which shall include, as a minimum, that prescribed in Appendix
III.
(d) Required information shall be recorded on the "Material Safety Data 
Sheet" shown in Appendix III or on a similar form approved by the Occupational 
Safety and Health Administration, US Department of Labor, and shall be kept on 
file, readily accessible to employees.
Section 6 - Work Practices
(a) Engineering controls shall be used wherever needed to keep 
concentrations of airborne antimony within the recommended environmental 
limit. Ventilation systems shall be designed to prevent the entry, 
accumulation, or recirculation of these materials in the breathing zones of 
employees.
(b) Exhaust ventilation systems discharging to the outside air shall 
conform to applicable local, state, and Federal air pollution regulations.
(c) Ventilation systems shall be subject to regular preventive 
maintenance and cleaning to ensure their continuing effectiveness. Continuous 
airflow indicators, such as appropriately mounted and calibrated water or oil 
manometers (marked to indicate acceptable airflow), are recommended and should 
be checked frequently and recorded at least quarterly. If such indicators are 
not used, the efficiency of the ventilation system should be verified by 
airflow measurements taken at intervals determined by the documented 
maintenance history of the system.
(d) Procedures for emergencies shall be established. Necessary emergency 
equipment, including appropriate respiratory protective devices, shall be kept 
in readily accessible locations.
(e) Where there is possibility of skin contact with antimony halides, 
employers shall provide facilities for quick drenching of the body within the 
immediate work area. Eye wash facilities shall also be conveniently located.
(f) Where antimony dust accumulates on work surfaces, it shall be removed 
by vacuum cleaning or wet methods. Cleaning may be performed by washing down
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with a hose, provided that a fine spray of water has first been laid down. 
Sweeping or other methods which can stir the dust into the air shall not be 
used.
(g) Waste materials contaminated with antimony shall be disposed of in a 
safe manner. The disposal method must conform to applicable local, state, and 
Federal regulations.
(h) Antimony compounds shall be stored so as to minimize exposures due to 
accidental leaks and spills. Storage areas must be cool, dry, well 
ventilated, and protected from sunlight. Antimony halides must be stored in 
glass carboys protected by wooden frames. Storage areas for halides must be 
isolated from manufacturing or production areas.
Section 7 - Sanitation Practices
(a) The pertinent requirements for plant sanitation, stated in 29 CFR 
1910.141, shall be complied with. The subsections entitled General (a), 
Toilet Facilities (c), Washing Facilities (d), Change Rooms (e), and 
Consumption of Food and Beverages on the Premises (g) are especially relevant 
to antimony.
(b) Employees exposed to antimony shall be provided with separate lockers 
or other storage facilities for street clothes and for work clothes.
(c) Employees exposed to antimony shall not wear work clothing away from 
the plant.
(d) Showers shall be provided for employees exposed to antimony. Workers 
shall shower before changing into street clothes.
(e) If accidental skin contact with antimony halides occurs, the exposed 
worker shall shower immediately.
(f) Employees shall wash their hands and mouths before eating or smoking 
during the workshift.
(g) No smoking or food shall be permitted in areas where antimony is 
present.
Section 8 - Environmental Monitoring and Recordkeeping
(a) Industrial Hygiene Surveys
After the promulgation of a standard based on these recommendations, 
employers shall determine by an industrial hygiene survey whether exposure to 
airborne antimony is in excess of the action level. Records of these surveys 
shall be retained until the next survey has been completed. If an employer 
concludes that there is no occupational exposure to antimony, the records 
shall show the basis for this conclusion. Surveys shall be repeated at least 
annually and within 14 days after any process change likely to result in 
occupational exposure to antimony.
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(b) Personal Monitoring
If it has been determined that occupational exposure to antimony occurs, 
the employer shall institute environmental monitoring.
(1) A program of personal monitoring shall be instituted to identify 
and measure, or to permit calculation of, the exposure of each employee,
Source and area monitoring may be used to supplement personal monitoring.
(2) In all personal monitoring, samples representative of exposure 
in breathing zones of the employees shall be collected.
(3) For each determination of the concentration of antimony, a
sufficient number of samples shall be taken to characterize the employee's
work and production schedules, location, and duties. Changes in production 
schedules shall be considered in deciding when samples are to be collected,
(4) Each operation shall be sampled at least once every 6 months. 
For intermittent operations, ie, those lasting less than 6 months, at least 
one monitoring regimen shall be conducted during each operation period, and 
monitoring should coincide with the periods of maximum potential exposure to 
antimony during these intermittent operations.
(5) If an employee is found to be exposed to antimony at
concentrations exceeding the recommended TWA concentration limit, control 
measures shall be Initiated, the exposure of that employee shall be measured 
at least once every week, and the employee shall be notified of the exposure 
and of the control measures being implemented. Such monitoring shall continue 
until two consecutive determinations, at least 1 week apart, indicate that the 
control measures have been effective and that the employee's exposure no 
longer exceeds the recommended exposure limit; routine semiannual monitoring 
may then be resumed.
(c) Recordkeeping
Records of environmental monitoring and other pertinent records shall be 
kept for at least 30 years after the employee's last work-related exposure to 
antimony. Records of environmental monitoring shall include an identification 
of the employee being monitored, duties and job locations within the worksite, 
time and dates of sampling and analysis, sampling and analytical methods used 
and available evidence of their precision and accuracy, the number, duration, 
and results of samples taken, TWA concentrations determined from these 
samples, and the type of personal protective equipment used by the employee. 
Employees shall have access to data on their environmental exposures and be 
permitted to obtain copies of the data. Records shall be made available to 
the designated representatives of the Secretary of Labor, of the Secretary of 
Health, Education, and Welfare, of the employer, and of the employee or former 
employee.
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II. INTRODUCTION
This report presents the criteria and the recommended standard based 
thereon that were prepared to meet the need for preventing occupational 
disease or injury arising from exposure to antimony, excluding stibine. The 
criteria document fulfills the responsibility of the Secretary of Health, 
Education, and Welfare, under Section 20(a)(3) of the Occupational Safety and 
Health Act of 1970, to "develop criteria dealing with toxic materials and 
harmful physical agents and substances which will describe...exposure levels 
at which no employee will suffer impaired health or functional capacities or 
diminished life expectancy as a result of his work experience."
After reviewing data and consulting with others, NIOSH formalized a system 
for the development of criteria on which standards can be established to 
protect the health and provide for the safety of workers from exposure to 
hazardous chemical and physical agents. The criteria and recommended standard 
should enable management and labor to develop better engineering controls and 
more healthful work practices, and simply complying with the recommended 
environmental limit should not be the final goal.
These criteria for a recommended standard for antimony are part of a
continuing series of documents developed by NIOSH. The proposed standard
applies only to workplace exposure to antimony arising from the processing, 
manufacture, handling, and use of antimony. The standard is not designed for 
the population-at-large, and any extrapolation beyond the occupational 
environment is not warranted. It is intended to (1) protect workers against 
the adverse effects of exposure to antimony especially on the heart, lungs, 
and skin, (2) be measurable by techniques that are valid, reproducible, and
available to industry and government agencies, and (3) be attainable with
existing technology.
The major hazards associated with occupational exposure to antimony are 
cardiac changes, respiratory changes including pneumoconiosis, and irritation 
of the skin and mucous membranes. One study suggested that antimony exposure 
may exert an adverse effect on reproductive capacity. The possibility also 
has been raised that antimony exposure may increase the risk of lung cancer. 
The carcinogenic, mutagenic, and teratogenic potentials of antimony compounds, 
along with possible effects of antimony on reproduction, remain to be 
determined.
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III. BIOLOGIC EFFECTS OF EXPOSURE
Extent of Exposure
Antimony (Sb) is a metal obtained chiefly as a byproduct or coproduct of 
base metal and silver ores, and is used in a variety of industries [1]. At 
standard temperature and pressure, antimony and most of its compounds are 
solid; hence, they are usually encountered as dusts in the industrial 
environment. Most occupational exposures are to antimony trioxide, a soft, 
flowing powder. Antimony pentachloride is the only compound occurring as a 
liquid at standard temperature and pressure. The antimony halides, unlike the 
oxides and sulfides, can severely burn the skin, eyes, and mucous membranes. 
Table XII-1 lists physical and chemical properties of antimony and some common 
antimony compounds.
Antimony is brittle and hard with a Mohs rating of 3-3.5. It alloys 
readily with many metals. When alloyed with antimony, lead is harder and more 
resistant to chemical corrosion than when unalloyed [1]. Until recently, the 
major use of antimonial lead has been for production of grids and terminals 
for storage batteries. This use is now declining because the automotive 
battery industry is adopting calcium-tin and low antimony alloys [2] .
The specific heat and electrical resistance of antimony make it useful in 
electronic semiconductors and thermoelectric devices [1,3]. The peculiar 
light-transmitting qualities of antimony trioxide and the various colors of 
antimony compounds make them outstanding pigments for ceramics, glass, 
metalware, and enamels. Plastics and flame-retardant chemicals are also major 
end-products. Tables XII-2 and XII-3 show additional uses, originating forms, 
and production tonnages of antimony.
About 25 countries throughout the world are involved in antimony 
production [1]. In 1976, the US imported almost 24,000 tons of antimony 
metal, oxide, and ore for consumption; predominant sources were the Republic 
of South Africa, Bolivia, the United Kingdom, and France. US production 
totaled almost 35,000 tons, of which 42% (over 14,900 tons) came from primary 
sources (283 tons from ore, 14,618 tons from primary smelters), and 58% 
(almost 20,000 tons) was secondary (recycled) metal [2] . Secondary antimony 
is recovered chiefly from battery scrap.
Domestic mine production totaled 283 tons during 1976, down 68% from 1975, 
the result of a long strike at one mine and the continued development of 
another. The two mining operations producing antimony metal in the US are in 
Idaho and Montana. A new smelter is expected to open in Texas [2],
Domestic consumption of primary antimony in 1976 was up over 1975 
consumption despite a loss of tonnage in metal products; the loss was more 
than offset by gains in nonmetal and flame retardant applications. Antimony 
trioxide, often referred to as antimony oxide, is in increasing demand as a 
fire retardant, and represents the largest class of primary antimony material 
produced in the US (about 10,600 out of 14,900 tons). In 1976, there were 
five major producers of antimony trioxide [2]. Most other antimony compounds 
are derived from the trioxide. Of these, antimony pentoxide, antimony tri— 
and pentasulfide, antimony tri- and pentachloride, and antimony potassium
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tartrate (tartar emetic) are materials of commercial significance in the 
United States. Table XII-3 shows the end uses of these materials.
NIOSH estimates that 1.4 million US workers are potentially exposed to 
antimony in their occupational environment. Exposures are largely to metal 
alloys and to the metal oxide and sulfide. Table XII-5 lists occupations that 
have the potential for antimony exposure.
Health problems associated with occupational exposure to antimony have 
been reported from textile dyeing [4]; antimony mining, smelting, and refining 
[5-14]; the abrasives industries [15]; and glass manufacturing [16]. Exposure 
problems associated with minor uses of the metal, such as in the chemical 
industry, in metal polishing and decorating, and in the pharmaceutical 
industry, have not been reported. Antimonial drugs are not known to be 
manufactured in the US at this time.
Historical Reports
Antimony was probably first used industrially by the Chaldeans around 4000 
BC to manufacture vases and vessels, according to a comment by Bradley and 
Fredrick [17], Reference to the use of the element as an eye cosmetic can be
found in the Bible, and both Dioscorides and Pliny discussed its use as a
medicine [18]. The Romans knew of antimony's emetic properties. When they 
allowed wine to stand in goblets made of antimony-rich alloys, sufficient 
antimony leached from the cup to induce vomiting [19],
(a) Occupational Exposures
The first known accounts of occupational hazards ascribed to antimony were 
written in 1713 by Ramazzini [20], In his description of diseases of 
chemists, Ramazzini recorded the case of a chemist who had inhaled fumes of 
antimony and sulfur after an accident that occurred while he was making a
preparation. For 4 weeks after the accident, the chemist was described as
being tormented by a cough and could think of no reason other than the acid 
fumes that had roughened his respiratory organs. Ramazzini [20] also reported 
that workmen who pulverized stibium (Sb2S3) to make glass suffered from 
vertigo and that their lungs were affected. Wright's translation of 
Ramazzini's account of the maladies occurring in glass workers is vivid:
But a far worse fate awaits those who make colored glass 
for bracelets and other ornaments for women of the lower 
class and for other uses. In order to color the crystal, 
they use calcinated borax, antimony, and a certain amount 
of gold; these they pound together to an impalpable powder 
and mix it with glass to make the paste needed for this 
process, and however much they cover and avert their faces 
while they do this they cannot help breathing in the 
noxious fumes. Hence it often happens that some of them 
fall senseless, and sometimes they are suffocated; or in 
the course of time they suffer from ulcers in the mouth, 
oesophagus, and trachea. In the end they Join the ranks of 
consumptives, since their lungs become ulcerated, as has 
been clearly shown by the dissection of their corpses.
12
Ramazzini pointed out that such symptoms were not observed among glass workers 
in a factory that did not make colored glass [20].
In 1910, McWalter [21] suggested that many of the obscure and 
characteristic disorders of printers were due to antimony rather than lead. 
He reported observing a number of printers with a form of neuritis similar to 
arsenic neuritis. He described the disorder as being nonfatal, characterized 
by languor, intense depression, pallor, a tremor-like writer's palsy but more 
painful and confined to the ulnar side of the hand, pain in the region of the 
bladder and urethra, temporary impotence, dyspnea without physical signs of 
lung disease, irritable hyperactivity of the heart, and gastric irritation. 
The author [21] recognized that many of the symptoms described could be 
produced by arsenic, a contaminant of the type metal. Lead was also thought 
to be a possible cause of some of the symptoms, although McWalter [21] noted 
that the men had few if any of the classic signs of plumbism.
Schrumpf and Zabel [22], also in 1910, described a chronic malady, similar 
to that observed by McWalter [21], occurring among 15-20% of young 
typesetters. In addition, Schrumph and Zabel noted a somewhat lower blood 
pressure, and found antimony in the feces. The arsenic content of the feces 
was not given although trace amounts of arsenic were stated to have been found 
in the metallic antimony used to make the type metal. The authors [22] did 
not explain what "traces of arsenic" meant. Examination of the workers' blood 
samples showed leukopenia with concomitant eosinophilia. The symptoms 
disappeared after suspension of work for 2-3 weeks. The results of 
experiments with rabbits, though poorly controlled, led Schrumph and Zabel to 
conclude that antimony, and to some extent arsenic, caused the illnesses in 
the workers. The authors [22] were convinced that lead did not cause the 
observed symptoms.
In 1913, Rambousek [23] expressed doubt that industrial poisoning was 
traceable to antimony or its compounds and that arsenic, usually present as a 
contaminant, was more likely the cause. No supporting data or information 
were presented.
Seitz, in 1923 [24] and again in 1924 [25], reported that workers in a
type foundry were found to have abnormal blood profiles. The factory workers 
were exposed to metallic dusts containing lead and antimony and to vapors that 
contained, according to Seitz, antimony in barely measurable concentrations. 
The method of analysis was not given. The most consistent blood changes among 
the workers Included more than a 50% reduction in the normal thrombocyte 
(platelet) count and a 50% increase over the normal eosinophil count. A 
slight lymphocytosis was also reported. Seitz [24,25] related the results of 
experimental studies in cats, rabbits, and guinea pigs that tended to suggest 
that antimony and not lead was responsible for the blood changes observed in 
the foundry workers.
Shirley [26] suggested in 1927 that antimony pentasulfide, present in 
rubber-compounding ingredients, was responsible for skin irritation leading to 
eczema or dermatitis, irritation of mucous membranes, ulcerations around the 
mouth, and a variety of gastrointestinal disturbances including anorexia, 
cramps, and diarrhea. The author [26] thought it doubtful that absorption of 
antimony caused any central nervous system disorders.
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In a reply to Shirley's article, Shirk [27] refuted the charges against 
antimony and stated that he knew of no cases of antimonial poisoning among 25- 
50 workmen engaged over a 12-year period in the manufacture of about 15 
million pounds of precipitated antimony sulfide (pentasulfide), Furthermore, 
no case had come to his attention from six other plants producing antimony 
sulfide, nor from rubber factories using the product. Shirk, however, did not 
refer to any medical reports to back up his assertion that the workers 
suffered no symptoms.
In 1928, Selisky [4] reported 200 cases of skin lesions ascribed to 
solutions containing antimony potassium tartrate that were being used as 
mordants in cloth dyeing operations. He described the condition as a pustular 
necrotic dermatitis commencing as a folliculitis and eventually resulting in 
atrophic scarring. Acid intermediate products, resulting from the addition of 
priming colors to the dye solutions, were thought responsible for the 
dermatitis. The addition of chalk as a neutralizer drastically reduced the 
number of cases [4].
In 1939, Feil [28] described adverse dermal and mucous membrane effects 
among workers engaged in the production of antimony metal, antimony trioxide, 
and crude or pure antimony sulfide. The antimony ore used in the foundry was 
reported to contain only small amounts of arsenic; the maximum concentration 
in the ore was 10 mg/kg (0.001%). Of 15 foundry workers studied, 14 had skin 
eruptions or histories of eruptions. At the time of examination, seven cases 
of active rash were noted. The eruptions, described as being itchy and 
resembling chickenpox or smallpox, were usually found on the neck, forearms, 
and lower extremities. Feil noted that the lesions disappeared with time 
(about 3 weeks), especially if the workers quit their jobs. Heat, 
perspiration, and scratching maintained the rash, according to the author. 
The rash was more prevalent in the summer. Other frequent diagnoses among the 
15 workers included conjunctivitis (7) and tracheitis, pharyngitis, and 
headache (5). Six anemias were also reported but details were not provided. 
Three workers had a decrease in sexual potency which seemed to be associated 
with high exposures at the foundry's furnaces.
Feil [28] also related that workers engaged in the production of yellow 
sulfur and antimony vermillion (antimony oxysulfide) had no signs of antimony 
toxicity even though they were "absolutely" covered with powder. The powders 
were described as amorphous antimony sulfides formed either by the reaction of 
antimony chloride and a hyposulfite or by the decomposition of a 
sulfoantimonate by an acid. The sulfides produced ranged from golden yellow 
to deep violet and were used as coloring agents or in the vulcanization of 
rubber [28].
(b) Therapeutic Use
The therapeutic use of antimony became widespread after it was discovered 
in 1906 that antimony, combined with an organic molecule, could be 
administered intravenously (iv) in doses much larger than those tolerated 
orally. This represented a significant advance in the treatment of tropical 
diseases [29]. Organic antimonial compounds became, and in many cases remain, 
the drugs of choice for the treatment of the different forms of 
schistosomiasis or bilharziasis (caused by parasitic flukes of the genus 
Schistosoma) and leishmaniasis (caused by parasitic protozoa of the genus 
Leishmania) [30], The trivalent antimonial compounds generally have been most
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effective against schistosomiasis; the pentavalent drugs have been used 
primarily against leishmaniasis and as drugs of second choice against 
schistosomiasis [18,30], The effects of antimonial drugs are discussed in the 
subsection on therapeutic exposures under Effects on Humans.
Effects on Humans
Most information on the biologic effects of antimony on humans is derived 
from clinical studies in which organic forms of antimony were used 
therapeutically and administered parenterally. Occupational exposures occur 
primarily by inhalation and skin contact with inorganic forms of antimony 
(metallic, inorganic salts, and hydrides). Though caution must be exercised 
in drawing strict parallels between occupational and therapeutic data, the 
latter may be valuable in assessing the occupational hazards of antimony. For 
this reason, information from therapeutic and from accidental exposures is 
reviewed in this document.
(a) Nonoccupational Exposures
(1) Accidental
Acute poisoning following the ingestion of antimony is characterized 
by a burning sensation in the stomach or other abdominal pain, nausea, intense 
vomiting, diarrhea, and possibly collapse [31,32]. Dunn [33] and Monier- 
Williams [31] recounted a 1928 incident of accidental antimony posioning at a 
company picnic. Lemonade made from fruit crystals was prepared in new white 
enamelware buckets for the firm's employees and was allowed to stand 
overnight. Approximately 70 of the 500 employees drank the lemonade, and 
practically all of these people became rapidly ill. Fifty-six employees were 
hospitalized for burning stomach pains, colic, nausea and vomiting, and 
collapse. Diarrhea was not observed. The severity of illness seemed to vary 
with intake, though in some cases hysteria may have added to the degree of 
distress and period of incapacity. Most patients returned to work within 3 
hours and some were able to eat dinner shortly after the incident. Two of the 
patients remained in the hospital overnight but were released without sequelae 
the next morning [31].
Analysis of the bucket enamel that had not been touched by the lemonade 
indicated 2.88% antimony trioxide [33]. The acid lemonade solution had 
dissolved the antimony from the enamel, and analysis found the lemonade to 
contain 0.013% metallic antimony. Each person who consumed a 300-ml 
tumblerful of the solution would have ingested 36 mg of antimony, or if 
expressed as tartar emetic, 100 mg of the drug. The British Pharmacopoeia 
listed the emetic dose of tartar emetic as 30-65 mg [33],
Werrin [32] recounted a similar incident that occurred in 1959. About 150 
children became ill at a church picnic after drinking pink lemonade. The 
drink had been prepared the preceding day, and antimony had leached from the 
agate lining of the pot. Each child had probably consumed 7.5 mg of antimony, 
equivalent to 20 mg of tartar emetic. The principal symptoms were nausea, 
intense vomiting, abdominal pain, and some diarrhea. Most children recovered 
within a few hours [32].
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Although antimonial compounds, usually tartar emetic, have reportedly been 
used as agents for suicide or homicide, the emetic properties of the tartrate 
generally make its use for these purposes of questionable effectiveness. A 
number of such cases were summarized by Poison and Tattersall [34].
Chronic antimony toxicity of nonoccupational origin is not commonly 
reported. In a discussion of clinical toxicology, Poison and Tattersall [34] 
described chronic antimony intoxication as resembling natural illness, with 
nausea, vomiting, loss of appetite, thirst, and diarrhea. Muscular cramps, 
sometimes severe, were considered to be an outstanding feature. Death was 
reported to follow chronic antimony intoxication [34], but no details were 
given.
(2) Therapeutic
(A) Effects on the Heart
The sudden death of a patient during a routine course of therapy 
for schistosomiasis was described by Khalil [35] in 1931. The patient had 
collapsed and died while seemingly well, 6 hours after an injection of 
antimony potassium tartrate. Death was ascribed to sudden heart failure 
although an autopsy was not performed. The death was typical of other cases 
Khalil had observed that rarely occurred before the sixth dose and usually a 
few hours after the injection [35] . Khalil suggested that the drug exerted a 
toxic effect on the heart and that strenuous muscular effort contributed to 
the deaths.
Mainzer and Krause [36] reported in 1940 that 9 of 12 bilharziac patients 
receiving routine therapeutic administration of antimony potassium tartrate 
had altered electrocardiograms (ECG's). The ECG changes were primarily in the 
T wave. Of the nine ECG's showing changes, three were considered 
pathological, four suspicious, and two were judged insignificant. 
Bradycardia, which the authors [36] considered significant and related to 
cardiotoxic effects of antimony, was also noted.
Numerous authors using many antimonial drugs have attempted to elucidate 
the action of antimony on the heart. A complete description of the ECG 
changes seen following antimonial therapy was provided by Honey [37] in 1960. 
Although Honey's patients had received antimony sodium tartrate, the effects 
observed have been seen regularly after administration of antimony potassium
tartrate [36,38-40], antimony sodium gluconate [41-43], antimony 
dimercaptosuccinate [41,44-49], stibophen [38,39,41,50], and antimonate of n- 
methyl glucamine [41] . Not all drugs produced the full range of effects 
described by Honey [37].
In all but one of Honey's 59 patients, ECG changes were seen toward the 
end of the course of therapy [37]. In the single case, the changes were seen 
very early. Changes varied from very slight (within normal limits) to severe 
changes that, in the absence of a history of antimony sodium tartrate 
administration, would have been interpreted as indicating severe myocardial 
disease [37],
ECG leads consisted of three standard and three augmented unipolar limb
leads and the precordial leads VI to V6. The following changes were
considered to be characteristic. The P wave became tall and broad in some
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leads, while R wave voltage became significantly lowered. In some patients, 
minor changes in the QRS axis were noted. No changes in PR or QRS intervals 
were found. The QT interval increased in most cases [37].
The most characteristic abnormalities seen were in the ST segment and T 
waves. The earliest change was a reduction in amplitude of the T wave in all 
leads. As this progressed, the T waves in the left precordial leads became 
unmistakably abnormal with decreased voltage; both the upstroke and downstroke 
became more gradual and prolonged. This accounted for much of the OT 
prolongation. Later on in therapy, the T wave became flat or diphasic in the 
three standard bipolar limb leads, and, in V5 and V6, the outermost precordial 
leads. At this time, the ST segment became straight, especially in the 
precordial leads V2 to V4, located over the heart. Characteristically, the 
terminal portion of the T wave dipped progressively further below the 
isoelectric line. This terminal negative phase of the T wave was accentuated 
by a prominent upright U wave in some instances. Later, in severely affected 
cases, the T wave became completely inverted, sometimes very deeply, 
especially in V2 and V4, Inversion of the T wave tended to appear later in V5 
and V6. In many patients, the U wave became exaggerated, either interrupting 
the downslope of a broad low T or following an inverted T or the terminal 
portion of a diphasic T. No consistent change in pulse rate was seen, though 
there was one case of serious ventricular arrhythmia. Honey [37] theorized 
that the longest intervals were associated with sinus arrest or sinoatrial 
block.
The ECG changes described above have been associated with both trivalent 
and pentavalent antimonial therapy, though more commonly with the more widely 
used trivalent compounds, especially those given iv [38,39,51], 
Unfortunately, the most effective drugs in the treatment of schistosomiasis 
also cause the greatest disturbance to the heart. The percentage of patients 
having altered ECG's has often approached 100% after iv administration of the 
trivalent antimony potassium or sodium tartrate [37-39], The percentage of 
patients with altered ECG's usually has been less than 80% for those receiving 
trivalent antimonials intramuscularly (im), probably because im administration 
allows more dilution of the antimony compound in the blood before the drug 
reaches the heart (DK Detweiller, written communication, May 1978).
ECG changes following treatment with pentavalent compounds have been 
infrequently observed. Germiniani et al [41] studied the ECG's of 30 patients 
under treatment for schistosomiasis or leishmaniasis. Both trivalent and 
pentavalent antimonials were used; however, only five patients received the 
pentavalent compound. Administration of trivalent and pentavalent drugs both 
resulted in flattened T waves, anomalous QT intervals, and myocardial ischemia 
of the subepicardial layer [41].
In contrast, Lopez and da Cunha [52] failed to see ECG alterations in
patients treated with the pentavalent drug despite the much larger doses given
of pentavalent than trivalent antimony in a study comparing the two drugs. 
The total dose of pentavalent antimony ranged from 4.95 to 19.35 g given iv 
over 5-10 days, whereas the total dose of trivalent antimony ranged from 214 
to 510 mg given iv over 2-9 days. All patients given trivalent antimony
sodium gluconate showed diffuse alterations in ventricular repolarization,
seen primarily in the T wave, accompanied by a sinus tachycardia in one case. 
In the group receiving the pentavalent drug n-methyl glucamine antimoniate,
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only one patient showed ECG changes; the authors [52] attributed the 
arrhythmia to the patient's advanced case of kala-azar.
Tarr [39] was similarly unable to find ECG alterations in three patients 
treated with the pentavalent drugs ethylstibamine or glucostibamine sodium. 
However, he did find the typical changes in the T wave of patients given 
either of two trivalent compounds, antimony potassium tartrate or stibophen.
The mechanism of myocardial toxicity due to antimonial drugs is not 
completely understood. According to one opinion, antimony becomes fixed to 
the cardiac cellular membrane and interferes with sodium permeability, thus 
slowing repolarization and causing ECG alteration until the antimony is 
excreted (DK Detweiller, written communication, May 1978). Pentavalent 
antimony compounds are generally excreted more quickly than trivalent, a fact 
which may help explain the apparent differences in myocardial toxicity between 
the two valence forms. Excretion is discussed further in this section under 
Distribution and Fate.
Honey [37] noted that the action of antimony on the myocardium appeared to 
be cumulative on an individual basis; ECG changes became progressively more 
severe during the course of therapy. However, taking the group of patients as 
a whole, there was no relation between total dose per unit of body weight and 
the degree of ECG change. Individual patient susceptibility apparently played 
a great part in the observed ECG changes. Honey believed that Asians and 
Africans (from Nigeria, Ghana, Sudan, Uganda, Mauritius, Iraq, and Kuwait) 
were more susceptible than Europeans to the cardiotoxic effects of antimony. 
Of 15 African or Asian patients, 11 had severe ECG changes; 7 of 45 European 
patients had changes classified as severe [37],
Others have noted that women may be more susceptible than men to the 
cardiotoxic effects of antimonial drugs [44,53,54]. Huang et al [53] reported 
that among Chinese, severe cardiac arrhythmia was more frequently encountered 
in female patients, especially during menstruation or lactation. The authors 
[53] were, however, not aware of any severe arrhythmia episodes occurring in 
pregnant women receiving antimony therapy. Lu and Liu [54] referred to a 
government report of the People’s Republic of China which stated that the 
female death rate due to antimonial drug intoxication was much higher than the 
male death rate. Neither group of investigators presented specific data.
Waye et al [44] noted that although only about 25% of their 38 US patients 
receiving antimony dimercaptosuccinate were women, the 3 patients who showed 
severe ECG changes were all women. No explanations were offered.
The cardiotoxic effects of antimony therapy occasionally have been severe 
enough to elicit the Stokes-Adams syndrome (periodic weakness, dizziness, or 
loss of consciousness from lack of cerebral blood flow due to recurring 
atrioventricular heart block). Dancaster et al [42], in 1966, reported such a 
case in a 26-year-old female bilharziac patient receiving antimony sodium 
gluconate. Twenty-four hours after her fourth daily injection (totaling 760 
mg of the drug), the woman suddenly lost consciousness. There was no pulse 
and her blood pressure could not be recorded. She stopped breathing
temporarily and became cyanotic but recovered after external cardiac massage. 
During the next 24 hours, she lost consciousness six times, about 90 seconds
in each case, all preceded by a ringing in the ears and blurring of vision.
The first ECG taken showed changes compatible with hypokalemia, with
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flattening of the T wave, and a prominent U wave. An ECG taken 24 hours later 
showed changes suggesting an inferior myocardial infarction. The authors [42] 
thought that the myocardial injury, possibly including patchy necrosis or 
infarction, could be due either to a direct effect of antimony on the 
myocardium or to coronary spasm caused by the antimony. The woman's ECG 
gradually returned to normal in 6 weeks. Similar case histories with other 
organic antimonial drugs and drug regimens have been reported [43-45,50],
Khalil [55], in 1936, estimated 0.2% mortality following antimony 
potassium tartrate administration in Egypt. This estimate probably involved 
under-reporting [55], Huang et al [53] indicated that mortality following 
antimony therapy in China had dropped from 0,4% in 1950 to 0,005% in 1958 due 
to improved methods of treatment.
According to Lu and Liu [54], cardiac intoxication caused 70-97% of 
reported antimony drug-related deaths, followed by hepatic or acute 
generalized intoxication, though no data were given. An autopsy on a person 
who died after 12 injections of antimony sodium tartrate, totaling 1,5 g of 
the drug, showed cardiac edema and fragmentation of myocardial fibrillar 
structures [37]. The heart gave appearances of a very recent moderate-sized 
myocardial infarction. Analyses for antimony showed: blood, 0,017 mg/100 g;
liver, 0.020 mg/100 g; skeletal muscle, 0.30 mg/100 g; and heart muscle, 0,20 
mg/100 g. The apparent affinity of antimony for muscle tissue was not 
discussed.
In 1947, Tarr [39] looked for trends in heart rate in the records of 181 
courses of antimony therapy. The investigation revealed an increase averaging 
10-15 beats/minute (range, 6-30) in 48 courses, a decrease in rate averaging 
10-15 beats/minute in 77 cases, and no change in the remaining 56. Tarr [39] 
was unable to draw any relationship between the T wave and heart rate changes. 
Other investigators [37,38,40,44,46] generally have failed to observe 
significant changes in heart rate in their patients receiving antimonial 
drugs.
(B) Effects on Blood
Hematologic disorders associated with antimony therapy have only 
rarely been reported and then only with the treatment of schistosomiasis [56- 
59]. The blood conditions observed could have been caused or contributed to 
by factors other than antimony, particularly the cases of hemolytic anemia and 
eosinophilia.
De Torregrosa et al [56] described two cases of hemolytic anemia and 
referred to six others, all of which occurred in schistosomiasis patients 
receiving stibophen. Five of the eight patients died of hemolytic reactions 
with anaphylactic shock. The authors [56], however, were not convinced that 
antimony had caused the reactions. They suggested that the anemias may have
resulted from an immunological response to the organic portion of the
stibophen molecule.
Eosinophilia in 24 of 36 patients receiving antimony dimercaptosuccinate 
was reported by Spingarn et al [57] in 1963. In six of these patients, the 
percentage of eosinophils rose to 55-60%. The authors [57] reported that the
eosinophilia was usually noted at the completion of therapy, implying that the
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eosinophilia was a response to the antimony drug, but it is also possible that 
histamine release in tissues damaged by the parasites caused the condition 
[60],
Kahn and Brod [58], in 1961, described a case of thrombocytopenic purpura 
that occurred in a 55-year-old woman being treated with stibophen for 
schistosomiasis. Both ecchymoses and petechiae were present. Ecchymoses were 
noted on the left buttock at the injection site and on the left shoulder. 
Petechiae were present on the face, all extremities, the back, the buccal 
mucosa, the hard palate, and the bulbar conjunctiva of both eyes. One retinal 
hemorrhage was noted. Initial laboratory findings were virtually normal 
except for a very low platelet count of 34,000/cu mm. The plasma prothrombin 
and whole blood clotting times were normal. Following several in vitro and in 
vivo challenge studies, Kahn and Brod [58] concluded that the stibophen- 
related thrombocytopenic purpura was an immunologic phenomenon involving 
antibodies and complement.
Rivera et al [59] reported another case of immune thrombocytopenic purpura 
due to stibophen in a 33-year-old man. Following the fourth injection of the 
third course of treatment, numerous petechiae and ecchymoses developed over 
the patient's entire body. Extensive subconjunctival hemorrhages were 
present, but the retinas were normal. There was marked periorbital swelling 
and purple discoloration. Submucosal ecchymoses were present in the oral 
cavity, fauces, tonsils, and vocal cords. All laboratory and clinical tests, 
including an ECG, were normal. Administration of plasma from this patient to 
another who also received stibophen produced thrombocytopenia without purpura. 
It was postulated that this case of thrombocytopenic purpura was due to the 
occurrence of a drug-antibody complex capable of destroying or agglutinating 
platelets and depressing megakaryocyte activity [59].
(C) Hepatic and Renal Effects
The therapeutic use of antimony has been associated with hepatic 
damage. O'Brien [50] stated in 1959 that acute fatal liver necrosis had 
occurred among a small proportion of West African soldiers treated during 
World War II with antimony potassium tartrate for schistosomiasis. The number 
treated and proportion affected were not given.
Elevated serum transaminase levels, indicative of cardiotoxic or 
hepatotoxic effects, have been reported following the administration of 
several antimonial compounds [44,57,61,62]. The enzyme glutamic-oxalacetic 
transaminase, found in various tissues, primarily the heart and liver, is 
released into the serum as the result of tissue damage; hence, serum glutamic- 
oxalacetic transaminase (SGOT) levels may increase following heart or liver 
damage. A value of 4-44 units is normal. Glutamic-pyruvic transaminase is 
another enzyme found in the serum (SGPT) that concentrates in the liver. A 
normal blood value is 3-36 units. Hepatic disease, such as parasitic 
infection, or insult, such as the toxic action of a drug, can result in 
increased concentrations of both enzymes in the blood,
Abdalla et at [61] determined SGOT and SGPT levels in 55 Egyptians before, 
during, and after antimony potassium tartrate therapy. Increases in SGOT and 
SGPT before treatment were seen in all cases, though the increases were 
moderate and more pronounced in hepatosplenic infections than in urinary or 
intestinal ones. SGOT and SGPT levels in all patients rose throughout
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treatment and reached 182 units/ml for SGOT and 178 units/ml for SGPT in the 
hepatosplenic group, which had consistently higher values than the urinary or 
intestinal groups. Fifteen days after treatment ended, serum levels of both 
enzymes had declined gradually in cases of urinary and intestinal
schistosomiasis, but were still high in hepatosplenic cases [61],
Asshauer [62] found that rises in SGOT and SGPT occurred simultaneously in
38 patients given antimony potassium tartrate or stibophen for
schistosomiasis. SGOT was normal in all cases before antimony therapy.
Following treatment, 59% of the cases had abnormally high values, the highest 
being 510 units. No relation to dose was found. SGPT was elevated in one 
case prior to treatment and in 57% of the cases after treatment. The maximum 
level found was 349 units. The increase in SGPT level also was not related to 
dose [62],
Waye et al [44], however, found a somewhat positive correlation between 
SGOT elevation and total dose of antimony dimercaptosuccinate. The highest 
value, 320 units, was found in a patient who had received 65 mg of the
drug/kg. Waye et al believed that SGOT could not be used as an index of 
cardiotoxicity during antimony therapy. Forty percent of their patients 
without significant ECG changes had SGOT elevations, but only one of three 
patients with severe ECG changes had a rise in SGOT. They [44] concluded that 
SGOT was a measure of hepatic, not cardiac, necrosis during antimony 
treatment. The authors [44] admitted, however, that more frequent SGOT
determinations might have revealed a greater incidence of elevated levels in 
patients with altered ECG1s.
Spingarn et al [57] noted considerable SGOT elevations in 17 of 23 
patients receiving antimony dimercaptosuccinate. Three patients had high 
levels (up to 86 units) before therapy, indicating that some heart or liver
damage could have occurred due to the parasitic disease. Following antimony
therapy, increases of up to 360 units over pretreatment values were seen. 
SGOT elevation was generally proportional to the dose administered. Of the 17 
patients with abnormal SGOT levels, 12 also had abnormal ECG's. These studies 
[44,57,61,62] indicate that antimony therapy was the major cause of the 
reported SGOT and SGPT elevations, but whether they indicated hepatic or 
cardiac intoxication is unclear.
Renal complications following antimonial therapy have been reported. 
Charlas and Benabadji [63] reported in 1962 that a 4-year-old girl being 
treated for kala-azar had developed azotemic nephritis 1 week after a second 
course of therapy with n-methyl glucamine antimoniate, a pentavalent compound. 
The nephritis, not known to be a complication of kala-azar, suggested metal 
poisoning to the authors [63] because it was characterized by an initial 
anuria followed by a polyuria. Based on the nature of the azotemic nephritis, 
the recent antimony therapy, and the lack of any other evident cause, the 
authors [63] concluded that the nephritis was caused by the antimonial drug.
Two cases of lupus erythematosus aggravated by the therapeutic use of 
anthiolimine, a trivalent antimonial drug, were described by Rollier et al 
[64]. In one case the drug was thought to be responsible for transforming 
edematous lupus erythematosus into severe systemic lupus erythematosus. The 
authors [64] viewed this response as exceptional since several patients had 
previously received anthiolimine without aggravation of their lupus.
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(D) Other Effects
The most common side effects of antimony therapy have been 
mentioned in articles that emphasized other, more severe, effects, More or 
less in passing, it was stated [35,37,43,47,56,58] that some patients 
experience some or all of the following symptoms: nausea, anorexia, vomiting,
dizziness, joint or muscle pains, headache, diarrhea, fever, and coughing. 
Reports have generally not given estimates of how widespread these effects are 
among patients. Khalil [35] found that the numbers of affected patients 
differed according to the drug administered. He estimated that in patients 
receiving antimony potassium tartrate, 10% experienced coughing in varying 
degrees of intensity. Nausea without vomiting occurred in about 1.6% of the 
cases, and with vomiting in 3.8%. After administration of stibophen, no cases 
of coughing occurred, nor was there nausea without vomiting. Vomiting was 
reported in 0.36% of these patients, and dizziness in 0,018%. The percentages 
were based on at least 2,000 patients [35],
An association between antimony therapy and the occurrence of herpes 
zoster infections has been noted by several investigators [64-66]. Aslamazov 
et al [65] observed herpes zoster (shingles) in 2 of 28 bilharzic patients 
under treatment with antimony sodium tartrate and in 1 of 42 patients treated 
with stibophen. Most et al [66] reported that herpes zoster infections had 
developed in 6 of 600 patients being treated with tartar emetic or stibophen. 
Rollier et al [64] reported shingles in the same patient whose lupus 
erythematosus had become systemic after treatment with anthiolimine.
(b) Distribution and Fate
Distribution and excretion profiles for man have been determined largely 
from therapeutic studies. In general, the studies show that trivalent 
antimony has a greater affinity for red blood cells [67] and is eliminated 
more slowly than are pentavalent compounds [68]. Antimony is primarily 
eliminated via the urine following parenteral administration.
Boyd and Roy [68] investigated excretion of a pentavalent compound, 
ethylstibamine, and compared it with a trivalent compound, antimony sodium 
tartrate. Estimates of antimony in the urine were made by the Gutzeit method 
of Sanger and Reigel [69],
Two patients each received a single 300-mg iv dose of ethylstibamine 
containing 123 mg of pentavalent antimony [68], Antimony in the urine was 
determined at frequent intervals for the first 3 days and then every 24 hours
for several days. The authors [68] reported that about 19% of the antimony
injected was excreted in the first 2.5 hours, 41% during the first 24 hours, 
6% during the second 24 hours, and 1.25% during the third 24 hours. 
Thereafter, daily excretion remained low (1% or less) and was measureable for 
as long as the two patients were followed (11 and 13 days). An average of 49%
of the antimony was excreted in the first 3 days. Reducing the dose to 150 mg
did not alter the excretion rate.
A trivalent compound, antimony sodium tartrate, was given in single iv 
doses of 50 or 60 mg to two patients [68]. These doses represented about 20 
and 24 mg of trivalent antimony. The resulting excretion pattern was 
distinctly different from that observed with the pentavalent compound. The 
data showed that about 2.5% of the antimony was excreted during the first 24
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hours and 2% in the second 24 hours; it decreased very gradually to about 1% 
or less during the next 24 hours. Total excretion after 3 days was estimated 
to be about 5% (see Table III-l). Concentrations in the blood were not 
reported.
TABLE III-1
URINARY EXCRETION OF TRIVALENT AND PENTAVALENT ANTIMONIAL DRUGS
Ref.
Total 
Dose of
Excretion, 
Cumulative Percent 
Days
Compound No. Sb (mg) Route 1 2 3
Trivalent Compounds
Antimony potassium 
tartrate 
(Tartar emetic)
[70] 19-120 iv 12
•
17 20*
Antimony sodium 
tartrate
[68] 20-24 iv 2.5 3.5 4.3
Lithium antimony 
thiomalate
[67] 34.5 im 11.4
Sodium antimony
dimercaptosuccinate 
(Astiban)
[71] 75-125
320-619
im
im
25**
36 38
Monosodium antimony 
thioglycollate
[67] 31 im 8.1
Pentavalent Compounds
Ethylstibamine
(Neostibosan)
[68]
[67]
123
123
61.5
127.5
iv
im
iv
iv
41
34
39
19
47 49 
37 38 
43 44
Antimony sodium 
gluconate
[67] 195 iv 43
Urea stibamine
it 1 ^  a f ► av 1 t.tA a1/ t 7 Q a/
[72]
Í* f  ►  A W /■ A lr  M
iv 35 41
**50% after 2 weeks
Following the same experimental design, a single dose of 300 mg of 
ethylstibamine was administered im to two patients [68], Averaging the
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results from the patients, 34% of the antimony was excreted during the first 
24 hours, 3% during the second 24 hours, and 1.5% during the third 24 hours. 
Thereafter, daily excretion rates were low (1% or less) and constant.
The work by Boyd and Roy [68] indicated that dose and route of 
administration of antimony drugs exerted little effect on the rate of 
excretion. Intramuscular administration produced a slightly slower excretion 
rate, a predictable finding in view of the slower absorption expected from im 
administration. The excretion patterns of a trivalent drug and a pentavalent 
drug were found to be different.
Otto et al [67] also compared the distribution and excretion patterns of 
trivalent and pentavalent compounds in a 1947 report. A total of 497 
determinations for antimony were made by Maren's colorimetric method on blood 
cells, blood plasma, feces, and urine of 14 patients being treated with 
antimony compounds. Two trivalent compounds, anthiolimine and monosodium 
antimony thioglycollate, and two pentavalent compounds, antimony sodium 
gluconate and ethylstibamine, were studied.
Distribution of the trivalent compounds in blood was characterized by 
rapid movement of antimony to the blood cells and continued higher 
concentrations in blood cells than in surrounding plasma. On the other hand, 
pentavalent antimony showed little or no affinity for blood cells, but 
concentrations in plasma were high (see Table III-2).
TABLE III-2
AVERAGE 24-HOUR ANTIMONY LEVELS IN ERYTHROCYTES, PLASMA, AND URINE 
AFTER INTRAMUSCULAR INJECTIONS OF TRIVALENT AND PENTAVALENT ANTIMONIALS
Concentration of Antimony
Average Cells Plasma 
Dose of (Mg/g) (jug/g) 
Sb given 
(mg)
Ratio 
Cells/Plasma
Sb
Excreted 
(% dose)
Trivalent Compounds
Anthiolimine 34.5 0.15 0.03 5.0 11.4
Monosodium antimony 
thioglycollate 31 0.35 0.07 
Pentavalent Compounds
5.0 8.1
Antimony sodium 
gluconate 195 0.6 0.32 1.9 43.0
Ethylstibamine 127.5 0.25 0.8 0.31 17.0
Adapted from Otto et al [67]
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Even after repeated heavy doses of the pentavalent drugs, the amounts of 
antimony recovered from blood cells were scarcely more than could be accounted 
for in light of known contamination of the cell fraction with plasma [67]. 
The high plasma concentration of pentavalent antimony and its corresponding 
low affinity for blood cells apparently enabled quick excretion. Trivalent 
antimony, on the other hand, became bound to blood cells and remained in
circulation for a considerable time.
Some variation in excretion rates was seen by Otto et al with the two
pentavalent compounds they studied. They theorized that rate of excretion may
to some extent be inversely proportional to the toxicity of the compound [67]. 
Valency seems to be the primary determinant of excretion rate, but the 
configuration of the organic molecule also seems to play a role.
Khalil [35], in 1931, reported on the analysis of urine, feces, sweat, 
milk, and sputum as potential routes of antimony excretion. The subjects were 
undergoing routine treatment with antimony potassium tartrate or stibophen. 
Antimony was reported to be excreted only in the feces following im or iv 
administration of either drug. During the 45 days of observation, 45-50% of 
administered antimony was excreted in the urine and 3.5% was excreted in the 
feces.
Baseline values of antimony concentrations in blood, urine, and feces of 
normal healthy Japanese city dwellers were measured by Hirayama [73] in 1959. 
The study participants had no known history of occupational or therapeutic 
exposure to antimony. Analysis for antimony was performed by a procedure that 
combined the microcolorometric methods of McChesney [74] and Elkind et al
[75].
Antimony concentrations in the whole blood of 104 subjects (79 men and 25 
women) ranged from undetectable to 13.5 ng of antimony/100 g of whole blood 
[73]. The overall median value was 2.4 ¿ig/100 g. Medians for men and women 
were 2.5 and 2.1 ¿tg/100 g, respectively. Twenty-four-hour urine values were 
determined for 80 men and 55 women. Urine values ranged from undetectable to
18.5 /ig/day. The overall median value was 5.3 ¿¿g/day; for men and women the 
medians were 5.4 and 5.1, respectively. Antimony excreted in the feces of 85 
men and 41 women ranged from a trace to 56 /¿g/day. Half of all the cases
measured were 13 ¿ig/day or less, and 95% were 35 jug/day or less. There were
no statistically significant differences due to sex in blood, urine, or fecal 
concentrations of antimony.
Hirayama [73] speculated that the baseline levels were probably common to 
industrial cities, resulting from factory soot containing antimony and factory 
waste fluid that had emptied into river and irrigation water. Ingestion of 
various plants and animals containing antimony had probably occurred, which
could explain the high antimony concentrations in the feces. The author [73]
thought it unlikely that enamel on eating utensils was a source of antimony.
The influence of cultural factors, including diet, in affecting biologic
antimony levels is not known.
The concentration and distribution of antimony in the human lung and other 
organs were studied by Molokhia and Smith [76] in 1967, Radioactive analysis
of 45 samples of lung tissue obtained from men and women 40-70 years of age
who were killed in accidents in Glasgow, Scotland, showed a mean wet-weight
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antimony concentration of 0.095 ppm, a range of 0.007-0.45 ppm, and a median 
concentration of 0.056 ppm.
Results of distribution studies from 15 lung pairs are shown in Table III- 
3; distribution of antimony was log-normal [76]. Antimony concentrations were 
more than twice as high at the apex of each lung than at the base, which led 
the authors [76] to conclude that the source of the accumulated antimony was 
airborne dust. No information was provided about occupations, smoklzg habits, 
places of residence, or disease states of the victims.
TABLE III-3
DISTRIBUTION OF ANTIMONY IN LUNG AND OTHER TISSUES*
Tissue
Mean Concentration 
(ppm Wet Weight)
Right lung, Apex 0.084
Middle 0.038
Base 0.033
Left lung, Apex 0.087
Base 0.035
Lymph glands 0.258
Right paratracheal hilar 0.429
Left paratracheal hilar 0.339
Visceral pleura 0.037
Trachea 0.007
Pulmonary artery 0.006
Pulmonary vein 0.007
Tongue 0.007
*Data determined from 15 lung pairs
Adapted from Molokhia and Smith [76]
(c) Occupational Exposures
Numerous authors [4-9,15,16,77-80] have stated that antimony causes 
occupational health problems. This has been questioned by several other 
authors [18,81,82], some of whom have noted that many of the reported symptoms 
and signs of occupational "antimony toxicity" are similar to those of arsenic. 
Arsenic is a common contaminant of antimony ore and is often found with 
industrial grades of antimony [83], Arsenic lies just above antimony in the 
periodic table [84], and its chemical, physical, and toxicologic properties 
are similar in several respects to those of antimony [5,85,86]. Arsenic, like 
antimony, is caustic to skin and mucous membranes and can cause eczema and 
other forms of dermatitis [87,88], congestion of the upper respiratory tract, 
and cardiovascular changes [8 7—93]. These similarities have caused
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considerable doubt in some investigators about the actual cause of the 
occupational toxicity ascribed to antimony, especially that related to mucous 
membrane and skin effects [77,81],
(1) Effects on the Heart
Reports of altered ECG’s in workers occupationally exposed to 
antimony trioxide and trisulfide have been made by Brieger et al [15] and 
Klucik and Ulrich [11]. Brieger et al found altered ECG's in 37 of 75 workers 
exposed to antimony trisulfide who were engaged in the manufacture of resinoid 
grinding wheels. Klucik and Ulrich found T wave depression, borderline normal 
QT waves, a prolonged atrio-ventricular transmission, prolonged QRS complexes, 
and ST segment changes in metal workers exposed to antimony trisulfide and 
trioxide. Details of these key studies are presented in this chapter under 
Epidemiologic Studies. They [11,15] are the only reports of altered ECG's in 
workers, and the only reports implicating inorganic antimony.
(2) Skin and Mucous Membrane Effects
Skin irritation and rashes resulting from occupational exposure to
antimony compounds, which often contain arsenic as a contaminant, have been
well documented [4-6,10,12,77,78]. These effects have most often been 
observed following exposure to antimony trioxide [5,77,81] and have been
usually associated with hot environments such as might occur during smelting
operations or in the summer months [5,12,77,81]. Antimony oxychloride, 
pentachloride, and trisulfide have not been reported to cause dermatitis.
Rothman [94] suggested in 1943 that antimony salts, as with salts of other 
heavy metals, form compounds with fatty acid radicals of the sebum and other
fats of the skin surface and are absorbed in these forms. No data were
presented.
Stevenson [78] gave a different opinion in 1965 on the cause of "antimony
spots•" After finding dermatitis in 23 of 150 workers exposed to antimony
trioxide at the antimony works at Newcastle-upon-Tyne, England, Stevenson 
noted that all affected workers were exposed to hot environments; 17 worked at
the furnaces. Workers in cooler but equally dusty parts of the factory had no
spots. The antecubital area, where sweat and flexing occurred, was most often 
involved. The dermatitis subsided in 3-14 days when the worker was 
transferred to a cooler part of the factory. Microscopic examination of the 
lesions showed epidermal cellular necrosis with associated acute dermal 
inflammatory cellular reaction. The lesions were found close to sweat ducts. 
A questionnaire survey disclosed that 6 men who bathed relatively infrequently 
did not have more severe or extensive lesions than the remaining 17. There 
were no positive reactions in patch tests conducted with dry antimony trioxide 
or with antimony trioxide suspended in water. Stevenson noted that antimony 
trioxide is soluble in lactic acid, which is present in sweat in increased
amounts following heavy exercise. From these findings, Stevenson concluded
that the lesions arose from the irritant properties of antimony trioxide on 
the dermis after dissolving in sweat and penetrating the sweat ducts [78].
Dermatitis in a worker engaged in the manufacture of fireproof packing 
material was reported by Paschoud [77] in 1964, A series of cutaneous contact 
tests of materials going into the final product gave negative results except 
with antimony trioxide. A positive test for arsenic was noted even though
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arsenic was not one of the ingredients in the mixture. Paschoud indicated 
that other workers exposed to antimony in the same plant also showed positive 
reactions to both antimony and arsenic. On the other hand, eczemas caused by 
arsenic in other workers showed negative tests for antimony. The author [77] 
concluded that the antimony trioxide powder contained impurities of arsenic 
and that sensitization to both occurred. Double sensitization was thought to 
be a more plausible explanation than cross-sensitization. Though the process 
was considered allergic, friction was emphasized as a causative factor [77],
Dermatitis, occurring in two workers producing an antimony trioxide-based 
powder for treating internal parasites in chickens, was reported by Thivolet 
et al [81] in 1971. The dermatitis was periodic, usually appearing in the 
warmer months and disappearing over holidays and during the winter. The 
lesions were in areas of friction and sweating, such as inside of elbows, 
popliteal hollows, inguinal folds, and scrotum, and were described as itchy 
varioliform or necrotic papular pustules.
Chemical analysis of the powder by an undefined method failed to show any 
traces of arsenic trioxide, and the concentration of the antimony trioxide was 
not given [81]. A series of skin tests with and without scarification was 
conducted on the two workers with the commerlcal antimony trioxide powder and 
its constituents to determine the cause of the rash. Pure antimony trioxide, 
pure arsenic trioxide, and Fowler's solution (a solution containing 1% arsenic 
anhydride) were also tested. Fourteen controls had the same tests. The 
concentrations used were not reported.
Results of the patch tests without scarification were negative with pure 
antimony trioxide in 10 controls and in both workers. The results were 
positive with pure arsenic trioxide in 9 of 10 control subjects and in 1 of 2 
workers, and were positive with Fowler's solution in 6 of 10 controls and in 
the same worker who had responded to arsenic trioxide [81].
With scarification, patch test results were positive with the commerical 
antimony trioxide powder and arsenic trioxide in both workers, and were 
positive with pure arsenic anhydride or the commercial antimony trioxide 
powder in four control subjects [81].
Thivolet et al concluded that the antimony trioxide in industrial or 
commercial preparations does not appear to play any role in the observed 
dermatitides, and that an arsenic contaminant was the causative agent. They 
[81] also concluded that the dermatitides were not due to an allergic process 
but were caused by the irritant properties of arsenic, the severity of which 
depended on the degree of individual perspiration,
Linch and Sigmund [82] reported in 1976 the results of laboratory patch 
tests on 45 women and 7 men who ranged from 17 to 35 years old. A blend of 
powdered antimony trioxide containing 0.29% arsenic was used. Adhesive 
patches with moistened gauze centers covered with test material were applied 
nine times, 24 hours each, over 3 weeks. This series was followed 2 weeks 
later by a single challenge patch to detect skin sensitization. Because no 
skin reaction was noted in any subject, the authors [82] did not consider the 
test material a primary skin irritant or a skin sensitizer. The effects of 
friction, heat, and sweating as contributing factors to irritation were not 
studied.
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Antimony pentachloride, leaking from a reactor (undefined), was cited by 
Cordasco [95] as the agent responsible for respiratory distress in a man 
acutely exposed to an undetermined concentration of the chemical. The patient 
had received second and third degree burns over most of his body as a result 
of the accident. The temperature of the material and the worker's protective 
clothing and equipment were not reported. Almost immediately following 
exposure, severe coughing, wheezing, dyspnea, and chest tightness developed. 
Moist rales were found in both base and midlung fields. Pulmonary edema 
developed which was treated successfully. Antimony pentachloride was also 
cited by the author [95] as the cause of two fatalities, but no details were 
provided.
(3) Effects on the Lungs
Exposure by inhalation to dusts and fumes of antimony or antimony 
compounds has resulted in respiratory illnesses, including pneumoconiosis [5- 
7,12,95,96], The amount of functional impairment resulting from most of these 
exposures in unclear. These reports will be discussed under Epidemiologic 
Studies.
(4) Effects on Blood
Occupational exposure to antimony has been linked to blood profile 
alterations, although reported changes have not been frequent, Seitz [24], in 
1923, reported thrombocytopenia and relative lymphocytosis in type foundry 
workers, Anisocytosis was reported by Oliver [10] in 1933 in one of six 
antimony oxide workers he studied, but he stated that differential white cell 
counts were generally average, and that the men appeared healthy and 
apparently had lost little if any time at work because of illness. Gallina 
and Luvoni [16] found blood profile alterations in workers exposed to antimony 
pentasulfide (see Epidemiologic Studies).
The most severe cases of blood changes following occupational exposure to 
an antimony compound were described by Nau et al [97] in 1944. Three metal 
refinery workers were poisoned by a gaseous mixture containing stibine, 
arsine, and hydrogen sulfide. The workers suffered severe hemolysis as 
evidenced by bloody urine and blackened vomitus. Blood bilirubin was 
elevated. Blood transfusions and fluid replacements were required. These 
severe symptoms have not been reported following exposure to other antimony 
compounds.
(5) Other Effects
To elucidate a relationship between induction of chromosome 
abnormalities and carcinogenesis, Paton and Allison [85] investigated effects 
of a variety of metal compounds on chromosomes in vitro. Human leukocytes 
were treated with 2.3 nM concentration of antimony sodium tartrate. One
hundred metaphases were examined; 12% of the cells displayed chromatid breaks. 
This amount of chromosome damage in human cells was reported to be significant 
at the 0,05 level; controls were not discussed, however. Only salts of 
antimony, arsenic, and tellurium produced chromosome damage. Although this
type of work is used as a screen for mutagenic agents, the results offer
limited information and cannot be regarded as conclusive. Nishioka [98]
reported no indication of mutagenic activity for antimony tri- and 
pentachloride in recombination assay experiments using bacterial strains.
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Epidemiologic Studies
In 1954, Brieger et al [15] recounted an unexplained increase in the
number of sudden deaths among factory workers engaged in the manufacture of
resinoid grinding wheels. The workers involved were all from one department 
and worked in air-conditioned rooms where machines mixed, molded, and pressed 
materials together. Following the replacement of lead with antimony
trisulfide for safety reasons, six sudden deaths and two deaths due to chronic 
heart disease occurred among 125 workers exposed for 8-24 months. Four of the 
dead persons were less than 45 years old. In the 16 years before the switch 
to antimony trisulfide, only one death, from coronary thrombosis, had occurred 
among the workers in that department. Brieger et al reported that heart 
disease was suspected in all but one of the sudden deaths. Since autopsies 
were not performed, confirmation of the suspected heart disease was not 
possible. An occupational hazard was suspected, which led to a survey of the 
plant.
Antimony trisulfide in concentrations usually exceeding 3.0 mg/cu m
(range, 0.58-5.5 mg/cu m) was found in the air [15]. Phenol formaldehyde 
resin was also used in the process, but concentrations of this compound in the 
workroom environment were not reported.
A clinical survey of the employees of that department revealed ECG changes 
in 37 of 75 workers examined. Alteration of the ECG's was mainly of the T 
wave. Brieger et al [15] did not define qualitatively or quantitatively the T 
wave changes but indicated that a cardiologist considered the alterations 
significant. Apparently, no control ECG's for the 75 workmen studied were 
available. Alterations in rate and rhythm were not observed. Following 
cessation of the use of antimony trisulfide in the process, presumably after 2 
years, no additional deaths or abnormal cardiac effects were noted.
Reexamination of 56 of the workers showed that altered ECG's persisted in 12, 
Duration of followup was not specified, but it was probably several years.
Of the 113 men examined in the survey, 14 had blood pressures exceeding 
150/90 mm and 24 had pressures under 110/70 mm. The ages and weights of these 
men were not given. X-ray examination revealed that 7 of 111 (63 per 1,000) 
workers had gastrointestinal ulcers; there were 59 known cases of ulcer in the 
total plant population of 3,912 (15 per 1,000). These figures are not
comparable; more cases of ulcer in the total plant population could have been 
detected if X-ray screening had been conducted. Irritation of the skin, 
mucous membranes, and respiratory tract was not found [15].
Urine samples collected at random from the workers contained 0.8-9.6 mg 
antimony/liter [15]. Antimony content of the urine was analyzed according to 
a modification of the colorimetric method of Fredrick [99]. Brieger et al 
[15] did not mention smoking, drinking, or medical histories of the workers. 
Experiments on rats, rabbits, and dogs conducted by these researchers 
(discussed under Animal Toxicity) tended to corroborate their occupational 
findings.
In 1960, Klucik and Ulrich [11] studied 42 metal workers exposed to 
antimony trisulfide and trioxide at concentrations ranging from 1.3 to 237 
g/cu m of inhaled air (sic). The concentrations reported could possibly be 
1000-fold in error and may actually have been 1.3-237 mg/cu m. The workers 
were often reassigned within the plant, making it difficult to establish
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exposure groups. Instead, the workers were divided according to the intensity 
and kind of complaints they expressed. Fourteen had frequent complaints that 
the authors [11] considered to be related to the heart, including hard 
breathing, weakness, sweating, stabbing pains or pressure in the chest, and a 
nonproductive cough. ECG's of these workers were compared with ECG's of the 
28 workers who had fewer subjective complaints that might be related to heart 
problems.
Abnormal ECG’s were found in 8 of the 14 workers with frequent subjective 
complaints. T wave depression, borderline normal QT waves, a prolonged atrio­
ventricular transmission, prolonged QRS complexes, and changes in the ST 
segment were noted [11]. In three workers, the positive ECG findings were 
unequivocal; in five, symptoms of disturbance were only probable and judged 
positive in light of the subjective complaints. Three QRS complex changes 
were noted in the group of 28 workers who complained less, but were thought 
equivocal. The average age of both groups was in the middle to late 40's.
Klucik and Ulrich's attempt to correlate antimony exposure and heart 
problems raises some doubts. The authors [11] admitted that some other 
factor, particularly arsenic, could have caused or contributed to the observed 
ECG changes. Second, their evaluation of the ECG's does not seem to have been 
made independently of the workers' complaints. Thus, ECG abnormalities and 
subjective complaints were positively correlated, but antimony was not proven 
to be the cause.
The ECG's of a number of workers taken before and after their workshifts 
were also examined. No significant changes were reported. The ECG of an 
individual experimentally exposed to the plant dust at 35 mg/cu m remained 
unchanged for an observation period totaling 26.5 hours. Procedures used to 
expose the individual were not given.
Renes [5] in 1953 reported a survey, conducted with the plant physician, 
of employees of a company engaged in mining, concentrating, and smelting 
antimony sulfide ore. Illnesses had been reported among the workers in the 
smelting operations and among maintenance workers who spent a substantial part 
of their time in the smelter building. According to Renes, the illnesses had 
begun soon after the initial operation of the smelter and had continued for 
more than 1.5 years.
During the first 5 months of operation, 69 of the 78 workers employed
longer than 2 weeks made a total of 218 visits to the plant physician.
Dermatitis and mucous membrane irritation were among the most common 
complaints, but most cases of dermatitis were seen during a 1-week period of 
heavy exposure. The dermatitis was usually found in sweaty, hairy friction 
areas such as the axillae, groin, and back of the neck. The lesions were 
described as nodular and ulcerative. More than 70% of the workers had 
experienced soreness or bleeding from the nose. In those complaining of
laryngitis, erosions or ulcerations of the vocal cords were always observed.
An unspecified number of workers complained of shortness of breath. Chest X- 
rays of six men acutely ill from "heavy" exposure to smelter fumes showed 
definite pneumonitis extending like a fan from each hilus. However, no 
evidence of peripheral parenchymal pulmonary damage was found. Table III-4 
summarizes the illnesses reported by Renes [5].
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TABLE III-4
EFFECTS OF OCCUPATIONAL EXPOSURE TO ANTIMONY TRIOXIDE
Diagnoses % Workers*
Dermatitis 20
Rhinitis 20
Laryngitis 11
Tracheitis 10
Pharyngitis 8
Bronchitis 7
Pneumonitis 5.5
Conjunctivitis 4
Septal perforations 3.5
Secondary sinusitis 1.5
*From a total of 69 examined
Adapted from Renes [5]
Undefined "heavy" exposure to smelter fumes was also said to have caused 
systemic effects such as abdominal cramps, diarrhea, vomiting, dizziness, 
nerve tingling, severe headaches, and prostration [5]. Antimony 
concentrations in the urine of seven of the nine heavily exposed men ranged 
from traces to 60 mg/100 ml. It is assumed that these were spot samples
although no information was given. The urine containing 60 mg/100 ml was
described as heavily discolored with albumin and was obtained from a worker 
who was severely ill. Another patient had an unspecified amount of arsenic in 
the urine. According to Renes [5], symptomatic treatment and removal from 
exposure for several days provided relief. Antimony or arsenic levels in the 
urine of the other workers were not reported.
The percentage concentrations of the hygienically important constituents 
present in the materials handled and produced by the workers are shown in 
Table III-5.
A study of the smelter environment 6 months after the operation began 
showed gross contamination of the air with dusts and fumes [5]. Renes divided 
the smelter into two zones for comparison: the electric furnace area, and the
cupel area. Breathing zone and general air samples for antimony and arsenic 
were taken from each area. Table III-6 shows the results.
An average antimony content of about 11 mg/cu m and an average arsenic 
content of about 0.73 mg/cu m were found in the overall smelter environment. 
At the cupel operation that used caustic soda to refine the antimony metal, 
12, 60, and 64 mg of sodium hydroxide/cu m of air were also found. 
Microscopic examination showed most of the particulate material to be less 
than 1 Mm.
One year later, according to Renes [5], engineering controls had lowered 
the average content of the air to approximately 6.8 mg antimony/cu m and 0.54
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mg arsenic/cu m. Table III-7 shows concentrations by area on the second 
survey. Renes noted that work-related illnesses were still occurring even 
though engineering controls had been installed.
TABLE II1-5
METAL CONSTITUENTS OF HYGIENIC SIGNIFICANCE IN SMELTER MATERIALS
Material 
or Substance
Concentration of Constituent: Elements (%)
Antimony Arsenic Selenium Tellurium Lead Beryllium Copper
Dross, iron 
refining cupel
67,6 4.1 0.04 0 0.28 0 0.4
Dross, arsenic 
refining cupel
56.9 2.1 0.03 0 0.30 0 0.4
Ore concentrate 21.5 3.6 0.01 0 0.04 0 0.1
Settled fume 35.1 5.3 0.02 0 0.15 0 0.2
Adapted from Renes £ 5]
ANTIMONY AND ARSENIC
TABLE III-6
CONCENTRATIONS IN SMELTER BUILDING (FIRST SURVEY)
Antimony Arsenic
(mg/cu m) (mg/cu m)
No. of Concentration No. of Concentration
Type of Sample Samples Range Average Samples Range Average
Electric Furnace Area
Breathing zone 12 0.92-70.7 12 0.04-4.66
10.07 1.10
General room 4 0,40-3.43 3 0.13-1.93
Cupel Area
Breathing zone 7 1.19-42.40 7 0.05-1.45
11.81 0.36
General room 8 0.91-22.90 8 0.02-1.59
Adapted from Renes [37
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TABLE III-7
ANTIMONY AND ARSENIC CONCENTRATIONS IN SMELTER BUILDING (SECOND SURVEY)
Antimony (mg/cu m)  Arsenic (mg/cu m)
No. of Concentration No. of Concentration
Type of Sample Samples Range Average Samples Range Average
Electric Furnace Area
Breathing zone 2 5.0-16.90 2 1.20-2.90
4.96 0.76
General room 4 0.29-3.90 4 0.01-0.33
Cupel Area
Breathing zone 3 3.30-17.60 3 0.08-8.10*
8.23 0.39
General room 6 0.23-37.00 6 0.01-2.10
*The value of 8.10 was not Included In the zone average because It 
resulted from an unusual and noncontlnuous step in the process.
Adapted from Renes [5]
Renes recognized that the symptoms observed among the workers were 
characteristic of both antimony and arsenic intoxication. However, antimony 
concentrations greatly exceeded the arsenic concentrations both in individual 
and average values (see Table III-8). The author [5] thought it significant 
that none of the most common early signs of arsenic intoxication, such as 
increased pigmentation of certain skin areas, keratoses of the palms and 
soles, loss of hair and nails, garlic-like odor of the breath and 
perspiration, or swelling of ankles, were reported among these workers. In 
addition, higher arsenic exposures, found in the electric furnace area, were 
not reflected by more intense or larger numbers of illnesses in that area. 
Therefore, Renes concluded that antimony trioxide, the predominant air 
contaminant, was responsible for the illnesses [5],
TABLE III-8
PERCENT DISTRIBUTION OF ANTIMONY AND ARSENIC CONCENTRATIONS IN SMELTER AIR
Substance Concentration Range (mg/cu m of air)
0.01-0.49 0.5-4. 9 5.0 and above
Antimony 7% 54% 39%
Arsenic 71% 27% 2%
Adapted from Renes [5]
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Belyaeva'8 [13] 1967 report is the only recent Investigation into the
effects of antimony on reproduction. She noted that Feil [28] had earlier 
found reduced sexual potency among some men workers in an antimony foundry 
(discussed under Historical Reports).
Belyaeva compared the reproductive experience of women working in an 
antimony metallurgical plant, located in the USSR, with that of a group of 
similar working women not exposed to antimony [13], Conditions and jobs were 
not defined. Workers in the metallurgical plant were exposed to unspecified 
concentrations of metallic antimony dust, antimony trioxide, and antimony 
pentasulfide. Belyaeva conducted extensive gynecologic examinations twice 
each year from 1962 through 1964 and reported that the exposed group had 
higher incidences than the control group of late-occurring spontaneous 
abortions (12.5% vs 4.1%), premature births (3.4% vs 1.2%), and gynecologic 
problems (77.5% vs 56%). Gynecologic problems included menstrual cycle 
disorders (61,2% vs 35,7%), inflammatory disease (30.4% vs 55.3%), and other 
diseases of the reproductive apparatus (8,4% of antimony-exposed women). No 
percentage was reported for controls in this last category. The author [13] 
also observed that the weights of children born to antimony-exposed women were 
not different at birth from those of control babies, but began to lag behind 
the controls at 3 months and were significantly less at 1 year of age. Table 
III-9 gives additional details.
TABLE III-9
WEIGHT OF NEWBORN INFANTS AND DEVELOPMENT OF CHILDREN UP TO 1 YEAR OLD
No. of Weight of Children (g)
Children At Birth At 3 months At 6 Months At 1 Year
Experimental 70 3,360 +60 6,300 +110 7,460 +120 8,960 +155
Control 20 3,350 +7 6,410 +100 7,950 +80 10,050 +90
Modified from Belyaeva [13]
Antimony concentrations in the blood of exposed workers were more than 10 
times greater than in the control group. Average urine levels of antimony for 
exposed workers ranged from 2.1 to 2.9 mg/100 ml. The highest value found was 
18.2 mg/100 ml, and the lowest, 0.5 mg/100 ml, Low levels of antimony were 
found in the urine of several persons in the control group, according to the 
report [13], but concentrations were not given (see Table 111-10).
Analysis of the antimony workers' biologic fluids by an undefined method 
detected antimony in breast milk (3.3 +2 mg/liter), in placental tissue (3.2-
12,6 mg/100 ml), in amniotic fluid (6.2 +2.8 mg/100 ml), and in umbilical cord 
blood (6.3 +3 mg/100 ml). Belyaeva [13] also conducted a study of the 
reproductive effects of antimony on rats (discussed under Animal Toxicity).
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Oliver [10] was the first of several investigators to study the health and 
working conditions of antimony workers at the antimony processing plant at
Newcastle-upon-Tyne, England. At the time of Oliver’s study (1933), six men 
were engaged in oxide manufacture, four of whom had worked at this for 13 
years, but had been antimony smelters for many years before oxide production
began [10], The two other men had worked with antimony for 2 and 3 years,
although they had been with the company for many years.
Observation within the smelter indicated that no special hygienic
precautions were taken, and according to Oliver, none appeared necessary. 
Respirators were provided for workers packing the final product, antimony 
trioxide, but they were not regularly worn. Despite considerable skin 
exposure, only a few cases of mild skin irritation were observed. Microscopic 
examination of the blood showed slight anisocytosis in one man. Differential 
white cell counts were average except for slightly elevated eosinophils. 
Chemical examination of the urine (method unspecified) did not detect 
antimony.
TABLE III-10
LEVELS OF ANTIMONY IN BLOOD AND URINE OF 
ANTIMONY METALLURGICAL WORKERS
Group of Subjects Sb in Blood (ma/lOO ml) Sb in Urine (mg/100 ml)
No.
Sub­
jects
Min Max Mean
+SE*
No.
Sub- Min 
jects
Max Mean
+SE*
Workers in dustiest 
shops (melting, 
pentasulfide, bene­
fication plant) 161 0.5 20.0 5.3 +0.6 133 0.5 18.2 2.9 +0.5
Workers in less dusty 
shops (chemical 
laboratory, quality 
control) 157 0.5 18.2 4.0 +0.5 139 0.5 16.2 2.1 +0.4
Control group 115 0 3.3 0.3 +0.06
a
- -
*Author did not state that these values were standard errors of the mean.
Adapted from Belyaeva [13]
Examination of the feces by an undefined method indicated that intake of 
antimony had occurred. Levels of antimony in the feces ranged from 10.3 to 
97.8 mg, but these amounts were not given per unit weight of feces. Because 
antimony was excreted in feces rather than in urine, Oliver concluded that 
antimony was poorly absorbed from the gut [10].
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A subsequent examination comparing fecal antimony content before and after 
more strict enforcement of hygienic work practices was conducted in three of 
the six men. The average fecal antimony level was 76 mg without strict 
hygienic supervision, and ranged from 5.1 to 35.7 mg with strict supervision 
[ 10] .
Oliver [10] stated that the men in the study appeared to have blood 
pressures below average for their ages, a situation he considered unusual 
among men engaged in heavy work. Weights of the six men ranged from 112 to 
159 pounds. Only one man was over 136 pounds. Three men were less than 63 
inches tall. Oliver concluded that the men were healthy and lost very little 
working time because of illness. He did not consider antimony to be a 
hazardous substance, but a nuisance to the occasional worker who suffered 
dermatitis.
In 1963, McCallum [12] reported the results of a survey of the same 
antimony processing plant at Newcastle-upon-Tyne. Air samples taken at 
various locations and over several weeks showed that antimony concentrations 
in the work environment generally exceeded 0.5 mg/cu m. The trioxide powder 
averaged less than 1 p  in diameter. The concentrations of antimony were 
particularly high during the relatively short periods when tapping operations 
(pouring molten metal) at the furnace were underway; the mean value at these 
times was estimated to be about 37 mg/cu m. Other parts of the factory had 
concentrations up to 5 mg/cu m.
Clinical and radiographic examinations of the workers (number not 
specified) revealed dermatitis and pneumoconiosis. McCallum [12] found 
situations of severe discomfort due to skin irritation in warm weather and 
occasional loss of work due to itching and subsequent secondary infections. 
The rashes consisted of papules and pustules around sweat and sebaceous glands 
and resembled lesions associated with chickenpox or smallpox. The rashes were 
found particularly on the forearms and thighs and the flexures where chafing 
from clothing was likely. Rashes were not observed on the face, hands, or 
feet. The "antimony spots" were reported to be transient, disappearing over a 
weekend or holiday and reappearing upon return to work. The author [12] noted 
that men with the cleanest personal habits were less likely to develop severe 
dermatitis, if at all.
Pneumoconiosis, resembling that of coal workers (classified by an 
international group [100] as a simple pneumoconiosis), was diagnosed by 
radiographic examination in an unreported number of the antimony process 
workers [12]. The lung changes appeared to be symptomless in nearly all 
cases, Two of the men subsequently developed tuberculosis which responded to 
chemotherapy and a third worker, the only one with respiratory symptoms, had 
chronic bronchitis and respiratory obstruction. Pulmonary function tests 
suggested that the latter subject had emphysema but no pulmonary fibrosis.
Spot samples of urine taken from three of the antimony process workers 
with pneumoconiosis had antimony concentrations of 425, 480, and 680 jug/liter
[12]. The case of a retired furnace worker suggested that antimony excretion 
may continue for some time after exposure ceases. In this subject, urinary 
antimony concentrations were 55 jug/liter after 7 months of retirement and 28 
Aig/liter after 4 years. Information on urinary levels while working, blood 
levels, and other possible exposure sources was not given. Even after 4 years 
of retirement, the furnace worker's urine antimony level was still higher than
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the peak background level found by Hirayama [73] among unexposed Japanese 
(discussed under Effects on Humans).
McCallum [79] reported in 1967 that improved radiological techniques had 
led to discovery of 26 cases of antimony pneumoconiosis. Eighteen cases were 
already under clinical observation following the 1963 study [12], All told, 
44 of 262 men employed at the Newcastle-upon-Tyne antimony works had 
pneumoconiosis ascribed to antimony. Another form of radiologically- 
discovered pneumoconiosis due to zirconium (processed in an adjacent factory) 
was present in eight men; eight others had shadows thought to result from 
mixed dusts. All pneumoconioses were of the simple type. Preliminary results 
of a new method [8] enabled improved distinction of different dusts in the 
lung.
Results of microscopic examination of a lung section from an antimony 
worker who had died from carcinoma of the lung also were reported [79] . 
Accumulations of dust particles and dust-laden macrophages lying in alveolar 
septa and in perivascular tissues were described. No fibrosis or inflammation 
was seen, suggesting that there was little or no reaction to antimony dust in 
the lung [79],
McCallum et al [8], in 1971, described the method for the detection and 
measurement of inhaled antimony trioxide dust retained in workers' intact 
lungs. The method depended on the dust absorbing monochromatic X-rays having 
two alternative wavelengths which lie on either side of the k critical 
wavelength of antimony. The antimony content of the lung was deduced from the 
differential attenuation of these two beams, using a scintillation counter as 
the detector.
One hundred and thirteen antimony process workers were screened by this 
method [8]. Most workers had been employed at the Newcastle-upon-Tyne factory 
for less than 20 years and had worked at different operations for varying 
periods. The amount of antimony in the lungs of these men ranged from 
undetectable levels to just over 11 mg/sq cm of lung area. The method of 
measuring lung area was not described. Although individual lungs varied a 
great deal, the authors [8] felt that an association could be made, 
particularly if only the first 20 years of employment were considered. An 
increase in radiographic category [100] of pneumoconiosis was associated with 
a rise in the mean period of employment [8]. The man with the highest level 
of antimony in his lungs (11.2 mg/sq cm) was employed at the factory for 35 
years, 16 of which he packed antimony trioxide. Higher median concentrations 
of an unspecified type of antimony were found in the lungs of the foremen and 
baghouse workers than in furnace workers: laborers and other workers had the 
least antimony in their lungs [8].
A continuing investigation into reports of lung cancer deaths among 
antimony process workers was reviewed in 1973 in a two-page abstract-type 
statement by Davies [14], then Chief Medical Advisor for the Employment 
Medical Advisory Service of England. The study was begun in 1962 after it was 
learned that a man engaged in the processing of antimony had died of lung 
cancer. Retrospective study found seven other deaths from lung cancer among 
antimony workers in the previous 8 years. Four of these men had worked at the 
antimony works at Newcastle-upon-Tyne, which had been studied by Oliver [10] 
in 1933 and by McCallum in 1963 [12] and 1971 [8], The other three men had 
worked in an antimony processing plant that had discontinued operations.
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For the period of 1961-1971, 1,081 men and women employees who had been 
working or had subsequently joined the workforce after 1961 were studied. At 
the end of 1971, 937 people were known to be alive and living in England, 20 
had emigrated and were lost to the study, 56 had died, and 68 were still being 
traced. Of the 56 deaths, 10 were ascribed to lung cancer. According to 
Davies [14], the number of lung cancer deaths in persons of all ages was 
higher among the antimony factory employees than might be expected according 
to the local community statistics (10 vs 8.0). Nine of the ten had worked 
solely at antimony smelting and related activities. Among this group of 
workers, the expected number of deaths from lung cancer was 5.7. It was also 
observed that 8 of 9 lung cancer deaths were from the 45-64 age group, where 
the expected rate was 4.5. Deaths from all causes among the antimony factory 
workers (including office personnel and others not exposed to antimony) were 
less than expected, 56 vs 65.8. Smoking habits were not reported nor was 
information on the exact procedures used for computing the reported death 
rates.
Additional data (KP Duncan, written communication, June 1978) followed the 
trends seen in the 1973 data, but also did not supply the needed information. 
Deaths from all causes remained lower than expected for the whole factory (95 
vs 108.11) and for the subgroup working in smelting and related activities (64 
vs 74.30). The number of deaths from all cancers was slightly greater than 
expected for the whole factory (31 vs 29.11) and for the smelter subgroup (25 
vs 19.93). There was a disparity between observed and expected deaths due to 
lung cancer for the whole factory (21 vs 14.03), but most of the excess 
occurred in the smelter subgroup (18 vs 10,25), The disparity was especially
prominent in the 45-64 age group (13 vs 1 . 2 2 ) ,  This recent communication,
like the earlier report, was brief. Essential information was absent,
including control (community) and factory population descriptions, data 
analysis, medical data, and environmental, blood, and urine antimony
concentrations.
In 1958, Karajovic [6] reported on the working conditions and clinical 
status of 101 men employed at an antimony smelter in Yugoslavia. Common 
complaints included shortness of breath, muscle pains, mild cough, dyspepsia, 
diarrhea, and a feeling of tiredness at work. Of the 101 men examined, 51 had 
catarrhal symptoms of the upper respiratory tract, 12 had conjunctivitis, and 
16 had ulcerated nasal septa. Roentgenography of the lung was performed on 62 
workers and revealed 31 cases without pathological findings, 17 cases 
designated only as type X, and 14 cases of simple pneumoconiosis. Emphysema 
with bronchitis was found in 22 workers, 8 of whom were less than 40 years 
old. There were four cases of tuberculosis, Karajovic [6] noted that there
were no symptoms of damage to the gastrointestinal tract, liver,
cardiovascular system, and central and peripheral nervous systems.
Sixteen cases of dermatitis were found among the workers studied, 13 of 
whom worked at blast furnaces. The skin rashes and itch were reported to have
been most prevalent during the summer. The dermatitis was described as
vesicular, varioliform, and efflorescent. The efflorescence underwent 
necrosis in the center and left scars that were hyperpigmented [6],
Roentgenographic examinations of 20 selected workers, 20-50 years old who 
had worked 3-15 years at the smelter, yielded 8 cases of simple 
pneumoconiosis, all among men who had spent most of their working hours at the 
blast furnaces and in the filtering plants. Tests of the workers with
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pneumoconiosis showed ventilatory function to be normal in three cases and 
slightly reduced in four. It was not tested in the remaining individual. 
Karajovic [6] also reported that blood pressure values were somewhat lower in 
five of the eight workers with pneumoconiosis, although no data were given. 
ECG's and hepatograms were normal. Data on the blood pressure determinations 
and ECG’s for the other 12 workers were not provided.
Analysis of blood and urine with Gutzeit's test did not detect antimony
[6]. A polarographic method detected 25 /ug antimony/liter of urine in three 
unidentified workers. Antimony was not reported to have been determined in 
feces.
A survey of the work environment showed that clouds of production dust 
were often visible. Gravimetric analysis showed dust loads to be 16-248 mg/cu 
m consisting of 2,150-12,800 particles/cu m. The vast majority of the 
particles were <0.5 w  in diameter, according to Karajovic [6], The mixed 
dust to which the workers were exposed contained antimony trioxide (36-90%), 
antimony pentoxide (1-6%), arsenic trioxide (0.3-9.0%), ferric oxide (2-4%), 
and total silica 1-12%, in addition to 1-7% free silicon dioxide [6] (the 
crystalline form of silica, which, unlike amorphous silica, can cause 
silicosis).
Karajovic did not doubt that the lung changes observed were contracted as 
a result of working in the antimony smelter; some workers with lung changes 
had no other work experience. There was some doubt, however, about whether 
the changes were attributable to antimony, silica, or both. The author [6] 
stated that radiographic changes in the lungs of miners with mixed silicosis 
differed from the changes seen among the smelter workers, a finding that 
implicated antimony oxides. The influence of arsenic trioxide in causing the 
observed effects was similarly unclear.
Cooper et al [9] presented data in 1968 on 28 persons who had worked at 
antimony smelting or ore processing operations for 1-15 years. 
Pneumoconiosis, determined roentgenographically, was demonstrated positively 
in three cases and was regarded as suspicious in five others. Cooper et al 
noted that the 28 employees had lost little if any worktime because of 
sickness.
Pulmonary function tests were conducted on 14 of the subjects [9]. The 
tests included vital capacity, lung volume, maximum midexpiratory flowrate, 
forced 1-second expiratory volume, minute ventilation, mixing efficiency as 
measured by closed helium circuit technique, tidal volume, maximum breathing 
capacity, and diffusing capacity. The authors [9] did not present specific 
data, but they reported that some isolated findings formed no consistent 
pattern of functional deficit. There were, however, several radiographic 
changes. One worker had definite small opacities, one had very early
unspecified changes, and two had negative chest roentgenograms. Three
remaining subjects with either suspicious or definite roentgenographic 
abnormalities had normal pulmonary function tests.
Cooper et al [9] had monitored the smelter environment in 1966 and found
that air concentrations of antimony ranged from 0.081 to 138 mg/cu m. The
highest concentration was associated with the bagging operation. Only in that 
operation did antimony concentrations exceed 75 mg/cu m. In the majority of
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cases, concentrations did not exceed 10 mg/cu m. Particle diameters were not 
given.
ECG's from seven of the workers, three of whom had pneumoconiosis, showed
six with normal tracings and one with a slight bradycardia. No other data
were provided [9].
The antimony concentrations in urine of these workers were determined in 
1962, 1965, and 1968 [9], The number of subjects sampled varied. The
antimony levels in the urine ranged from 7 to 1,020 /xg/liter, with most 
between 70 and 800 /ug/liter. No correlations between urine antimony levels, 
roentgenographic abnormalities, and pulmonary function tests could be 
established. Cooper et al [9] also conducted a limited experimental study of 
the effects of antimony on animals, which is described under Animal Toxicity.
Le Gall [7] reported in 1969 that pnemoconiosis was diagnosed in 10 of 40 
workers who operated or worked near furnaces used to produce antimony oxide. 
Though the cases were labeled as silicosis, Le Gall believed that the 
pneumoconiosis was caused by antimony. Concentrations of antimony trioxide in 
the factory ranged from 0.3 to 14.7 mg/cu m, and most particles were reported 
to be smaller than 3 pm in diameter. The extent of exposure to silica is 
unclear; the article stated that the presence of silica in dust of the foundry 
could not be proved, but at another point, it stated that the ore being used 
contained 1-20% silica. Sulfur dioxide was also found in the air [7],
Urine samples from a few workers did not show the presence of antimony
[7]. The workers had been employed at the foundry for 6-40 years, and, except 
in one case, the pneumoconiosis could not have resulted from other 
occupations. One affected worker had no work experience except his present 
job at the oxide furnace, where antimony exposure could be assumed to be
relatively high, and silica exposure low or nonexistent. Clinical signs
included shortness of breath, coughing, some expectoration, prolonged 
expiration, and sparse adventitious sounds. The tests used were not 
specified. The radiographs were described as showing moderate, dense 
reticulonodular formations scattered through the pulmonary fields. There was 
no overt illness.
Gallina and Luvoni [16] reported in 1958 on their investigation into a
series of illnesses among six workers in a Milan glass manufacturing plant.
The affected workers were engaged in preparing a mixture used to produce 
yellow glass. The disturbances began 15-20 days after the introduction of a 
new mixture that was intended to produce a more satisfactory color than the 
old mixture [16], The previous mixture contained carbon, sulfur, and sodium 
sulfate. In addition to these ingredients, analysis of the new mixture showed
1,04-1.74% antimony pentasulfide. The affected men were reported to have been 
exposed to unspecified large amounts of dust when they filled the mixer by 
shoveling and emptied it by pouring the mixture into trolleys. A worker's 
only respiratory protection was a single handkerchief applied over the mouth 
[16].
Case histories indicated that the workers began to feel ill 1-2 hours 
after their workshifts began. Vomiting was a usual occurrence. Malaise, 
nausea, abundant salivation, a pasty metallic taste, and diarrhea were common. 
Most workers felt better after vomiting [16],
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Clinical examination of the men yielded evidence of systemic toxicity 
[16], Analysis of the urine samples showed that antimony had reached the 
circulation. Urinary levels of antimony (determined by the colorimetric 
method of Maren [101]) ranged from 3 to 21 jug/100 ml and were virtually
unchanged 8 days later [16]. Exactly when the dust exposures were first 
determined was not stated.
In all the men they studied, Gallina and Luvoni [16] found metamyelocytes 
in the blood. Metamyelocytes constituted 2-6% of the total white cell count. 
Monocyte counts tended to be elevated, in one case to 15%. Hemoglobin values 
were generally found to be 90-100% of normal except for two cases that were 
66% and 82%. A decreased percentage of lymphocytes was seen in cases 5 and 6, 
although case 5 had 14,000 total leukocytes/ml of blood. Gallina and Luvoni 
suggested that these changes indicated a slight modification in the secondary 
leukopoiesis under the toxic stimulus of antimony.
The investigators [16] also reported rapid and very evident hepatic 
involvement. Clinical examination of the six employees exposed to antimony 
pentasulfide revealed enlarged livers with rounded edges that were painful 
upon palpation in several cases. Urobllinurla was present in all cases. 
Hepatic function tests were apparently not conducted, and no evidence of any 
renal involvement was observed.
Upper respiratory tract irritation was reported in 1966 by Taylor [96] 
following the exposure of seven men to antimony trichloride fume. Antimony 
trichloride as a 98% solution in concentrated hydrochloric acid was being used 
as a chemical catalyst in an unexplained enclosed process in which it was 
circulated at a high temperature (100 C) and pressure (about 7-14
atmospheres). Such a corrosive mixture occasionally produced leaks in the two 
nickel alloy reciprocating pumps. The men had complete protective clothing 
(neoprene suits, boots, gloves, and plastic eye shields or airline helmets), 
but six of the exposed men had removed the helmets or did not wear
respirators, and the seventh had taken no precautions at all. Exposure to the 
fume ranged from several minutes to 8 hours. Three men were exposed briefly 
to both fume and spray. Environmental measurements suggested that the workmen 
were exposed to air containing up to 146 mg/cu m of hydrochloric acid and 73 
mg/cu m of antimony. Taylor suggested that the transient (1-2 days)
irritation of the upper respiratory tract were due primarily to the HC1 vapor. 
Dyspnea and nasal ulceration were not seen in these workers.
Taylor [96] also noted slightly delayed gastrointestinal symptoms
experienced by five of the seven men exposed to the antimony trichloride.
Nausea, abdominal pain, and anorexia were the most common complaints; vomiting 
also occurred. The symptoms were somewhat delayed, usually occurring toward 
the latter part of the workday or on the following day. Anorexia persisted in 
one case for 10 days. Because antimony was found in excess of 1.0 mg/liter in 
the urine of five workers, Taylor concluded that the gastrointestinal symptoms 
were due to systemic action of antimony, not to local action as a result of 
ingestion.
Linch and Sigmund [82] attempted in 1976 to measure the health status of 
workers in a plant that manufactured antimony trioxide. Personal samples 
taken between 1971 and 1975 indicated antimony dust concentrations in the
range of 0.3-56 mg/cu m. Of 61 samples, 59 exceeded 0.5 mg/cu m of antimony.
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In the breathing zone samples, 25-40% of the dust was respirable as measured 
by a cyclone separator.
No acute reactions (ie, dermatitis, eye irritation, or pulmonary, 
gastrointestinal, or upper respiratory tract effects) were reported in the 37 
permanent workers then employed, or in any of the 499 workers employed since 
the plant began operations 24 years earlier [82]. However, information was 
not available regarding cause of death or the current health status of most of 
the 499 former employees. Further, no information was available from medical 
examinations performed before employment or after it ended. The limited 
medical records available (140 X-rays and reports for 52 workers) disclosed 
two cases of arteriosclerotic changes, one case of pericardial calcification, 
one lung cancer, two heart cases (undefined), and a death from cirrhosis of 
the liver. The authors [82] did not consider the observed medical episodes 
unusual in a total work population of that size.
Animal Toxicity
Short- and long-term animal exposures to antimony or antimony compounds 
have been reported to cause lung damage [9,102-105], myocardial damage 
[15,17,106,107], liver degeneration [17,102,103], splenic damage [102], and 
changes in the blood [17,102]. Skin effects following cutaneous contact were 
not observed in the animals studied [104,108], LD50's of antimony compounds 
following oral, intraperitoneal (ip) and subcutaneous (sc) administration are 
listed in Table III-ll.
TABLE III-ll
LD50's OF ANTIMONY AND COMPOUNDS
Compound Species Route LD50 
mg/kg
Ref .  
No.
Tartar emetic Rat oral 300 [17]
f t If
ip 11 [17]
Antimony trifluoride Mouse oral 804 [17]
t f II sc 22.9 [106]
Antimony Rat i-P 100 [17]rr Guinea pig II 150 [17]
Antimony trisulfide Rat ir 1,000 [17]
Antimony pentasulfide t l f t 1,500 [17]
Antimony trioxide If t f 2,250 [17]
Antimony pentoxide II f t 4,000 [17]
Bradley and Fredrick [17] conducted chronic feeding studies in rats in 
addition to LD50 tests. The animals were fed daily doses of antimony 
potassium tartrate and antimony metal up to 100 mg/kg and 1000 mg/kg, 
respectively, for up to 12 months. No tolerance was found to antimony at any 
dose level. Antimony potassium tartrate produced consistent and reproducible
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injury to the heart, indicated by what was described as an increase in the 
connective and fibrous tissues of the myocardium. There was a marked 
variation in the staining of myocardial fibers. These changes were similar to 
the cardiomyopathies observed in the hearts of the animals surviving the acute 
tests, which are described later in this section.
Levina and Chekunova [103] investigated the acute and chronic toxic 
effects of antimony trifluoride. Parallel experiments were conducted with 
other antimony compounds including antimony trioxide, trisulfide, and 
pentasulfide. To assess the toxic influence of the fluoride, experiments with 
sodium fluoride were conducted simultaneously with the antimony studies.
The LD50 for antimony trifluoride following a single sc injection in mice 
was found to be 22.9 mg/kg [103], Subcutaneous administration of antimony 
trioxide, trisulfide, and pentasulfide at 50 mg Sb/kg did not kill the animals 
or cause any significant toxic effects during the 10-30 days of observation.
Doses of 500 mg/kg of antimony trioxide or 100 mg/kg of sodium flouride killed
all the animals.
Levina and Chekunova [103] also reported that single intratracheal 
administrations to rats of antimony trifluoride, ranging from 2.5 to 20 mg, 
always resulted in death accompanied by labored breathing and convulsions 
attributed to asphyxia. Rats survived doses of 1.0-1.5 mg and appeared to be 
normal again after a severe loss of weight. Introduction of 20 mg of antimony
trioxide or trisulfide produced an unspecified weight loss in the treated
animals; no other signs of toxicity were reported. Rats survived 
administration of 5 mg of sodium fluoride in the trachea but not 10 mg. The 
authors [103] did not give the volume or acidity of the solutions used in 
these experiments. They noted that antimony trifluoride readily hydrolyzes, 
producing hydrogen fluoride. The marked local action of antimony trifluoride 
on lungs (described below) was believed to be due to the formation of the 
irritant hydrogen fluoride.
Levina and Chekunova also described the results of a 1-month study in
which 25 sc injections of antimony trifluoride or trioxide were given to rats, 
in each case at a dose of 89 (ig Sb/kg. Antimony trifluoride produced a severe 
local reaction that limited the study to 1 month. Compared with controls, 
antimony trifluoride produced a significant reduction of weight and, near the 
end of the month, a tendency toward hyperglycemia. Average blood sugar values 
expressed in mg/100 ml were 141 +29 for antimony trifluoride, 115 +16 for 
antimony trioxide, and 92 +4 for controls. No differences were found in
oxygen consumption or central nervous system integration, though the tests
used were not explained. At the end of the study, the rats were killed and 
various organs were taken for examination. Weights of the lungs, adrenals, 
and kidneys as compared with those of controls were signicantly increased in 
the antimony trifluoride-treated animals. Less severe changes were observed 
in the antimony trioxide-treated animals, described only as vascular 
distensions and small hemorrhages in parenchymatous organs [103],
Gross et al [108] reviewed their findings in 1955 on the effects of 
antimony trioxide in rats by several routes of administration. A single oral 
administration of 2.5 g of antimony trioxide, approximately 16 g/kg of body 
weight, produced no ill effects. No deviation from controls was observed in
growth rate or food consumption during 30 days after oral antimony 
administration. A single intraperitoneal injection of 200 mg of antimony
44
trioxide produced some peritoneal adhesions seen at examination 2 months later 
in all three rats tested. The dust deposits were attached to the peritoneal 
wall as capsules, confined by a thin connective tissue. One year after the
injection, no adhesions and only very small foci of dust deposition were 
found. No significant alterations were observed in the liver, kidney, spleen, 
or intestinal walls.
No abnormalities were noted in the organs of rabbits receiving one iv 20- 
mg dose of antimony trioxide nor in rabbits receiving repeated iv injections 
totaling 200 mg (53 mg/kg) at 2-day intervals. The animals were observed for 
up to 1 year. In an extended study, 2% antimony trioxide added to a basal
diet caused animals to gain weight at a slower rate than controls, No gross
or microscopic abnormalities of organs or tissues were noted after 7.5 months 
at the end of the feeding experiment [108],
Felicetti et al [109] studied clearance of inhaled trivalent and 
pentavalent radio-labeled antimony aerosols. In a tartrate complex, 124Sb was 
used as the tracer. Twenty hamsters were exposed to the trivalent and 34 to
the pentavalent aerosols. The median aerodynamic diameters determined from 
radioactive distribution of both aerosols was 1,6 tm ; therefore, differences 
observed in the biologic behavior of the aerosols were attributed to valence 
state.
Whole-body clearance of both aerosols occurred in two phases; the initial 
clearance, which was rapid, eliminated 90% of the day 1 body burden by the 7th 
day after exposure. The average body burden on the first day after exposure 
for the trivalent and pentavalent aerosols was 65% and 60%, respectively, of 
that found in animals killed on the day of exposure. This indication of rapid
24-hour clearance was followed by a slower clearance phase during which the 
remaining antimony was eliminated with a biologic half-life of about 16 days. 
No statistically significant differences in excretion patterns were observed 
between the two aerosol groups [109].
Distribution of blood antimony between red blood cells (RBC), and plasma 
differed with the two valence states. Uptake of trivalent antimony by the RBC 
was more rapid than with pentavalent antimony, but at 24 hours the ratios of 
antimony in the RBC to the serum were similar regardless of the valence [109],
Tissue concentration and retention data, corrected for physical decay, 
indicated the solubility of both aerosols by their rapid loss from the lungs 
[109], Two hours after exposure, when the first animals were killed, less 
than 1% of the body burden of either aerosol remained in the lungs. High 
gastrointestinal tract content in animals killed early in the experiment 
probably resulted from considerable upper respiratory tract clearance. Tissue 
deposition patterns in the two aerosol groups were similar, with greatest 
antimony concentrations in the liver, skeleton, and pelt. However, a 
significant difference was the greater deposition of trivalent antimony in the 
liver. This indicated to the authors [109] that extensive reduction of 
pentavalent to trivalent antimony had not occurred. Apparently, deposition in 
the heart did not differ from that in other muscle tissue, because the heart 
was not discussed. Trivalent antimony was consistently found in higher 
concentrations in muscle than was pentavalent, but these concentrations were 
not among the higher levels found.
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The degree of uptake of inhaled antimony probably depends on particle size
and solubility [104,110], According to Thomas et al [111], both of these
factors can be influenced by the temperature at which antimony aerosols are 
generated. They [111] found that particles formed at 100 C were more soluble 
and had a greater aerodynamic diameter (1.6 nm) than particles generated at 
500 C (0.7 tim) and at 1,000 C (0.3 ¿zm) . It was speculated that the tartrate 
became an oxide at the two higher temperatures. Larger particles resulted in 
greater deposition in the upper respiratory tracts of dogs and mice and were 
cleared more rapidly from the lungs [111],
(a) Effects on the Heart
Death was attributed to myocardial failure in experiments conducted by
Bradley and Fredrick [17], reviewed in part earlier (Table III-ll). Rats
dying a few days after injection showed labored breathing, weight loss,
general weakness, hair loss, and evidence of myocardial insufficiency. 
Myocardial congestion with engorgement of cardiac blood vessels and dilation 
of the right heart were noted. Experiments with guinea pigs showed similar 
changes [17].
Microscopic changes in the hearts of animals surviving the LD50 tests were 
also found by Bradley and Fredrick. They [17] observed a marked variation in
the staining of myocardial fibers. Intensely red staining cells showed
indistinct fibrillar structures. The changes appeared more numerous in the
subendocardial and epicardial zones. A fine stippling of dark staining
pigment was present within numerous muscle fibers and was more noticeable in 
animals receiving antimony metal. In the hearts of the group receiving 
antimony potassium tartrate there was an increase in "connective and fibrous 
tissues of the myocardium" [17].
Brieger et al [15], in 1954, exposed rats, rabbits, and dogs to dusts
containing concentrations of antimony trisulfide ranging from 3.07 to 5.6 
mg/cu m for 7 hours/day, 5 days/week for at least 6 weeks. Most inhaled
particles measured 2 p  or less. Parenchymatous degeneration of the
myocardium was found in rats and rabbits. Definite and consistent functional 
disorders of the heart were manifested by ECG changes, primarily a flattened T 
wave.
Bromberger-Barnea and Stephens [106] reported in 1965 that antimony sodium 
and potassium tartrates produced a progressive decrease in myocardial 
contractile force when injected as a single dose of 10-15 mg/kg body weight 
into the coronary circulation of isolated canine hearts. This decrease was 
not reversible. The same dose injected iv was fatal in intact open-chested 
dogs; death resulted within 120 minutes. ST segment changes were seen in the 
ECG's of both isolated and intact hearts.
(b) Effects on the Lungs
In 1945, Dernehl et al [102] reported pathologic changes produced in 
guinea pigs that inhaled antimony trioxide at concentrations averaging 45.4 
mg/cu m. Exposures were for 2 hours daily, 7 days/week for the first 3 weeks, 
and then increased to 3 hours daily. The total hours of exposure ranged from 
33 to 609. The authors [102] assumed that the maximal retention was 50%, from 
which they estimated a theoretical daily retention of 1.6 mg. Of 24 guinea
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pigs retaining amounts varying from 13 to 424 mg, all showed extensive 
pneumonitis; all those retaining 50 mg or more showed scattered subpleural 
hemorrhages [102],
Lipoid pneumonia developed in rats after inhalation of antimony trioxide 
for 25 hours/week over 14.5 months, according to a 1952 report by Gross et al
[105], Fifty rats were exposed at 100-125 mg/cu m; particles averaged 0.5 ^m. 
Antimony trioxide induced cellular proliferation, swelling, and desquamation 
of alveolar lining cells. Fatty degeneration became increasingly evident in 
the alveolar macrophages and led to subsequent necrosis and rupture of the 
cells. Lipids from these cells were demonstrable as sudanophilic droplets and 
crystals, were soluble in fat solvents, and gave a positive reaction for 
steroid. The authors [105] stated that pulmonary fibrosis appeared to be
secondary to the irritant action of the liberated lipids. The absence of 
fibrosis in lymph nodes, where antimony was heavily deposited, was considered 
evidence that antimony did not directly cause pulmonary fibrosis. Similar but 
less severe lesions were produced after intratracheal injection [105].
Gross et al [104] further studied the effects of antimony trioxide on the 
lungs and reported the results in 1955. Fifty rats were exposed at 
concentrations ranging from 100 to 125 mg/cu m for 25 hours/week over 14.5
months. Twenty rabbits were exposed at 89 mg/cu m, 25 hours/week for 10 
months. There were numerous spontaneous deaths due to pneumonia, especially 
among the rabbits. Of the experimental animals, 85% of the rabbits and 18% of 
the rats died. The difference between species was thought to be due to unlike 
clearance mechanisms, greater sensitivity of rabbit lung tissue, and the 
occurrence of more bacterial infections among rabbits. Microscopically, lungs 
of both species resembled the 1952 findings except there was a more pronounced 
interstitial pneumonia in rabbits, and less diffuse fibrosis. Lymph node
deposits of antimony in rabbits were small and few. Despite considerable
antimony trioxide in rat lymph nodes, there was no indication of fibrosis, a 
finding that Gross et al thought remarkable. Both species exhibited the 
pneumonitis considered secondary to lipid accumulation [104] .
Cooper et al [9], in 1968, presented the results of exposure studies of 
rats to powdered antimony ore or antimony trioxide at an aerosol concentration 
of 1,700 mg/cu m. The exposed animals consisted of two groups, each composed 
of 10 male and 10 female Sprague-Dawley albino rats. Use of control groups 
was not reported. Animals received from one to six exposures, 1 hour each, 
every 2 months, for 66 to 311 days with the trioxide and for 66 to 366 days 
for the powdered ore. Some animals from each group were killed and examined 
periodically during the experiment. Immediately after exposure to antimony 
ore, the lungs of some rats exhibited a generalized pulmonary congestion with 
mild edema, which the investigators [9] thought was the result of an acute 
chemical pneumonitis. This was predominantly a transitory response and was 
not seen in the group exposed to the trioxide. Exposure to the trioxide or 
the ore produced similar effects except for the acute response to the ore. At 
66 days after exposure to either antimony compound, dust-laden phagocytes were 
seen lying free within the alveolar spaces or intermingled with cells of the 
septa. In some rats there was a tendency for the cells to form small 
focalized deposits throughout the lung. With subsequent exposures, these 
focalized deposits became increasingly prominent. The phagocytic response 
persisted 311 days after trioxide exposure and 366 days after exposure to 
antimony ore without any appreciable chronic pneumonitis [9],
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Levina and Chekunova [103] reported in 1964 that a single dose of 2,5-20 
mg of antimony trifluoride in the rat trachea invariably proved to be fatal, 
with labored breathing and convulsions attributed to asphyxia. Post-mortem 
examination revealed acute serous or serohemorrhagic edema; the lungs were 
about three times their normal weight. Only with doses of 1.0-1.5 mg did the 
rats survive. Pulmonary edema apparently had occurred in the latter rats 
also, but it was reported that their lung weights had returned to normal after 
a month. Cellular infiltrations of interalveolar septa, areas of atelectasis, 
and areas where the bronchial epithelium had separated were evident. It is 
not clear whether the effects seen in these rats were due to antimony or to 
fluoride, or were agonal.
The only overt change produced by the introduction of 20 mg of antimony 
trioxide, trisulfide, or pentasulfide into the trachea was a reduction in 
animal weight for a few days. At inspection a month after the compounds were 
given, the lungs exhibited signs of macrophage reaction, collections of
lymphoid elements around vessels and bronchi, and atelectatic areas showing
accumulations of epithelioid cells [103],
(c) Effects on Blood
Dernehl et al [102] recorded blood changes in six guinea pigs that had 
inhaled antimony trioxide at concentrations averaging 45.4 mg/cu m. The 
affected guinea pigs had probably retained at least 293 mg of antimony 
trioxide in their lungs. White cell counts of the treated animals were lower 
than in controls. A. decrease in polymorphonuclear leukocytes and a relative 
increase in lymphocytes were the most outstanding feature of the differential 
cell counts. Red blood cell counts and hemoglobin values remained normal.
The blood of Bradley and Fredrick's [17] rats showed eosinophilia after 
LD50 doses of all compounds tested but was apparently otherwise normal.
(d) Effects on the Liver, Kidneys, Spleen, and Adrenal Glands
Dernehl et al [102] found that 11 of 15 rats retaining at least 77 mg of
antimony trioxide in their lungs had fatty degeneration of the liver. 
Hyperplasia of the lymph follicles of the spleen was also observed, as were 
phagocytes filled with antimony trioxide. Fifty percent of the spleens 
examined showed decreased numbers of polymorphonuclear leukocytes. There was 
also an abnormal amount of blood pigment in 62% of the spleens examined [102],
During their determinations of ip LD50's of antimony compounds, Bradley 
and Fredrick [17] found that the livers of nearly all experimental rats showed 
moderate periportal congestion and in some instances pigmentation by blood. A 
mild hepatotoxemia was seen, characterized by functional hypertrophy with many 
of the hepatic cells appearing cloudy with finely reticulated cytoplasm. 
Numerous plasma cells were found in the liver. In animals given antimony 
potassium tartrate, there was slight periportal connective tissue increase 
with capillary congestion and infiltration of a few lymphocytes into the 
livers. Antimony oxides produced no changes in the spleen, but in animals 
that received antimony metal or tartrate, there was a slight congestion and a 
moderate diffuse hyperplasia. Glomerular congestion with coagulated material 
in the tubules was seen in the kidneys of the animals given antimony metal or 
tartrate.
48
Levina and Chekunova [103] found that 25 sc injections (each 15 mg/kg over 
a 1-month period) of antimony trifluoride produced liver and kidney changes in 
rats. The liver showed a moderate degree of cloudy swelling, fatty 
infiltration, and areas of edema. The most marked degenerative changes were 
seen in the kidneys, including cloudy swelling of the epithelial cells lining 
the convoluted tubules, nuclear pyknosis, karyolysis and desquamation of 
epithelium, hemorrhages, protein masses in the lumina of tubules, 
accumulations of cell elements between tubules, and occasional shriveled 
glomeruli [103].
Minkina et al [107] investigated the effects of antimony trioxide and lead 
acetate on the adrenals and on biologic amines in rats and reported the 
results in 1973. Antimony trioxide was administered sc five times a week for 
3 months, for a total dose of 165 mg (1/20 the LD50). No changes were 
observed after four injections of the antimony compound, but, after 20 
injections, a broadening of the cortical layer was found, due primarily to 
growth of the fascicular and retriculate zones. The cell size in these zones 
was increased, as were the nucleus diameter and monoamine oxidase activity. 
The authors [107] indicated that these were signs of increased adrenocortical 
functional activity, which virtually disappeared after 35 injections and were 
completely gone after 47 injections. Minkina et al considered this finding an 
example of what was translated as habituation to a toxin but did not explain 
the phenomenon.
(e) Effects on Skin and Eyes
Gross et al [108] described the irritant properties of antimony trioxide 
on rabbits and rats in a 1955 report. Acute tests of the eye and skin were 
performed, and an extended study investigated the effect of antimony trioxide 
on the healing of open wounds. The antimony trioxide used in these 
experiments had an average particle size of 1.3 jum and contained up to 0.2% 
arsenic as a contaminant.
The eye irritation tests were conducted by Gross et al in three groups of 
10 rabbits each according to the method of Carpenter and Smyth [112]. A 1-ml 
aqueous suspension, containing 1.50 mg of the dust, was instilled in the right 
eye of each animal; the left eye served as a control. Examination of the 
eyes at 1, 2, and 7 days showed no irritative effects of the conjunctiva or
the cornea [108],
Cutaneous toxicity tests were conducted in three groups of eight rabbits 
each [108], Antimony trioxide dust (2.6 g) was incorporated into an aqueous 
methyl cellulose paste and applied lightly to about two-thirds of the torso 
which had been carefully clipped 24 hours earlier. The treated area was 
covered, and the material held in contact with the skin for 1 week. Gross et 
al [108] reported no significant local reactions from the single application. 
Signs of systemic toxicity were not observed, indicating to the authors [108] 
that absorption through the skin had not taken place. No data on antimony in 
the blood or excretion of antimony were given.
The effect of antimony trioxide on wound-healing was also investigated 
[108], though the rationale for this type of experiment was not given. One 
gram of dry antimony trioxide powder was packed into a 2.5-cm incision on the 
shaved back of each of 10 rats. A duplicate incision made on the opposite
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side that was left undisturbed served as a control. Although the dust-filled 
wounds tended to heal somewhat slowly, Gross et al believed that the delay was 
within the limits that could be expected with any nonspecific foreign body.
In another type of wound-healing experiment, Gross et al [108] excised 
circular areas 1 cm in diameter by electrocautery from the shaved backs of 
rabbits and rats. Five wounds were made on each animal. The wounds were
dusted with 100 mg of antimony trioxide and then covered by a membrane that
was cemented to the surrounding skin. The lesions were inspected
periodically, and some were totally excised for microscopic examination after 
1 week, 2 weeks, or 1 month. According to the authors [108], the wounds 
healed cleanly and rapidly.
(f) Carcinogenicity, Mutagenicity, Teratogenicity, and Reproductive 
Effects
Several reports suggestive of potential carcinogenic, mutagenic, or 
reproductive effects in animals following exposure to antimony have been 
published. The report of most concern in this section is the 1967 paper by 
Belyaeva [13], which is the only evidence of adverse effects on reproduction 
due to antimony exposure.
Animal studies were undertaken following Belyaeva's observations of 
reproductive disorders among women working at an antimony metallurgical plant 
(discussed under Epidemiologic Studies). Rats were given single and multiple 
exposures extending over 60 days to antimony, and their reproductive function, 
litter size, and weight of offspring were studied.
In the acute experiment, Belyaeva [13] injected antimony metal dust 
(diameters up to 5 fm ) in a single ip dose of 50 mg/kg to each of 30 female 
rats. The animals were mated while in estrus, 3-5 days after treatment.
Fifteen became pregnant; 8 at the first mating, 5 at the second mating (1 
month after treatment), and 2 only after the third mating. Of the 15 rats 
that failed to conceive, 6 were mated once, 7 twice, and 2 were mated three 
times. In the control group, only one rat failed to conceive after mating 
once. The experimental animals that became pregnant produced fewer offspring 
per animal than controls (5.7 vs 7.8) (see Table 111-12).
In the second experiment [13], 24 female rats repeatedly inhaled antimony 
trioxide dust 4 hours daily for 1.5-2 months, at a concentration of 250 mg/cu 
m. Procedures for mating were like those used in the acute experiment except 
that dust exposure continued after mating until 3-5 days before delivery, when 
the rats were moved to individual cages. Sixteen of the 24 exposed rats 
conceived. The ten control females all became pregnant.
Table 111-12 shows that the number of pups born to antimony-exposed dams 
was less than that of controls (6.2 vs 8.3). No other differences were noted.
Microscopic studies of 23 rats (from both the single and repeated exposure 
groups) showed uterine and ovarian changes which, Belyaeva suggested, would 
tend to interfere with the process of maturation and development of egg cells. 
The ovarian follicles either lacked ova or contained uncharacteristic ova. 
Cortical hyperemia of the ovaries and follicular cysts were common, as was 
metaplasia of the uterus. In some animals, the tubes also showed metaplasia. 
These effects on the reproductive organs were most clearly seen in the animals
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treated ip with metallic antimony. In the rats exposed by inhalation to 
antimony trioxide, the most notable changes were in the lungs, liver, kidneys, 
and pancreas; changes in reproductive organs were not as clearly expressed 
[13].
TABLE III-12
EFFECTS OF ACUTE AND CHRONIC EXPOSURES TO ANTIMONY
ON 'THE LITTER SIZES AND WEIGHTS OF NEWBORN RATS
Exposure No. of 
Females
Mean Weight 
of Dams 
(g)
Mean
Litter
Size
Weight of 
Infants at 
Birth (g)
Weight of 
Infants After 
3 Weeks (g)
Single ip Metallic Antimony
Exposed 30 190.0 +5.2 5.4 +0.2 5.5 +1.1 32 +9.2
Control 12 188.5 +2.5 7.8 +0.5 5.4 +0.5 28.1 +0.4
Repeated Inhalation Antimony Trioxide
Exposed 24 195.5 +7.2 6.2 +1.0 5.6 +1.2 25.2 +2.8
Control 10 197.8 +14.0 8.3 +0.2 5.5 +1.6 23.5 +3.4
Modified from Belyaeva [13]
The reproductive organs of the treated rats that became pregnant were 
found to be normal except for some changes among the acutely treated rats. 
Uterine metaplasia and follicles without egg cells were observed in a few 
cases. Gross inspection of the placentas and newborns, and microscopic 
examination of several fetuses showed no morphological changes [13], Belyaeva 
concluded from these findings that antimony may adversely influence the 
condition and function of the reproductive apparatus. The report cannot be 
regarded as conclusive, however. There was no discussion of vaginal smears; 
it is unclear how the author [13] determined that mating had occurred. Rates 
of resorption and fetal death among the experimental and control groups were 
likewise not discussed. A definitive interpretation of Belyaeva's [13] work 
is not possible without further evidence.
Casals [113], in a 1972 report, administered a solution of antimony 
dextran glycoside containing 125 or 250 mg Sb/kg to pregnant rats on five 
occasions between the 8th and 14th day of gestation. No fetal abnormalities 
were observed nor could the drug be detected in the six fetuses examined.
Andronikashvili et al [114] investigated the concentration of some heavy 
metals in nucleic acids in the process of neoplastic growth. In 1974, they 
[114] reported that RNA and DNA isolated from tumor tissues in rat livers 
(Sarcoma M-l and Walker-256 carcinosarcoma) contained considerably greater
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amounts of a number of trace elements including antimony than those found in 
DNA and RNA isolated from the livers of control rats. The role of metals in 
nucleic acids during normal and neoplastic growth has not been explained, 
making interpretation of these results difficult [114].
In 1972, Trifonova [115] reported on the distribution of antimony in 
tumorous rats. Ten rats received grafts of sarcoma-45 tumors; 10 others were 
controls. All animals received five ip injections of metallic antimony 
totaling 300 mg/kg suspended in peach oil [115], Antimony was found to have 
accumulated in greater concentrations in the lungs of the tumorous rats than 
in controls. Antimony concentrations in muscles and skin of tumorous rats 
were also greater than in controls. The spleens and livers of both groups 
showed small concentrations of antimony. The author [115] did not speculate 
on the meaning of these results.
The carcinogen 3,4 benzo(a)pyrene, injected simultaneously with antimony 
into rats, was taken up by the lungs in greater amounts (21%) than in animals 
treated with benzo(a)pyrene alone, according to Erusalimski and Suspa [116].
Kanisawa and Schroeder [117] reported in 1969 that 76 mice given 5 jug of 
antimony potassium tartrate/ml of drinking water throughout their lifetimes 
showed no increased incidence of tumors or other indications of
carcinogenesis. There were 71 control mice.
Correlation of Exposure and Effect
Exposure to antimony and its compounds in the occupational setting has 
been associated with numerous health problems, including dermatitis and mucous 
membrane irritation, pneumoconiosis, ECG alterations, hepatic involvement, and 
hematologic changes. Many of these symptoms have also been described
following occupational exposure to arsenic, a common contaminant of antimony 
ores and antimony compounds used in industry. Confounding exposures have made 
it difficult to evaluate cause-and-effect relationships. Studies of the 
effects of therapeutic administration of antimonial drugs are relevant because 
the antimony given has been considered responsible for heart, hematologic, 
hepatic, and renal abnormalities in the absence of arsenic contamination.
(a) Effects on the Heart
Two epidemiologic studies have implicated antimony in heart disease and 
ECG alterations among workers [11,15], Brieger et al [15] noted eight deaths, 
attributed to heart disease, following occupational exposure to antimony 
trisulfide at relatively low airborne concentrations (0.58-5.5 mg/cu m). 
According to the report, most samples were over 3.0 mg/cu m; however, no 
information on frequency and duration of sampling was given. In the 
department where the deaths occurred, 37 of 75 workers showed ECG changes,
primarily of the T wave. There was only one death in 16 years preceding the
use of antimony trisulfide, and there were no further deaths reported after 
the use of antimony trisulfide was discontinued.
Following the deaths, Brieger et al [15] exposed rats, rabbits, and dogs 
to the same dust present in the work environment. Rats and rabbits exposed at
3.07 and 5.6 mg/cu m, respectively, 6 hours/day, 5 days/week for 6 weeks 
appeared to be normal but showed definite and consistent ECG changes. The T
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waves were especially affected. Dogs were exposed at 5.5 mg/cu m 7 hours/day, 
5 days/week for 10 weeks; their ECG's were reported to suggest some myocardial 
injury, but the changes were not specified.
Klucik and Ulrich [11] found abnormal ECG’s in workers exposed to antimony 
trisulfide and trioxide in a metallurgical plant. The ECG changes consisted 
of T wave depression, borderline normal QT waves, prolongation of 
atrioventricular and QRS transmission, and changes in the ST segment. All 
workers with ECG alterations also had symptoms that the authors [11] 
considered to be indicative of heart problems. The concentrations reported 
(1.3-237 g Sb/cu m) could have been a result of editorial error, sampling 
error, or may actually have been accurate measurements of extremely high 
concentrations. There was also known arsenic contamination.
These two studies [11,15], implicating antimony trisulfide and a mixture 
of antimony trisulfide and trioxide, are the only evidence of adverse effects
on the heart in workers. Cooper et al [9] found no ECG changes in seven
workers exposed to antimony trisulfide ore and antimony trioxide, although one 
case of slight bradycardia was noted. Karajovic [6] did not find ECG
alterations among workers exposed to antimony trioxide and pentoxide dust that 
contained 0.3-0.9% arsenic trioxide. Investigators of other antimony 
compounds have not reported the measurement of worker ECG's [5,7,10,12,13,16], 
In rats, Bradley and Fredrick [17] reported myocardial damage following 
exposure to antimony metal, antimony potassium tartrate, antimony tri- and 
pentasulfide, and antimony tri- and pentoxide. Bromberger-Barnea and Stephens
[106] reported a progressive decrease in myocardial contractile force in open- 
chest preparation dogs that ended in death following a single 10-15 mg/kg iv 
dose of antimony sodium or potassium tartrate.
The evidence needed to characterize the effects of various antimony
compounds on the heart is far from complete. A primary problem in these 
determinations is identifying what, if any, influence is exerted by arsenic. 
Industrial antimony compounds are generally contaminated with small amounts of 
arsenic, a substance also associated with myocardial damage and ECG changes 
[89-93] ; thus, it is difficult to ascribe observed ECG changes in antimony 
workers to antimony itself.
Pharmaceutical grades of antimony, however, contain no significant amounts 
of arsenic; therefore, effects due to arsenic should not occur following 
exposure to these compounds. Unfortunately, no data are available on antimony 
exposures in pharmaceutical workers. However, it is highly significant that 
patients who received arsenic-free antimony drugs in treatment against 
parasitic infections [36-45,49-50] showed essentially the same ECG changes as 
those observed among the antimony workers [11,15], and in animals exposed to 
antimony compounds [15,17], The common denominator in all of these situations 
was antimony.
(b) Effects on the Lungs
Both Renes [5] and Karajovic [6] reported respiratory illnesses 
accompanying dermatitis and mucous membrane irritation in the worker 
populations they studied. Renes stated that pneumonitis and bronchitis 
occurred in workers exposed to antimony trioxide at 0.40-70.7 mg/cu m. 
Karajovic reported that of 101 men working at an antimony smelter exposed to 
concentrations of mixed dust totaling 16-248 mg/cu m that included silica with
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antimony oxides, 4 had tuberculosis and 22 had emphysema with bronchitis. 
These symptoms were probably more related to silica than to antimony exposure.
Karajovic conducted X-ray examinations of 62 of the workers, which 
revealed 14 cases of pneumoconiosis, all without fibrosis. Ventilatory 
function was normal in three workers, slightly reduced in four, and not tested 
in the remaining individuals. Antimony oxides, representing the bulk of the 
dust load, most likely caused the pneumoconiosis, but the cause of the 
slightly reduced ventilatory function is not clear.
McCallum [12,79] reported 44 cases of pneumoconiosis in 262 workers 
exposed to antimony trioxide and metal dusts at concentrations reported to 
exceed 0.5 mg/cu m. The pneumoconiotic workers seemed to be free of symptoms. 
Microscopic examination of a lung section from a deceased antimony worker 
showed an accumulation of dust and dust-laden macrophages lying in alveolar 
septa and perivascular tissues, but there was no fibrosis or inflammation 
[79], This finding might be expected in most work situations where large 
amounts of dust are generated and inhaled.
Cooper et al [9] reported 3 definite and 5 suspicious cases of 
pneumonconiosis from a group of 28 workers exposed to antimony ore and 
antimony trioxide in concentrations ranging from 0.08 to 138 mg/cu m, with 
most exposures under 10 mg/cu m. Unspecified decrements in pulmonary function 
were observed in 4 of 14 workers tested, which presumably included the workers 
with pneumoconiosis.
Le Gall [7] reported pneumoconiosis in 10 of 40 workers exposed to 0.3-
14.7 mg/cu m containing antimony metal and trioxide. Airborne silica and 
sulfur dioxide were also present. X-ray examinations showed moderate, dense 
reticulo-nodular formations scattered throughout the pulmonary fields. 
Shortness of breath, coughing, some expectoration, prolonged expiration, and 
sparse adventitious sounds were noted. Antimony dust was probably responsible 
for the pneumoconioses, though silica cannot be disregarded. One affected 
employee had worked only at the oxide furnace, where antimony exposure could 
be assumed to be high and silica exposure low or nonexistent [7],
Animal experiments have resulted in lung changes similar to those 
described in workers. Dernehl et al [102] found pneumonitis in guinea pigs 
exposed to antimony trioxide at concentrations averaging 45 mg/cu m for 33-609 
hours. In addition, subpleural hemorrhages were seen with the heavier 
exposures. Lipoid pneumonia and pulmonary fibrosis were reported by Gross et 
al [105] in rats repeatedly exposed to antimony trioxide at 100-125 mg/cu m.
Fibrosis has not been reported in humans following levels of exposure common
to the occupational environment.
In describing the effects of high (1,700 mg/cu m) intermittent exposure to 
antimony trioxide or antimony ore on the lungs of rats, Cooper et al [9] noted 
dust-laden phagocytes lying free within the alveolar spaces or intermingled 
with cells of the septa. In some rats, the phagocytes formed focalized
deposits throughout the lungs. These observations are similar to those of 
McCallum [79], who described the lungs of a deceased antimony worker.
Macrophage reaction in rats was also noted by Levina and Chekunova [103] 
following intratracheal administration of 20 mg of antimony trioxide, 
trisulfide, or pentasulfide. Animal studies have not addressed the issue of
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pulmonary function impairment, but the decrements noted in humans by several 
investigators [6,7,9] may suggest functional impairment of the lungs as a
result of antimony exposure.
(c) Skin and Mucous Membrane Effects
Dermatitis and mucous membrane irritation are two prevalent complaints of 
antimony workers; arsenic, however, produces the same effects [87-89], One 
author [81] considered arsenic wholly responsible for the observed skin
condition. Opinions have differed as to whether the dermatitis was an 
allergic response [77] or due to local irritation [78,81],
Renes [5] recorded the full range of skin and mucous membrane effects 
among smelter workers exposed to antimony (0.40-70.7 mg/cu m) with concomitant 
exposure to arsenic (0,02-4.66 mg/cu m). Twenty percent of the workers had
dermatitis, which was usually found in sweaty, hairy, friction areas of the 
body. Most cases occurred during a 1-week period of heavy exposure (LE Renes, 
written communication, March 1978). Numerous cases of irritation of the 
conjunctival, nasal, and respiratory mucous membranes, and ulceration of the 
nasal septum and larynx were also seen, Renes noted that many common early 
signs of arsenic intoxication were not present in these workers [5].
Karajovic [6], like Renes, described respiratory tract irritation,
conjunctivitis, ulcerated nasal septa, and dermatitis in antimony smelter
workers. The dermatitis was more prevalent during the summer months. Of 16 
workers with skin problems, 13 worked at the blast furnaces in hot
temperatures with resulting perspiration.
Stevenson [78] also pointed out the importance of heat in the occurrence 
of the dermatitis. Two furnacemen who worked with one side of their bodies
next to heat had lesions only on that side. The major site of irritation in
other workers was the antecubital area of the forearms where rubbing and 
perspiration occurred. Patch tests using dry antimony trioxide or antimony 
trioxide suspended in water produced no positive reactions. These findings 
are compatible with those of Thivolet et al [81], who observed that dermatitis 
was produced in patch tests with scarification, but not without scarification. 
Skin tests on rats and rabbits by Gross et al [108] showed no effects.
Microscopic examination of the lesions studied by Stevenson [78] showed 
them to be adjacent to sweat ducts. Stevenson noted that antimony trioxide is 
slightly soluble in water, but soluble in lactic acid, which is present in 
sweat in increased amounts following heavy exercise. He believed the 
dermatitis resulted from antimony penetrating the sweat ducts and causing 
local irritation of the underlying dermal tissues.
Although Paschoud [77] regarded the dermatitides as allergic, the local 
irritant response appears to be a more reasonable conclusion. The observed 
irritant effects appear to be attributable to antimony, even though arsenic 
may have been a factor.
(d) Effects on Blood
Exposure to antimony has been associated with blood profile alterations. 
Gallina and Luvoni [16] found evidence of slightly abnormal leukopoiesis in 
all six workers they studied who were exposed to antimony pentasulfide.
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Metamyelocytes were present as 2-6% of the differential white cell counts, and 
monocytes were also elevated.
Thrombocytopenia and lymphocytosis in type foundry workers were noted by 
Seitz [24], and one case of slight anisocytosis in a worker exposed to
antimony trioxide was reported by Oliver [10] . These two reports are more 
than 40 years old and probably represent high exposures.
Lowered white cell counts, a decrease in polymorphonuclear leukocytes, and
lymphocytosis were found in guinea pigs following very heavy exposure to
antimony trioxide (such that at least 293 mg was retained in the lungs), 
according to Dernehl et al [102], Bradley and Fredrick [17] reported 
eosinophilia in rats that had received the LD50 dose of antimony.
Severe hemolysis occurred in three metal refinery workers exposed to a 
gaseous mixture containing unspecified high concentrations of stibine, arsine, 
and hydrogen sulfide, according to Nau et al [97],
Antimony therapy for schistosomiasis, which has involved very high 
therapeutic doses of antimony, has been linked to hemolytic anemia, 
thrombocytopenic purpura, and eosinophilia [56-58]. These cases are rare. It 
is significant that all human and animal blood changes that have followed 
exposure to antimony have involved extreme levels of exposure that would be 
unusual in the workplace.
(e) Hepatic Effects
Gallina and Luvoni [16] reported hepatic involvement in six workers 
exposed to a coloring mixture containing 1.04-1.74% antimony pentasulfide. 
The livers were enlarged in all cases and painful upon palpation in some. 
Urobilinuria was present in all six workers. Karajovic [6], however, noted a 
lack of liver symptoms among smelter workers. Antimony has not been 
implicated in liver involvement by other authors.
In animals, fatty degeneration of the liver was demonstrated by Dernehl et 
al [102] in rats retaining 77 mg or more of antimony trioxide. Bradley and 
Fredrick [17] found that the livers of nearly all LD50 experimental rats 
showed moderate periportal congestion. There was functional hypertrophy, with 
many hepatic cells appearing cloudy with finely reticulated cytoplasm. Plasma 
cells were found in the liver.
Elevated liver enzymes, SGOT and SGPT, in patients receiving antimony 
drugs [44,57,61,62] indicate that antimony may adversely affect the liver at 
therapeutic doses. Elevated SGOT and SGPT, however, may also indicate damage 
to the heart. ECG alteration was not correlated with SGOT elevations by Waye 
et al, indicating to them [44] that SGOT was a measure only of hepatic damage 
during antimony treatment. It was noted, however, that more frequent SGOT 
determinations might have revealed a higher incidence of SGOT elevation in 
patients showing ECG alterations [44]. Consequently, the effect of antimony 
on the liver remains unclear.
(f) Gastrointestinal Effects
Gastrointestinal effects related to occupational antimony exposure have 
not received extensive investigation, but have been mentioned in several
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studies. Brieger et al [15] recorded a higher incidence of gastrointestinal 
ulcers in workers exposed at 0.58-5.5 mg antimony trisulfide/cu m than in 
unexposed workers. Renes [5] considered abdominal cramps, diarrhea, vomiting, 
dizziness, nerve tingling, and severe headaches to be systemic effects 
resulting from heavy exposure to antimony smelter fumes.
Gallina and Luvoni [16] noted malaise, nausea, frequent vomiting, abundant 
salivation, a pasty metallic taste, and diarrhea in six workers exposed to a 
mixture containing 1.04-1.74% antimony pentasulfide. The disturbances began 
15-20 days after the introduction of the mixture and were thought to be 
systemic [16],
Gastrointestinal symptoms noted by Taylor [96] were also considered to be 
of systemic origin. Five of seven men exposed to high concentrations of 
antimony metal (up to 73 mg/cu m) and hydrochloric acid (up to 146 mg/cu m) 
experienced nausea, vomiting, abdominal pain, and anorexia. Because antimony 
in urine of five workers exceeded 1.0 mg/liter, and because the symptoms 
persisted for up to 10 days, systemic action is more probable than local 
irritant effects arising from ingestion of the chemical. The same symptoms 
have been observed following parenteral administration of antimony drugs 
[35,37,43,47,56,58].
Carcinogenicity, Mutagenicity. Teratogenicity, and Effects on Reproduction
Firm conclusions cannot be drawn from the Davies [14] report suggesting an 
increased tendency to contract lung cancer in antimony workers. A 
retrospective survey was undertaken in 1962 following the lung cancer death of 
an antimony worker and the subsequent discovery of seven other lung cancer 
deaths among antimony workers in the preceding 8 years. Of 1,081 people 
formerly employed at the factory in question, 56 were known to be dead. Ten 
of these deaths were ascribed to lung cancer; 8 were to be expected from local 
mortality rates. Nine of the ten lung cancer deaths occurred among the 
factory subgroup engaged in smelting or related activies: 5.7 lung cancer 
deaths were to be expected in this group.
Recent followup information (KP Duncan, written communication, July 1978) 
again showed a disparity between observed and expected deaths due to lung 
cancer in the antimony factory population (21 vs 14.03), most of which 
occurred in the factory subgroup engaged in smelting and related activities 
(18 vs 10.25), The difference was especially prominent in workers 45-64 years 
old (13 vs 7,22). The absence of pertinent information, including community 
and factory population descriptions, data analysis, and environmental, blood, 
and urine antimony concentrations make it impossible to accept the findings 
without further scientific evaluation and confirmation.
Erusalimski and Suspa [116] reported that when the carcinogen 3,4 
benzo(a)pyrene was injected simultaneously with antimony into rats, it was 
taken up by the lungs in greater amounts than in animals treated with 
benzo(a)pyrene alone.
Kanisawa and Schroeder [117] reported no increase in the incidence of 
tumors in mice given 5 Mg antimony potassium tartrate/ml of drinking water 
throughout their lifetimes. Further animal studies to evaluate the cancer 
potential of antimony are in progress under a NIOSK contract.
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Evidence of effects of antimony on reproduction is confined to a single 
report by Belyaeva [13], A group of 318 antimony-exposed female workers was 
stated to have had higher incidences than controls of late-occurring 
spontaneous abortions (12,5% vs 4.1%), premature births (3.4% vs 1.2%), and 
gynecologic problems (77.5% vs 56%), which included menstrual cycle disorders, 
inflammatory disease, and other diseases of the reproductive apparatus. 
Inflammatory disease was the only category in which there were more cases 
among controls than exposed women, an unexplained finding. Exactly what 
constituted a menstrual cycle disorder was not stated.
The antimony workers studied by Belyaeva were exposed to mixed dusts of 
antimony metal, trioxide, and pentasulfide. Exposure duration and 
concentrations were not given, but concentrations of antimony in the blood of 
the exposed workers ranged from 0.5 to 20.0 mg/100 ml, and, in the urine, from 
0.5 to 18.2 mg/100 ml [13]. These levels are probably common among antimony 
workers.
Antimony was also found in the breast milk, placental tissue, amniotic 
fluid, and umbilical cord blood of the exposed group, indicating the presence 
of antimony in the developing fetus, as well as in the mother [13]. Belyaeva 
noted that antimony affected the taste of breast milk, a possible explanation 
for differences in mean weight of babies in control and exposed groups at 1 
year of age, assuming that breastfeeding was practiced. There was no followup 
of the children to ascertain trends in weight gain after the period of
breastfeeding.
Belyaeva's [13] animal studies supported the findings of human 
reproductive effects due to antimony. Rats given metallic antimony in a 
single ip dose of 50 mg/kg showed decreased ability to conceive, produced 
fewer offspring, and showed microscopic uterine and ovarian changes that were 
believed to complicate normal development of ova. Rats repeatedly exposed by 
inhalation to antimony trioxide at 250 mg/cu m produced fewer offspring than 
controls, but no clearly expressed changes were seen in the reproductive 
organs. The offspring of treated rats were unaffected.
The high control figures reported by Belyaeva [13] for the category of
gynecologic problems were unexplained. Reproductive effects ascribed to 
antimony have apparently not been studied by other investigators and need to 
be confirmed. Casals [113] reported that no antimony was detected in rat 
fetuses whose mothers had received im antimony dextran glycoside during
gestation; these results tend to conflict with those of Belyaeva. However,
Bradley and Fredrick [17] noted frequent abortions in rabbits given repeated 
high oral doses of metallic antimony.
Summary Tables of Exposure and Effect
The effects of short- and long-term exposures to antimony on humans and 
animals, presented in Chapter III, are summarized in Tables 111-13, 111-14,
and 111-15, Human data appear in Tables 111-13 and 111-14 and animal toxicity 
data are listed in Table 111-15.
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TABLE III-13
EFFECTS OF OCCUPATIONAL EXPOSURE TO ANTIMONY
Concentration Sb in
Compound mg/cu m Urine,
and Ref. No. (particle size) Duration mg/1 Effects
Inhalation
Antimony trisulfide
[15]
Antimony pentasulfide
[16]
0.58-5.5
NR*
Antimony trisulfide and 1.3-237 
antimony trioxide g/cu m (sic)
[11]
Antimony trisulfide, 
metal, and trioxide
[13]
NR
8-24 mo
15-20 d
NR
NR
0.8-9.6 ECG changes, cardiac
deaths, ulcers
.03-.24 GI upset, hepatic
involvement, blood 
profile alterations
NR ECG changes, hard
breathing, weakness, 
sweating, cough, 
chest pain
5-182 Female reproductive
problems, infant 
weight gain lower 
than normal
Antimony trioxide [5]
Antimony trioxide and 
pentoxide, arsenic 
trioxide (also 
silicon) [6]
Antimony trioxide and 
antimony metal [12]
0.40-70.7 
(most <1 Aim)
16-248 
for antimony 
(most <0.5 aon)
<6 mo
<0.5
«1 Aim)
NR
NR
Trace-
600
.025
Skin and mucous 
membrane irritation, 
respiratory illness, 
GI disturbance
Skin and mucous 
membrane irritation, 
tuberculosis
.425-,68 Pneumoconiosis, skin 
irritation
EFFECTS OF OCCUPATIONAL EXPOSURE TO ANTIMONY
TABLE III-13 (CONTINUED)
Compound 
and Ref. No.
Concentration 
mg/cu m 
(particle size) Duration
Sb in 
Urine, 
mg/1 Effects
Inhalation
Antimony trioxlde, 
antimony ore [9]
0.081-138 1-15 yr .007-1.02; 
most .07-,8
Pneumoconiosis
Antimony trioxlde [8] NR « 1  Atm) .5-35 yr NR II
Antimony oxide (also 
silica, S02) [7]
0.3-14.7 
(most <3 /an)
NR Undetected If
Antimony trioxide [14] NR NR NR Possible increased 
risk of lung cancer
[10] NR 2-13 yr Undetected Mild dermatitis, 
slight anisocytosis
[82] 0.3-56 
(0.57-1.46 pm)
NR .052-1.02 No effects
Antimony trichloride 
and HC1 [96]
73
146
Several 
min-8 hr
>1 Respiratory tract 
irritation, gastro­
intestinal symptoms
Skin Contact With Liquid
Antimony pentachlorlde 
[95]
One-time NR 2nd and 3rd degree 
burns, respiratory 
distress
*NR-Not reported
TABLE 111-14
EXPERIMENTAL AND THERAPEUTIC EFFECTS OF ANTIMONY ON HUMANS
Compound and Ref. No. Dose, mg Duration Effects
Experimental Patch Tests
Antimony trioxide (arsenic 
contaminant) [77]
- - Dermatitis
If [81] - - Dermatitis with scarif­
ication, none without
Antimony trioxide (0,29% arsenic) [82]
Therapeutic
— No effects
Antimony potassium tartrate [50] Therapeutic dose - Death, liver damage
Antimony tartrate (K or Na) [37] 522-913 10-41 d ECG changes
Antimony tartrate (K or Na)
stibophen, or anthiolimine [64-66]
Therapeutic dose - Rise of Herpes zoster 
infections
Antimony sodium tartrate [56] »I - Hemolytic anemia
[58] If - Thrombocytopenic purpura
Antimony dimercaptosuccinate [57] II - Eosinophilia, elevated 
SGOT, ECG alteration
n-Methyl glucamine antimonate [63] II - Nephritis
Trivalent organic antimony [52] 214-510 iv 2-9 d ECG changes
Pentavalent organic antimony [52] 4,950-19,350 iv 5-10 d No ECG changes
TABLE III-15
EFFECTS OF ANTIMONY ON ANIMALS
Compound Species Dose or 
Exposure
Effects Ref.
No.
Antimony potassium Rat 
tartrate 
Antimony metal 
Antimony trisulfide 
Antimony pentasulfide 
Antimony trioxide 
Antimony pentoxide
Antimony potassium "
tartrate 
Antimony metal 
Antimony trisulfide 
Antimony pentasulfide 
Antimony trioxide 
Antimony pentoxide
Antimony sodium or Dog
potassium tartrate
11 mg/kg
100 mg/kg 
1000 mg/kg 
1500 mg/kg 
3250 mg/kg 
4000 mg/kg
Single sublethal 
ip dose
10-15 mg/kg 
single iv dose
All LD50's, myocardial [17] 
failure, liver damage, 
eosinophilia, splenic 
changes with metal 
and tartrate
Chronic heart 
changes, liver 
damage with 
tartrate
[17]
Progressive decrease [106] 
in myocardial 
contractile force, 
then death
Antimony potassium 
tartrate
Antimony trisulfide
Mouse
Rat, 
dog, 
rabbit
5 Mg/ml drink­
ing water for 
lifetime
3.07-5.6 mg/cu m 
7 hr/d, 5 d/wk, 
for 6 wk
No increase in [117]
incidence of tumors
Heart disorders in [15] 
rats and rabbits
Metallic antimony Rat 50 mg/kg single 
ip dose
5 cc single
intratracheal
dose
5 ip injections 
totaling 300 
mg/kg
Failure to con- [13]
ceive, fewer off­
spring, changes in 
reproductive organs 
in females
Increased uptake of [116] 
carcinogen 3,4 
benzo-a-pyrene 
in lungs
Higher antimony [115]
levels in blood, 
lungs, muscles, and 
skin of tumorous rats 
than in controls
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TABLE 111-15 (CONTINUED) 
EFFECTS OF ANTIMONY ON ANIMALS
Compound Species Dose or 
Exposure
Effects Ref.
No.
Metallic antimony Rabbit
Antimony trifluoride Rat
Antimony trioxide 
or trisulfide
Rat
5-55 mg orally 
every other day 
for 30, 60, 90 d 
Larger doses
2.5-20 mg single 
intratracheal dose
1.0-1.5 mg single 
intratracheal dose
15 mg/kg 25 sc 
doses over 1 mo
20-mg single
intratracheal
dose
No effects [17]
Frequent abortions
Labored breathing, [103]
convulsions, death
Lung edema [103]
Liver, kidney [103]
damage
Weight reduction, [103]
macrophage reaction
Antimony trioxide
Antimony ore
Antimony trioxide
Guinea av 45.4 mg/cu m 
pig 33-609 hr
" av 45.4 mg/cu m 
138-609 hr
Rat 100-125 mg/cu m
25 hr/wk 14,5 mo
" 1,700 mg/cu m 1 hr/
2 mo over 66-366 d
1,700 mg/cu m 1 hr/ 
2 mo over 66-311 d
165 mg sc 5 times/ 
wk over 3 mo
250 mg/cu m 4 hr/d 
7 d/wk, 1.5-2 mo
Pneumonitis, sub- [102]
pleural hemorrhage
Liver degeneration, [102]
splenic damage, 
blood profile alter­
ations
Lipoid pneumonia [105]
Acute pulmonary con- [9] 
gestion, phagocytic 
response
[9]
Habituating effect [107]
on adrenals and bio­
logic amines, bio­
chemical imbalance 
in liver and brain
Fewer offspring, [13]
lung, liver, kidney 
and pancreatic 
changes
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TABLE III-15 (CONTINUED)
EFFECTS OF ANTIMONY ON ANIMALS
Compound Species Dose or 
Exposure
Effects Ref.
No.
Antimony trioxide 
<2% arsenic
Rabbit 1.5 mg/d to eyes 
for 1, 2, or 7 d
No effects [108]
tl II 25 g to skin for 
1 wk
11 [108]
11 Rat 1 g into wound Healed slowly [108]
tf Rat,
Rabbit
100 mg on wound 
for 1, 2, or 4 wk
No effects [108]
Antimony dextran 
glycoside
Rat 125 or 250 mg/kg 
of mother's weight 
im 5 time8 between 
days 8 and 14 
of gestation
No fetal abnormali­
ties, no antimony 
detected in fetuses
[113]
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IV. ENVIRONMENTAL DATA
Environmental Concentrations
In studying pneumoconiosis among smelter workers exposed to antimony 
trioxide, Cooper et al [9] found especially high concentrations at the bagging 
operations, where 138 mg antimony/cu m was measured. At ten other locations, 
concentrations ranged from 11 to 75 mg/cu m. At thirteen more locations, 
measurements ranged from 1.0 to 9.8 mg/cu m. A range of 0.081 to 0.95 was 
found at thirteen additional locations. No further specifications of these 
areas or the methods used in attaining the measurements were given.
McCallum [12] found the highest airborne antimony concentration in a 
smelter to occur during the tapping operation at the metal furnace. Duplicate 
samples of 1-2 cubic feet of air taken at breathing level on several days over 
3 weeks revealed that the antimony concentration reached 36.70 mg/cu m during 
this brief operation. The workplace air concentrations of antimony at 19 
other sample sites ranged from 0,53 to 5.34 mg/cu m. The analytical method 
and flowrate used were not given.
Renes [5] collected air samples in another smelter with an electrostatic 
precipitator except for the first 17 samples, which were obtained with the 
Greenberg-Smith impinger apparatus. Aliquots of each sample were analyzed 
chemically and spectroscopically. Results of these two methods did not vary 
by more than 2%. The average antimony concentration in the electric furnace 
zone was 10.1 mg/cu m before corrective measures had been instituted, and 4.7 
mg/cu m after these improvements. The average antimony concentration in the 
cupel zone measured 11.8 mg/cu m before, and 8.2 mg/cu m after the changes, 
Before and after electric furnace zone average concentrations of arsenic were 
1.10 mg/cu m and 0.8 mg/cu m, respectively. Cupel zone average arsenic levels 
were 0.4 mg/cu m both before and after changes. The zones had been 
established by what appeared to be a reasonable division after studying the 
smelting processes and the workers' medical situation. More of Renes's [5]
sampling data are presented in Tables III-6, III-7, and III-8,
Okawa [118] evaluated health hazards due to lead and antimony exposure in 
a plant that rebuilt internal combustion engines of all types. Operations 
included all phases of rebuilding, from tearing down old engines to touchup 
painting of newly rebuilt engines. Worker exposures to lead and antimony were 
measured with personal air sampling equipment. All samples were taken with
MSA Model G personal sampling pumps attached to Millipore cellulose membrane 
filters with 0.45-jim pores. The sampling rate was 1.8 liters/minute, and the 
sampling times ranged from 1.5 to 2.75 hours per sample.
A total of six samples were collected on five workers: the lead pot
assembler, two engine assemblers, a crankshaft grinder, and a valve grinder. 
Only two samples showed detectable concentrations of lead (above 0,006 mg/cu 
m); 0.18 mg/cu m was found in one of two samples taken on the lead pot
assembler, and 0.10 mg/cu m was found in the valve grinder's sample. Antimony 
levels in all six samples were below the limits of detection (0,02 mg/cu m) 
for the method used.
Two other health hazard evluations [119,120] demonstrated no detectable 
exposures to antimony. Gunter and Nelson [119] evaluated a plant that
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prepared camouflage netting for use by the military. Before the netting was
received at this plant, it was treated with antimildew agents containing lead, 
chromium, antimony, and tin. The process in question included unpacking the
netting, cutting it to specification, sewing an edge on the netting, and 
folding, repacking, and shipping it out again. Eight-hour breathing zone
samples taken on 25 workers were collected on AA filters using MSA Model G 
pumps operating at 1.5 liters/minute. Lead, chromium, antimony, and tin were 
analyzed by atomic absorption spectroscopy. All samples were below laboratory 
detection limits.
Moseley [120] evaluated the machinists' area/composing room of a large 
newspaper. The area was ventilated by a blower for air conditioning and 
heating with three ceiling exhaust vents. The source of antimony exposure was 
8-9% antimony content of molten lead being cast into pigs used for spacing.
Area samples were collected on 37-mm cellulose membrane filters with a Model G
MSA vacuum pump operated at 2 liters/minute and analyzed by atomic absorption 
spectrometry. In all samples, antimony concentrations were below the limits 
of detection for the method used.
In an industry-wide study of the antimony industry, Donaldson and Cassady 
[121] monitored air levels of three major antimony producers. All three 
plants produced antimony oxide, but exposures were different in several
respects. Two producers, Plants B and C, roasted antimony sulfide ore in
rotary kiln-type furnaces to produce antimony oxide. Plant A oxidized
antimony metal with air to form antimony oxide. Plant A was the only plant 
that produced antimony metal in addition to the oxide. Plant B manufactured 
several other chemicals besides antimony oxide. Plant B workers were exposed 
to soluble nickel, cadmium, and chromium as well as to antimony, arsenic, and 
sulfur dioxide, which were present in all the plants.
Personal samples were collected in the three plants [121]. The pumps worn 
by each worker during his shift (6-7 hours) operated at 2.0 liters/minute and 
collected dust on a 37-mm mixed cellulose ester membrane filters with 0.8-jtzm 
pores. General area sampling was also done. Analyses for both antimony and 
arsenic were performed by atomic absorption. Sulfur dioxide concentrations
were estimated with detector tubes.
Results indicated that antimony concentrations in general area samples 
from all three plants ranged from 0.01 to 5.6 mg/cu m; breathing zone 
concentrations of antimony were 0.05-8.7 mg/cu m [121]. Arsenic 
concentrations found in the general area samples from the three plants ranged 
from nondetectable to 3.4 Mg/cu m. Breathing zone concentrations of arsenic 
plants ranged from nondetectable to 87.0 Mg/cu m. Sampling data from all
plants are given in Tables IV-1 to IV-5. Essentially no sulfur dioxide was 
found in the plants except during upset furnace conditions at Plant A.
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TABLE IV-1
PLANT A
GENERAL AREA SAMPLE RESULTS, APRIL 1975
Location Total Time
(min)
Sb
(mg/cu m)
Â8
(mg/cu m)
Blast furnace 454 0.11 0.007
Slag tapping-blast furnace 454 0,26 0.0012
11 455 1.14 0.0024
Doubling furnace No. 2 451 1.13 0.0027
Starring furnace No. 1 458 1.12 0.0034
Starring furnace No. 2 457 0.52 0.0021
Casting area 453 2.02 0.0040
Warehouse 451 0.61 0.0018
Burner end of No. 1 starring 
furnace 437 1.24 0.0029
Oxide furnace 436 0.14 0.0011
Charge scale 417 0.36 0.0014
Change room 432 0.54 0.0006
Adapted from Donaldson and Cassady [121]
TABLE IV-2 
PLANT A
SUMMARY OF RESULTS OF AREA SAMPLING FOR ANTIMONY AND ARSENIC 
BY PLANT OPERATION, MARCH 1976
Sb As
Operation
No. of 
Samples
Range 
mg/cu m
Mean 
mg/cu m SD
Range 
mg/cu m
Mean 
mg/cu m SD
Oxide manufacture 6 0.09-3.07 2.23 1.11 0.008-0.37* 0.022 0,011
Doubles furnace 4 0.89-2.10 1.45 0,50 0.002-0.010 0.006 0,004
Singles furnace 4 0.41-1.83 1.27 0,63 0.005-0.013 0,009 0,003
Maintenance 9 0.09-6,21 0.94 2,00 0,001-0.018 0,005 0.007
Laborers 22 0.09-4.91 1.26 1,08 0.001-0.041 0,009 0.010
Miscellaneous 6 0.05-3,74 1.11 1.35 0.001-0.047 0,010 0,020
*One arsenic value of 0.160 mg/cu m believed to be in error was dropped 
before calculating the mean.
Adapted from Donaldson and Cassady [121]
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TABLE IV-3
PLANT A
PERSONAL AIR SAMPLE RESULTS, MARCH 1976
Operation/ Total Time Sb As
Occupation (min) (mg/cu m) (mg/cu m)
Oxide 
Furnace operator
If
If
If
Packer
If
455
464
460
471
457
470
0.090
2.980
3.070
2 .0 1 0
2.590
2.610
0.008
0.022
0.037
0.017
0.160
0.024
Singles Furnace 
Tapper
Conveyor operator
Doubles Furnace 
Furnace operator
Furnace helper
Maintenance 
Blacksmith 
Maint, man— shop 
Mechanic 
Mechanic shop 
Maint, welder 
Bricklayer
Laborer
505
480
466
460
401
456
437
455
431
480
447
440
447 
458 
470 
442 
440
448 
451 
477 
485 
482 
457 
466 
487 
454 
456 
468 
461 
427
1.62
1.22
0.41
1.83
1.30
0.89
2 .1 0
1.52
0.15
0.11
0.09
0.09
0.09
0.70
6 . 2 1
0.20
0.09
1.63
1.92
0.94
1.34
0.38
1.61
0.67
1.07
1.600
0.230
0.980
0.120
0.140
0.005
0.008
0.010
0.013
0,002
0.003
0 .0 1 0
0.007
0.001
0.001
0.001
0,002
0.002
0.002
0.017
0.002
0,001
0.013
0.009
0.002
0.041
0.004
0.013
0.005
0.005
0.009
0,003
0.007
0.001
0.001
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TABLE IV-3 (CONTINUED)
PLANT A
PERSONAL AIR SAMPLE RESULTS, MARCH 1976
Operation/ Total Time Sb As
Occupation (min) (mg/cu m) (mg/cu m)
Laborer 453 1.240 0.008
ft 454 1.880 0.010
ft 458 2.100 0.029
ft 443 0.470 0.002
tl 439 1.640 0.01111 441 4.910 0.025
ft 459 1.530 0.009ft 450 1.230 0.004
Sweeper— yard 458 3.740 0.047
Fork lift operator 464 0.580 0,002
Gardener 443 0.050 0.001
Scale operator 459 1.210 0,009
Warehouse operator 455 0.460 0,003ft 452 0.500 0,003
Other ' 225 0.69 0,002
If
Oxide furnace
360 1.92 0,008
operator 428 10.86 0,089
Laborer 456 10.24 0,044
Adapted from Donaldson and Cassady [121]
TABLE IV-4
PLANT B
AIR SAMPLING RESULTS, APRIL 1975
Job Description 
and Area
Type of Concentration 
Sample Antimony Arsenic Nickel
Furnace operator Breathing zone 1,25 0.039 —
If ft 3,25 <0,035 —
If If 0,21 <0.035 —
If tf 1,20 <0.035 —
f t ft 0.78 <0,035 —
ft General air 0,28 <0,035
f f tf 0.01 <0.035 0.018
f t ft 0.43 <0.035 —
ft tl 0.83 <0,035
Adapted from Donaldson and Cassady [121]
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TABLE IV-5
PLANT C
GENERAL AIR AND PERSONAL SAMPLES, JUNE 1975
Location Total Time
(min)
Sb
(mg/cu m)
As
(mg/cu m)
Type of 
Sample
Operator— new system 420 2.7 0,0169 Personal
Operator— miscellaneous 420 5.0 0,0267 II
Bagging & No. 4 man 420 8.7 0,0560 It
Ore dumper (Wore air hood; 
Sampler not under hood) 420 4.5 0,0155 II
Top of coders 400 5,6 0,0061 General
At bagging station 405 2.3 0,0143 ir
At ore hopper— operator 
wore air-supplied hood 405 2.8 0,0092 li
to dump ore 
Ore feed, second level 410 1.8 0.0017 ft
outside 
On I-beam over bagging 
operation 390 2.6 0.0162 it
At control panel 
At operator's desk
390 1.9 0.0105 ft
400 2,9 0,0147 it
Feed oxide, out-of-doors, 
2nd deck 405 5.3 0,0057 it
Adapted from Donaldson and Cassady [121]
Sampling and Analytical Methods for Antimony in Air
(a) Sampling Methods for Particulate Antimony
Although impinger and electrostatic precipitation methods have been used 
to sample antimony-containing aerosols [122,123], collection on filters is 
more appropriate for personal sampling [124], Reasons for filter preference 
include ease and convenience of use, less interference with work operations, 
and less chance for spillage. The collection efficiency of Millipore Type AA 
37-mm diameter filters for antimony potassium tartrate aerosol (1.08 mg Sb/ 
cu m), sampled at 1.5 liters/minute, was found to be 99,7% [125],
The antimony content of blank filters has been reported by several
authors. Some glass fiber filters have been found to contain relatively large 
amounts of antimony, up to 0.23 jug Sb/sq cm, or approximately 2.3 ng Sb on a 
37-mm filter [126], Such high blank values indicate that these filters are 
not acceptable for personal sampling, where as little as 1 /¿g Sb may be 
collected. Cellulose-mixed ester membrane filters were found by neutron 
activation analysis to have only 0,00024 ng Sb/sq cm (about 0,0024 ng on a 37- 
mm filter) [127]. Cellulose acetate membrane filters were reported to contain
0.000013 ng Sb/sq cm, or about 0.0013 ng on a 37-mm filter [128], Polystyrene
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filters used for area sampling were found to have blank values of 0.00018 fig 
Sb/sq cm, or about 0.0018 fig per filter [128], and less than 0.001 fig Sb/sq cm 
(0,01 fig per filter) [129,130].
(b) Sampling Methods for Vapors
Volatile antimony compounds include some of the halides, which either are 
soluble or decompose in water [131]. No reference to sampling methods for 
these compounds was found in the literature. The sampling method recommended 
for volatile antimony compounds uses a midget impinger containing 5% mercuric 
chloride in 6N hydrochloric acid. This will not distinguish individual 
volatile and particulate antimony compounds.
(c) Analytical Methods
Early analytical methods for antimony were based on reduction of antimony 
solutions by zinc, with evolution of stibine. The antimony deposited after 
pyrolysis of the stibine was determined gravimetrically [132] or 
colorimetrically [69]. The detection limits were 1-10 fig of antimony.
A number of wet chemical methods are available for the determination of 
milligram quantities of antimony in various alloys [133], but most are not 
sensitive enough for levels found in industrial hygiene work.
Fredrick described a sensitive colorimetric method for antimony based on 
rhodamine B in 1941 [99], The detection limit demonstrated for standard
solutions was 0.1 -fig of antimony/5 ml of solution. Although Fredrick [99] 
realized the potential application of the method in industrial hygiene, sample 
handling procedures were not considered. In 1945, an improved method
involving extraction of the metal-dye complex was described by Webster and
Fairhall [134], and wet-ashing methods for determination of antimony in 
biologic samples were developed by Maren [101],
Results of a collaborative test on a rhodamine B method were reported in 
1964 by the American Conference of Governmental Industrial Hygienists (ACGIH)
[135]. Ten laboratories participated in the analysis of three sample
solutions containing 3-8 fig antimony/ml. The overall coefficient of variation 
was 10,5%, and the average coefficient of variation within replicates for each 
analysis was 5%. Average recovery was 105,2%, As a result of this test, 
cooled reagents became required. The improved method was subsequently
recommended by ACGIH for air and biological samples [122], by NIOSH for urine
[136], and by Tabor et al for air samples [124]. The working range for a 50- 
liter air sample is 0,02-0.4 mg Sb/cu m.
Several other less thoroughly studied colorimetric methods have been 
published. These include procedures based on methyl fluorone [137], Brilliant 
Green [138-139], Malachite Green [140], iodine [141,142], and silver
diethyldithiocarbamate [143], A kinetic method with photometric end-point 
detection for microgram amounts of antimony was published in 1972 [144].
Spot tests have been used to detect traces of antimony compounds,
including stibine. A ring-oven method for detection of particulate antimony 
compounds depends on conversion of the antimony to stibine, with detection by 
silver nitrate-impregnated paper [145,146], Rapid detection of 10-20-yg
amounts of antimony can be made with a modified Reinsch's test [147], Feigl
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and Chan [148,149] described spot tests using mercuric cyanide that are useful 
for 100-jug quantities of elemental or bound antimony. Silver 
diethyldithiocarbamate can be used to detect as little as 60 pg of antimony in 
60 nanoliters of solution [150], To detect as little as 20 pg of antimony in 
20 ml of body fluids, a copper reduction was described [151],
Chromatography is one of the few analytical techniques specific for 
individual antimony compounds including different oxidation states of 
antimony. Applications of gas-liquid chromatography have been described for 
determination of antimony trichloride [152], antimony triiodide [153], 
antimony pentafluoride [154], and triphenyl antimony [155],
Electrochemical methods also have application in trace determination of 
antimony. Dubois and Monkman [156] described the use of polarography for 
determination of antimony in air samples taken on glass fiber filters. 
Minimal sample manipulation is required. Tri- and pentavalent antimony can 
be determined separately, and the method is useful for microgram quantities 
[156], Other polarographic procedures describe the determination of antimony 
using thiocyanate electrolyte [157] and in organic compounds [158], An ion- 
selective electrode sensitive to as little as 10 nanomoles/liter of either 
tri- or pentavalent antimony was reported in 1975 [138].
Spark source mass spectrometry has been used for determination of many 
elements, including antimony, in biological samples [159,160], Detection 
limits were on the order of 0.1 ppm, but accuracy was probably not better than 
+25%.
In clinical investigations of antimony process workers, McCallum [79] and 
others [161] made estimates of the antimony burden in intact lungs by X-ray 
spectrophotometry. The minimum detection limit was approximately 2 mg/sq cm. 
This method was described in Epidemiologic Studies.
Bloch [162], in 1970, described a gamma-ray spectrometric method similar 
to that of McCallum [79] for determining antimony concentrations in the lungs 
of antimony workers. This technique also was reported to have a minimum 
sensitivity of approximately 2 mg/sq cm. Recent information indicates that 
antimony concentrations in intact lungs may be assayed by this method at 
levels as low as 50 ppm (P Bloch, written communication, March 1978), but the 
method for calculating ppm was not described.
Neutron activation analysis (NAA) has been used by several investigators 
to determine elements in atmospheric particulates [127-129,163,164], Good 
sensitivity for many elements, minimal sample manipulation, and the ability to 
determine twenty or more elements simultaneously have been cited as advantages 
of NAA, which requires expensive equipment and extensive data processing 
[165], An absolute detection limit of approximately 0.3 ng of antimony/filter 
has been reported with 57-mm cellulose ester filters [128], and another group 
that used polystyrene filters found the detection limit to be 0,03 pg per 20 X
25-cm filter [163], Photon activation analysis was also applied to determine 
antimony particulates in air but with much poorer sensitivity than NAA [130],
More than thirty elements, including antimony, have been determined in 
biologic materials by NAA [76,166-175]. Accuracy within 5% of the calculated 
value on samples containing 0.1-10 ng of antimony was reported in studies on
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biologic materials [166], Neutron activation anaylsis was also used for 
antimony in other matrices, including natural waters [176], pharmaceutical 
products [177], and laundry aids [178],
Analysis of airborne particulates by emission spectroscopy was 
demonstrated for 15 elements, including antimony [179], but no working range 
of concentrations was given. Another publication indicated that the detection 
limit in biologic materials is on the order of 15 jug of antimony per sample by 
conventional methods [180], However, other analytical methods based on 
emission spectra may be modified to be more sensitive. For example, Braman et 
al [181] converted antimony to stibine with sodium borohydride and obtained a 
detection limit close to 0.5 ng per sample. Inductively coupled plasma 
emission spectroscopy has a detection limit of 0.2 ppm for antimony, about the 
same sensitivity as flame atomic absorption [182], An emission spectrographic 
method of analysis for microsamples (less than 400jug) was described by Svoboda 
and Kleinmann [183] in which the lower limit of detection for antimony was 4- 
10 ng.
Atomic absorption spectrophotometry (AAS) is one of the most widely used 
methods for the determination of antimony. Three major variations of the 
method have been developed: flame atomization, hydride generation, and
flameless atomization.
A method evaluated and found acceptable by NIOSH [125] for determination 
of particulate antimony in air is based on flame AAS. The sensitivity of 
flame AAS is typically on the order of 0,3-0,5 ppm in the aspirated solution 
for 1% absorbance (5-10 ng total Sb in the sample), limiting the lower end of 
the working range to about 0.05-1,0 mg/cu m for a 360-liter air sample 
(approximately 18-36 jug/sample) [125,184,185], Sensitivities about 50-100 
times better than this may be obtained with either the hydride generation 
method or flameless atomization using a graphite furnace.
The graphite furnace (flameless) method has a sensitivity of about 120 
pg/5-50-/im portion [186-189] or about 5-15 ng for an ashed air filter sample. 
A flameless method developed by NIOSH is presented in Appendix II. This 
method is recommended because a 50-liter air sample is adequate for analysis, 
as opposed to a 360-liter air sample required for equivalent sensitivity with 
flame AAS.
The first applications of hydride generation techniques to the 
determination of antimony used magnesium and titanium trichloride or zinc as 
reductants [190-192], Subsequently, sodium borohydride showed advantages as a 
reductant because of its wide applicability and usefulness in both solid and 
solution forms [193-195], Absolute sensitivity of 10 ng antimony was reported 
for an argon-hydrogen burner system [193], With the use of a long path for 
the atomization of the hydride, a sensitivity of 0,6 ng was demonstrated 
[194], Applications include the determination of antimony and other hydride- 
forming metals in steel [196], natural waters [197], and foods [198], An 
automated procedure has been developed [199],
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V. ENGINEERING CONTROLS, PERSONAL PROTECTION, AND WORK PRACTICES
General Control Principles
Occupational exposure to antimony and its compounds can be controlled by 
applying accepted industrial hygiene principles (1) at the point of 
generation, (2) in the general work environment, and (3) at the actual point 
of exposure to the worker. Although antimony and its compounds are associated 
with numerous processes, the control principles and methods can be applied to 
all.
Control methods applied at the point of generation include local exhaust 
ventilation, isolation, enclosure, process modification, and containment. 
These methods are generally the most effective means of control.
If control at the source cannot be made fully effective, methods must be 
used that minimize contamination of the work area. These include general 
dilution ventilation, good housekeeping, and good work practices.
In addition to control at the source and in the general work environment, 
personal protection must be afforded. Personal protective equipment 
(respirators, face shields, eyewear, hats) separates the worker from the 
contaminated environment. Individual protection involves some risks and 
problems, including the possibilities of equipment failure, improper fit or 
use, the discomfort of wearing the equipment, and Increased risk of accidents 
due to restriction of vision or impairment of movement. Because of these 
drawbacks, the use of some personal protective equipment, such as respirators, 
should be relied upon only as a last resort, and not as an alternative to 
adequate engineering controls.
Appropriate application of source, work area, and personal protection 
control methods should provide effective worker protection under most 
conditions. A continuing health education program, environmental monitoring, 
and accurate and complete recordkeeping are also essential to a complete 
control system. Periodic inspection and quality checks of all aspects of the 
control system are necessary to ensure the system's continued effectiveness.
Engineering Controls
Guidance for specific design criteria for mechanical ventilation can be 
found in Industrial Ventilation— A Manual of Recommended Practice [200] and in 
Fundamentals Governing the Design and Operation of Local Exhaust Systems
T 20T T .
Complete enclosure or isolation of a process is a highly effective means 
of reducing worker exposure. The most effective method of control is a 
combination of local exhaust ventilation and enclosure. Because antimony ore 
is extremely brittle, certain operations (ie, reduction and screening) result 
in high workplace air concentrations of antimony dust. Local exhaust 
ventilation and enclosure should be used to control the dust. In addition, 
wetting the ore with a light water spray assists in reducing the amount of 
dust generated. Local exhaust ventilation and enclosure methods, as 
recommended by NIOSH for control of arsenic [89], are also recommended for the
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control of antimony in smelting operations, where it is common for antimony 
trioxide fume to remain suspended in the air for an exceptionally long time 
[200] .
In some operations, either local exhaust or enclosure may alone be 
sufficient. Local exhaust ventilation (exhaust hoods) can be located over 
pots containing molten metal for control of fumes, over crushing and packout 
operations for control of dust, and in areas where antimony trichloride or 
other halides may release irritating fumes. The toxic gas stibine can occur 
as a byproduct when storage batteries are overcharged [97]; therefore, 
appropriate ventilation controls should be used to control both hydrogen and 
stibine in battery charging areas,
A combination of isolation of the operation and process modification is 
another control possibility. In smelting, fettling, general furnace 
operation, and in battery charging, hazards can be minimized or eliminated 
through isolation and automation of processes.
Whenever mechanical ventilation is used to control antimony exposure, 
measurements that demonstrate the system's efficiency should be conducted 
frequently and recorded at least quarterly. Continous airflow indicators, 
such as water or or oil manometers, are recommended. Devices that measure air 
velocity (ie, anemometers) can also be used to determine the efficiency of the 
system. In addition to frequent checks, measurements should be conducted 
after any change in process, operation, or control method that might result in 
reduction of control efficiency. The employer should maintain a record of 
ventilation measurements, including the location of the test site, date, and 
results of tests. These records should be retained for 1 year.
Personal Protection
Working with antimony can lead to skin irritation and skin ulcers. To 
minimize or prevent skin contact, coveralls or long-sleeve shirts with 
trousers, gloves, and appropriate shoes and headwear should be worn.
Where antimony trichloride or other antimony halides may contact the skin, 
special care is necessary due to the very irritant properties of these 
compounds. Workers should wear gloves with gauntlets and aprons made of
rubber or other material resistant to penetration by antimony halides, as well 
as chemical safety goggles or face shields (8-inch minimum) with goggles if 
spills or splashes are possible. Eye protection should follow the guidelines 
listed in 29 CFR 1910,133 to prevent damage to the eyes resulting from 
exposure to antimony.
The use of respirators should be limited to periods of installation and 
testing of engineering control equipment, nonroutine maintenance and repair, 
and during emergencies when concentrations of airborne antimony may exceed the 
recommended TWA. Requirements for a respiratory protection program are given 
in Chapter I, Section 4 of this document; the program should comply with the 
requirements of 29 CFR 1910,134, The selection of respiratory protective 
devices should comply with the provisions of 30 CFR 11,
Neither respiratory protective equipment nor personal protective clothing 
are to be regarded as substitutes for proper engineering controls.
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Work Practices
Good work practices include recommended emergency procedures, proper use 
of facilities, careful sanitation practices and cleaning, and safe handling 
and storage. The importance of these practices should be continually 
emphasized.
(a) Emergency Procedures
For all work areas in which emergencies involving antimony may occur, 
employees should be properly trained to follow general specified procedures 
along with any others that may be appropriate for a specific operation or 
process.
Facilities for quick drenching of the body within the immediate work area 
should be provided whenever contact with antimony halides may occur. If 
halides contact the skin or mucous membranes, the involved area should be 
flushed with large quantities of water. The skin should then be washed with 
soap and water. Contaminated clothing should be removed promptly and not 
reworn until thoroughly washed.
If particulates or solutions of antimony halides have contacted the eyes, 
they should be washed out promptly with copious quantities of gently flowing 
water. The eyelids should be held open with the fingers during washing. The 
injured employee should receive medical attention at once.
Approved protective clothing and respirators should be ready for use by 
persons essential to emergency operations and should be stored in readily 
accessible locations. A worker who has received inhalation exposure to a 
halide should be moved immediately to fresh air and should receive medical 
attention.
Procedures should be prepared for maintenance or cleanup of areas where 
leaks or discharges of antimony have occurred. Employees not essential to 
emergency operations should be evacuated from the affected areas during 
emergencies, and perimeters of these areas should be delineated, posted, and 
secured.
Only personnel properly trained in emergency procedures and protected 
against the attendant hazards should clean up spills or control and repair 
leaks. After cleanup, protective clothing and equipment should be removed and 
decontaminated, and the cleanup personnel should shower.
Emergency telephone numbers should be prominently displayed,
(b) Handling and Storage
Procedures should be followed to avoid unintentional chemical reactions. 
Antimony and antimony compounds can generate highly toxic stibine gas under 
reducing conditions. Contact with various acids generates stibine; this 
potential must be recognized and avoided.
Three cases of accidental industrial poisoning by a mixture of arsine, 
stibine, and hydrogen sulfide have been documented [97]. Gases were liberated 
when water was added to a hot dross that contained metallic aluminum compounds
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(arsenic, antimony, and free sulfur) to speed up the operation. Arsine, 
stibine, and hydrogen sulfide were formed from the reaction of the metals with 
the liberated nascent hydrogen. Workers became extremely ill as a result, but 
recovered.
Stibine has been generated when storage batteries were overcharged [202]. 
The amounts of stibine in battery room atmospheres have been reported to be 
generally less than 1 ppm (about 5.1 mg/cu m), although 5 ppm (about 25 mg/cu 
m) has been determined directly over large open battery cells. Under various 
experimental conditions, maximum stibine concentrations of 45 ppm (about 225 
mg/cu m) were detected in undiluted battery gases. Other potential sources of 
stibine generation are welding and cutting with blow torches, soldering, zinc 
etching, preparation of antimony trichloride, steel burnishing, purification 
of type metal with caustic soda, and procedures in laboratories and industry 
where nascent hydrogen comes in contact with metallic antimony or soluble 
antimony compounds [203]. Workers should be made aware of such possibilities 
at their workplace.
Antimony oxides, antimony sulfides, and antimony metal do not present 
storage problems, though the corrosive halides do. Drums and pails are 
adequate for some grades of antimony trichloride, but glass carboys are 
necessary for pharmaceutical-grade trichloride and for all other halides. 
Carboys should be protected by wooden frames. Liquid halides can be poured 
from the carboys, but the solid antimony trichloride must be removed by 
breaking the glass container. Procedures for breaking the glass have been 
outlined by the Manufacturing Chemists Association [204], Storage containers 
should be kept tightly closed. Storage areas should be cool, dry, well- 
ventilated, protected from sunlight, and away from manufacturing areas.
Information on antimony and its compounds should be recorded on the 
"Material Safety Data Sheet" shown in Appendix III or on a similar form 
approved by the Occupational Safety and Health Administration, US Department 
of Labor. Workers should be made familiar with this information as part of 
the continuing education program outlined in Chapter 1.
(c) Sanitation Practices
Employers should provide rest areas, smoking areas, and facilities for 
food preparation, storage, dispensing, and eating that are physically
separated from work areas to prevent ingestion of antimony.
Employees should not eat or smoke in areas where antimony is present. 
Signs should be posted that prohibit eating and smoking in work areas.
Workers should wash their hands before putting anything in their mouths and
before and after using toilet facilities.
A daily change of work clothing should be provided for workers. Separate
lockers for work clothing and street clothing should be available. Workers
should not wear their work clothing away from the workplace, but should shower 
and change into street clothing before leaving. Contaminated clothing should 
be put in closed containers until it is washed.
Washing and shower facilities, including eyewash fountains and quick- 
drench units for emergencies, should be provided by the employer and should be
easily accessible to employees. The portions of 29 CFR 1910,141 pertaining to
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facilities that are especially relevant to antimony are subsections (a) 
General, (c) Toilet Facilities, (d) Washing Facilities, (e) Change Rooms, and
(g) Consumption of Food and Beverages on the Premises.
(d) Laundering
Used work clothing should be laundered frequently, preferably daily. 
Clothing should be washed with soap or other detergent and water. Precautions 
should be taken to protect personnel who handle and launder soiled clothing. 
These employees should be advised of the hazards of, and means of preventing, 
exposure to antimony. If an outside laundry facility is used, the launderers 
should be advised of the hazards and proper procedures Involved in handling 
contaminated work clothing. Contaminated clothing that is to be transported 
to an outside laundry facility should be placed in containers and sealed.
(e) Decontamination
To reduce antimony dust exposures in the work area, cleaning by vacuuming, 
wet mopping, or hosing is advised. No dry sweeping or blowing should be 
permitted. Liquid spills should be copiously flushed with water and channeled 
to a treatment system or a holding tank for reclamation or proper disposal. 
Tanks that have contained antimony trichloride may be cleaned according to 
guidelines offered by the Manufacturing Chemists Association [204].
(f) Disposal
Waste materials contaminated with antimony should be disposed of in a 
manner not hazardous to employees. The disposal method should conform to 
applicable local, state, and Federal regulations.
78
VI. DEVELOPMENT OF STANDARD
Basis for Previous Standards
The first maximum allowable concentration (MAC) for antimony dusts, fumes, 
and mists was recommended in 1947 by the American Conference of Governmental 
Industrial Hygienists (ACGIH) [205], The recommended value was 0.1 mg/cu m of 
air. No basis for the recommendation was given.
In 1948, the ACGIH adopted the term "Threshold Limit Value" (TLV) to 
replace maximum allowable concentration. Both terms were imprecise, implying 
to some a ceiling, and to others a time-weighted average (TWA). Antimony was 
one of five substances that had values raised from 1947 values. The TLV for 
antimony became 0.5 mg/cu m [206].
In his 1950 text on industrial toxicology, Elkins [207] proposed a MAC of 
1 mg/cu m, citing the animal experiments by Dernehl et al [102]. However, 
Elkins [207] wrote that his MAC proposal of 1 mg/cu m was based on 
insufficient information. That same year, the ACGIH [208] continued to 
recommend a TLV of 0.5 mg/cu m for antimony dusts, fumes, and mists.
TLV's adopted in 1953 by the ACGIH were, for the first time, defined as 
maximum average concentrations over an 8-hour workshift that should not be 
exceeded rather than as ceilings not to be exceeded even momentarily [209], 
The recommended value for antimony, however, remained at 0.5 mg/cu m.
In his 1956 review of TLV's, Smyth [210] cited the studies by Bradley and 
Fredrick [17] and Dernehl et al [102] and suggested that the TLV of 0.5 mg/cu 
m was low enough to prevent injury.
The ACGIH published documentation for the TLV of 0.5 mg/cu m in 1962 
[211]. The value was based on the industrial studies of Brieger et al [15] in 
1954 and Renes [5] in 1953. A later ACGIH documentation, published in 1966, 
stated that the recommended level of 0.5 mg/cu m would prevent accumulation of 
antimony in the body [212], The 1971 documentation [213] cited industrial 
studies by Klucik et al [11,214,215] and continued to recommend 0.5 mg/cu m.
Notices of intent to change the TLV for antimony and its compounds were
published by ACGIH in 1975 and 1976 [216,217], The changes proposed separate
TLV's for the handling and use of antimony trioxide, and for the production of 
antimony trioxide. A TLV of 0.5 mg/cu m was proposed for handling and use, 
and a TLV of 0.05 mg/cu m was proposed for production. The 0,05 mg/cu m value
for antimony trioxide production was most likely based on the epidemiologic
report of Davies [14] that suggested an increased incidence of lung cancer 
among antimony production workers.
In 1976, the term "Short-Term Exposure Limit" (STEL) was instituted by the 
ACGIH. It was defined as the maximal concentration to which workers could be 
exposed for up to 15 minutes continuously without suffering from intolerable 
irritation, chronic or irreversible tissue change, or narcosis of sufficient 
degree to increase accident proneness, impair self-rescue, or materially 
reduce work efficiency, provided that no more than four excursions per day 
were permitted, with at least 60 minutes between exposure periods, and
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provided that the daily TLV-TWA was also not exceeded [217], The STEL for 
antimony and compounds was tentatively set at 0.75 mg/cu m but did not appear 
in the 1976 documentation [218],
In 1977, the ACGIH [219] again listed the TLV for antimony as 0.5 mg/cu m 
with notice of intended changes. The tentative STEL value of 0,75 mg/cu m 
proposed the year before was not adopted and did not appear in the 1977 list.
The most recent intended change, appearing in 1977, was a TLV of 2 mg/cu m 
proposed for soluble salts of antimony. This value was based on the reports 
of Taylor [96] and Cordasco [95], who studied accidental poisoning by antimony 
trichloride and pentachloride, respectively. The proposed TLV's of 0.5 mg/cu 
m for handling and use of antimony trioxide, and 0,05 mg/cu m for antimony 
trioxide production remained in the notice of intended changes.
Tables in Occupational Exposure Limits for Airborne Toxic Substances— A 
Tabular Compilation of Values from Selected Countries were published by the 
International Labour Office in 1977 [220]. The environmental limits for 
antimony in other countries are presented in Table VI-1.
The Occupational Safety and Health Administration, US Department of Labor, 
has adopted the 1968 ACGIH TLV for antimony of 0.5 mg/cu m determined as a TWA 
concentration limit [221] as the Federal standard (29 CFR 1910.1000).
TABLE VI-I
HYGIENIC STANDARDS OF SEVERAL COUNTRIES 
FOR ANTIMONY AND COMPOUNDS IN THE WORKING ENVIRONMENT
Country Standard 
(mg/cu m)
Qualifications
Finland 0.5 Not stated
Federal Republic of Germany 0.5 8-hour TWA
Democratic Republic of Germany 0.5 Not stated
Rumania 0.5 11
USSR 0.5 For antimony dust
0.3 For flourides and chlorides (tri-
and pentavalent); obligatory control
of HF and HC1
1.0 For trivalent oxides and sulfides
1.0 For pentavalent oxides and sulfides
Sweden 0.5 Not stated
USA 0.5 8-hour TWA
Yugoslavia 0.5 Not stated
Modified from references 220 and 222
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Basis for the Recommended Standard
(a) Permissible Exposure Limit
Adverse health effects reported for antimony and its compounds in 
occupational settings include effects on the heart, respiratory system, skin 
and mucous membranes, and a suggestion of reproductive problems.
Many nonoccupational reports have implicated antimony in adverse heart 
effects manifested by ECG alterations, primarily a flattening or inversion of 
the T wave. These effects have followed iv or im administration of antimony 
salts in high multiple doses (about 0.5-6.0 mg/kg per dose) for the treatment 
of parasitic infections [36-50],
Brieger et al [15] noted seven deaths of antimony workers attributed to 
cardiac disease. Of 75 workers in the department where the deaths occurred, 
37 had altered ECG's, primarily of the T wave, Concentrations of antimony 
trisulfide in the department ranged from 0,58 to 5.5 mg/cu m, with most 
samples over 3.0 mg/cu m, according to Brieger et al. According to Bradley 
and Fredrick [17], rats had myocardial damage after LD50 administration of 
antimony. T wave alterations were also found in rats and rabbits given 
inhalation exposures of 3.07 and 5.6 mg antimony/cu m, respectively, for 6 
hours/day, 5 days/week for 6 weeks [15]. Similar abnormal ECG's in workers 
exposed to antimony trisulfide and trioxide were described by Klucik and 
Ulrich [11] at concentrations that were reported to range from 1,3 to 237 g 
Sb/cu m (sic); however, these stated concentrations may be in error, since 
they are inordinately high. It may be questioned whether arsenic, present as 
a contaminant in industrial antimony compounds, caused the observed ECG 
changes because arsenic has produced the same effects [89-93]. Although some 
reports have failed to note ECG changes in antimony workers [9,10], ECG 
alterations in animals [15,17], in patients receiving arsenic-free antimony 
drugs [36-50] , and in workers exposed at concentrations generally above 3 
mg/cu m are judged to be due to antimony.
Simple pneumoconiosis, manifested as moderate, dense reticulo-nodular 
formations scattered throughout pulmonary fields on X-rays [7], is a frequent 
finding among antimony workers [6,7,9,12,79], Fibrosis appears to be absent
[6.79], According to some reports, workers seem to be free of symptoms
[12.79], but decrements in pulmonary function have been reported occasionally
[6,7,9], Quantitative information was lacking in these reports, as were 
specifics on the procedures used. Environmental levels were reported to 
exceed 0.5 mg/cu m for antimony trioxide and antimony metal dust [12,79], to 
be mostly less than 10 mg/cu m (range, 0.08-138 mg/cu m) for antimony ore and 
trioxide [9], to measure 16-248 mg/cu m for a mixed dust that included 
antimony oxides and silica [6], and to be 0.3-14,7 mg/cu m for antimony metal 
and trioxide [7], Airborne exposures to antimony workers generally involved 
materials other than antimony. Contaminants have included silica and arsenic 
as well as other particulates and gases characteristic of smelter operations.
Reported environmental concentrations frequently lack detail, such as 
whether they constituted breathing zone or area measurements and what specific 
operations were evaluated; however, most environmental levels appear to be 
greater than 0.5 mg/cu m and less than 10 mg/cu m. The bulk of the dust loads 
consisted of antimony or antimony compounds in these cases and it is 
reasonable to conclude that simple pneumoconiosis was attributable to the
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antimony dusts. It is unknown whether the effects were due to worker 
exposures at 10 mg/cu m or less or whether they were the result of higher 
concentrations.
A question was raised in 1973 concerning increased mortality due to lung 
cancer in a group of antimony smelter workers in England that originally 
numbered 1,081 people [14], Of 56 deaths recorded from 1961 to the end of 
1971, 10 were due to lung cancer; 68 individuals in the cohort remained 
untraced. Eight deaths from lung cancer occurred among individuals 45-64 
years old who were engaged in antimony smelting or related activities. The 
eight deaths represented a two-fold excess over the number expected from a 
comparison with local death rates. Because of the small group, the excess 
deaths were not necessarily considered by the author [14] to be due to 
antimony. In the factory and office as a whole, the number of deaths from all 
causes was less than expected. Because of the lack of knowledge of smoking 
habits and the small size of the study group, the findings were considered by 
the author [14] to be equivocal. The study was to be continued to include a 
detailed investigation of smoking habits.
A recent update of the figures reflected essentially the same two-fold 
ratio, 13 deaths observed vs 7.2 deaths expected (KP Duncan, written 
communication, July 1978), With the exception of observed vs expected 
figures, further data have not been forthcoming. Many questions remain such 
as smoking habits of the workers, the makeup of the local (control) group used 
to generate the expected estimate, work locations and worker histories, other 
smelter contaminants, environmental levels of antimony and contaminants, and 
changes that have taken place in processes or procedures. Therefore, the 
question raised in 1973 on lung cancer in antimony workers in England remains 
equivocal. Because of the lack of definitive data, lung cancer is not judged 
to be a factor at this time in consideration of a recommended occupational 
exposure limit for antimony and its compounds.
Dermatitis and mucous membrane irritation are common complaints of 
antimony workers [5,6,77,78]. Renes [5] correlated most incidents of 
dermatitis with a 1-week period of heavy exposure when concentrations reached
70.7 mg/cu m, but some cases of dermatitis and mucous membrane irritation
occurred at exposures in the range of 0,4-70.7 mg/cu m. The occurrence of
dermatitis seems to be related at least as much to conditions of heat, 
perspiration, and friction, as to actual exposure level.
Of concern is the single report of Belyaeva [13] in which 318 antimony- 
exposed female workers were stated to have higher incidences than controls of 
late-occurring spontaneous abortions (12.5% vs 4.1%), premature births (3.4% 
vs 1.2%), and gynecologic problems (77.5% vs 56%). Although subsequent animal
findings in female rats by the same author [13] were reported to support the
findings of human reproductive effects due to antimony, the dose (50 mg/kg ip) 
and the concentration (250 mg/cu m) given to rats were high and of 
questionable relevance to the occupational setting. Many procedural points 
were not discussed and a definitive interpretation of the work is not possible 
without further evidence. The percentage of gynecologic problems reported in 
the control group (56%) seems abnormally high. It is unclear whether the 
overall working conditions in this smelter were representative of smelter 
conditions in the US.
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Blood and urine levels of antimony were reported to be about the same in 
dusty operations as in less dusty operations, such as the chemical laboratory 
or in quality control [13]. Average urine levels of antimony for exposed 
workers ranged from 2,1 to 2.9 mg/100 ml. The highest value found was 18,2 
mg/100 ml and the lowest was 0.5 mg/100 ml. These levels would appear to be 
reasonable when compared with the statement by Renes [5] that one heavily 
exposed worker had a urinary antimony level of 60 mg/100 ml. Clearly, further 
work is needed on the effects of antimony on reproduction. At this time, the 
available information on reproductive effects is insufficient to make 
recommendations pertaining to an occupational exposure limit for antimony.
The present Federal limit for occupational exposure to antimony and its 
compounds is 0.5 mg/cu m (as Sb) as a time-weighted average concentration 
limit. Stibine is excluded from this recommended standard because it is a 
transitory byproduct of operations involving other sources of antimony, and 
decomposes rapidly in the air. From a review of the data and all available 
information, it is believed that a TWA limit of 0.5 mg/cu m will afford worker 
protection from the health effects associated with exposure to antimony 
including dermatitis, mucous membrane irritation, pneumoconiosis, and ECG 
alterations. Therefore, NIOSH recommends that the current Federal limit of
0.5 mg/cu m as a TWA concentration limit be retained.
(b) Medical Surveillance and Recordkeeping
Medical surveillance should include preplacement and periodic examinations 
with attention directed to the skin, lungs, and heart. Chest X-rays should be 
taken annually to screen for possible pulmonary problems including 
pneumoconiosis that may be attributed to antimony exposure. Several authors
[6,7,9] have suggested that pulmonary functional impairment may be a feature 
of antimony pneumoconiosis; therefore, tests of ventilatory function should 
also be required on an annual basis. Because of the findings of ECG 
alterations in workers exposed to antimony trisulfide [15] and also in rats 
and rabbits [15], annual ECG's of antimony-exposed workers should also be 
mandatory.
The uncertain nature of the evidence of liver dysfunction makes a 
requirement for liver function tests difficult to justify. However, liver 
function tests are encouraged because of their possible relationship to 
antimony exposure as well as their relevance to an evaluation of general 
health.
The research is inconclusive with regard to possible adverse effects of 
antimony exposure on reproduction. Belyaeva [13] reported that women working 
with antimony experienced more late spontaneous abortions, premature births, 
and gynecologic problems than did women not exposed to antimony. Animal 
experiments [13] suggested that antimony may interfere with the normal 
development of ova. No investigation of the fertility of male antimony 
workers or further animal experiments involving either sex has been reported. 
Until Belyaeva's findings are confirmed or refuted, NIOSH recommends workers 
be advised that a single report indicates that there may be an increased risk 
of reproductive disorders resulting from occupational exposure to antimony.
Because of the possibility of chronic lung changes and cardiac alterations 
as a result of antimony exposure, medical records of antimony workers should 
be kept for 30 years after termination of employment.
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(c) Sampling and Analysis
Personal sampling with a membrane filter is the primary recommended 
technique, since most antimony compounds in the industrial environment exist 
as particulates. A Millipore type AA or equivalent cellulose ester membrane 
filter with 0.8-Mm pores provides optimum sampling efficiency. The residue 
obtained from digesting the collected particulate matter in a mixture of 
nitric, perchloric, and sulfuric acids is diluted with distilled water; 
aliquots are analyzed for antimony at 217.6 nm by flameless atomic absorption. 
If lead is present in the sample, the 231,2-nm resonance line should be used.
The recommended sampling method for volatile antimony compounds uses a 
midget impinger containing 5% mercuric chloride in 6N hydrochloric acid. The 
sample solutions are diluted with distilled water and analyzed directly by 
flameless atomic absorption.
Analysis by atomic absorption spectrophotometry has been successfully used 
to monitor air for antimony and antimony compounds. The flameless method is 
relatively simple and quick, and is highly sensitive. Recommended procedures 
for sampling and analysis are discussed in Chapter IV and are presented in 
greater detail in Appendices I and II.
(d) Personal Protective Equipment and Clothing
The irritant properties of antimony make it necessary to protect the skin 
and eyes from contact with antimony materials. Coveralls with long sleeves, 
head and neck protection, and gloves should be worn during exposure to 
antimony dusts. When antimony halides may contact the skin, gloves with
gauntlets and aprons made of rubber or other material resistant to antimony 
halides should also be worn to prevent burns. Because of the occurrence of 
conjunctivitis following antimony exposure [5,6], it is important to protect 
the eyes from antimony by wearing chemical safety goggles in work situations 
where antimony could contact the eyes. Respirators should be worn when
airborne concentrations of antimony exceed 0.5 mg/cu m, but this should occur 
only during unusual circumstances, ie, during installation and testing of 
engineering controls, during nonroutine maintenance or repair, or during
emergencies. For initial selection of a respirator to be assigned to an 
individual worker, a quantitative fit test of facepiece to face seal is 
recommended for negative pressure respirators, This method provides a
numerical index of respirator fit, does not rely solely on the subjective 
response of the wearer, and therefore provides more reliable protection than 
qualitative fit testing. Procedures and allowable leakages as specified in A 
Guide to Industrial Respiratory Protection [223] should be followed. All 
protective clothing and equipment should be provided by the employer and be 
cleaned, maintained in good condition, and replaced as necessary by the 
employer.
(e) Informing Employees of Hazards
Continuing education is important in a preventive hygiene program for
employees exposed to hazardous materials such as antimony. Workers should be
periodically informed by properly trained persons of the possible sources of 
antimony exposure, the adverse health effects associated with excessive
exposure to antimony, the engineering and work practice controls in use and
being planned to limit exposure to acceptable concentrations, and good
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personal hygiene and housekeeping practices. The procedures used in 
environmental and medical monitoring should also be explained, and the 
benefits to workers of participating in these environmental and medical 
monitoring procedures should be stressed.
(f) Work Practices
To prevent the intake of antimony, NIOSH recommends that storage, 
handling, dispensing, and eating of food be prohibited in antimony exposure 
areas. While antimony does not pose a fire hazard, its deposition on smoking 
materials may result in inhalation or ingestion of antimony during smoking; 
therefore, smoking as well as carrying uncovered smoking materials in the
workplace should be prohibited. Workers should shower and change clothes 
before leaving work so as to minimize their exposure to antimony and to
prevent contamination outside the workplace.
(g) Monitoring and Recordkeeping Requirements
In workplaces where antimony is present, an annual industrial hygiene 
survey is recommended to determine if exposure exceeds the action level, If
there is occupational exposure to antimony, ie, if the action level is
exceeded, personal sampling representative of the worker's exposure should be 
instituted on at least a semiannual basis. Records of sampling and analysis 
should be preserved for at least 30 years after the last work-related exposure 
to antimony to enable correlations between air levels of antimony in the 
workplace and any health effects on workers. Medical records should be kept 
for the same period. The Toxic Substances Control Act of 1976 requires that 
"Records of...adverse reactions to the health of employees shall be retained 
for thirty years from the date such reactions were first reported to or known 
by the person maintaining such records."
(h) Action Level
Many workers handle small amounts of antimony or work in situations in 
which, regardless of the amount used, there is only negligible contact with 
the substance. Under these conditions, it should not be necessary to comply 
with some provisions of this recommended standard that were prepared primarily 
to protect workers' health under more hazardous conditions. Concern for 
worker health requires that protective measures and emergency procedures be
instituted below the enforceable limit to ensure that exposures stay below
that limit. For these reasons, the action level has been defined as one-half
the recommended TWA environmental limit, thereby delineating those work 
situations that do not require the expenditure of health resources for
environmental and medical monitoring and for associated recordkeeping.
However, because of nonrespiratory hazards such as those resulting from eye
contact or skin contact, NIOSH recommends that the appropriate work practices
and protective measures be required regardless of airborne concentration.
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VII. RESEARCH NEEDS
The most serious research needs in connection with occupational exposure 
to antimony are resolution of the questions of reproductive hazard and 
carcinogenic potential. The available literature does not supply conclusive 
evidence for an evaluation of these issues. The only epidemiologic survey 
[14] that suggested an increased risk of lung cancer was merely a statement 
issued to workers engaged in antimony oxide manufacture; it cannot be 
considered scientific or complete. Research is in progress under a NIOSH 
contract to determine the carcinogenicity of antimony trioxide. Research is 
also needed to determine if antimony acts synergistically to promote 
carcinogenic properties of other substances.
Belyaeva [13] reported increased incidences of late spontaneous abortions, 
premature births, and gynecologic problems in women antimony workers, as well 
as less-than-normal weight gain in their infants. With animal experiments, 
the same author [13] substantiated the findings of reproductive disorders. 
More animal research should be undertaken to confirm Belyaeva's results. 
Possible behavioral consequences of exposure to antimony in utero should also 
be investigated.
Epidemiologic studies of worker populations exposed to antimony at or near 
the recommended environmental limit would serve to evaluate the adequacy of 
the limit. These studies should attempt to distinguish exposures to antimony 
from mixed exposures to antimony and arsenic. As a minimum, these studies 
should include environmental air measurements, identification of jobs, 
description of work practices and overall plant conditions, work, medical, and 
exposure histories, and carefully derived control rates for morbidity and 
mortality comparisons.
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IX. APPENDIX I
METHODS FOR SAMPLING ANTIMONY IN AIR
General Requirements
(a) Collect air samples representative of the breathing zones of 
individual workers to characterize the exposure from each job or specific 
operation in each work area.
(1) Collect samples as near as practicable to the face of workers 
without interfering with freedom of movement.
(2) Collect samples to permit determination of exposures for every
job involving antimony in sufficient numbers to express the variability of the
exposures for the work situation.
(b) Suggested records:
(1) Date and time of sample collection;
(2) Sampling rate and duration;
(3) Total sample volume;
(4) Location of sampling;
(5) Temperature, pressure, and relative humidity at time of 
sampling; and
(6) Other pertinent information regarding worker and work setting.
Sampling for Particulate Antimony and Compounds
(a) The sampling equipment consists of:
(1) A portable, battery-operated personal sampling pump calibrated 
to +5% of the required flowrate.
(2) A 2-or 3-piece filter cassette containing an 0 . 8 - i m  cellulose 
ester membrane filter (Millipore type AA, or equivalent) supported by a 
cellulose backup pad for collecting the sample.
(b) The sampling rate must be accurately (+5%) maintained at the target 
value, which should lie within the range of 1,5-2.5 liters/minute, Samples 
should be taken for a time period that will provide at least 2,5 ng Sb in the 
sample.
(c) Upon completion of sampling, plastic plugs are replaced on the inlet 
and outlet openings of the cassette and an appropriate identification is 
attached. A minimum of four samples are taken for each operation and averaged
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on a time-weighted basis. Note the suspected identities of all substances 
present in the air sample.
(d) To determine background correction, a field blank and a laboratory 
blank are analyzed along with the samples. The field blank is a filter that 
is handled in exactly the same manner as the samples (ie, placed in a 
cassette) except that no air is drawn through it. The laboratory blank is a 
clean, unused filter which has not been handled.
Sampling for Volatile Antimony Compounds
(a) The sampling equipment consists of:
(1) A prefilter unit (if needed), consisting of an 0.8-//m membrane
filter in a cassette filter holder. Possible interactions between reactive,
volatile antimony compounds and the prefilter may cause erroneously low 
readings in the impinger sample.
(2) A midget impinger containing 10 ml of absorbing solution. The 
absorbing solution is made by dissolving 50 g mercuric chloride in 1 liter of 
61i hydrochloric acid.
(3) A personal sampling pump capable of calibration to +5% of the 
required flowrate, which should be 1.5-2.5 liters per minute.
(4) The sampling pump is protected from splashover or water 
condensation by an absorption tube loosely packed with glass wool and inserted 
between the exit arm of the impinger and the pump. Connect the impinger via 
the absorption tube to the pump and the prefilter assembly (if needed) with a 
short piece of nonrubber, flexible tubing. The air being sampled should not
be passed through any other tubing or other equipment before entering the
impinger.
(b) After sampling, remove the impinger stem and rinse it with 2 or 3 ml
of distilled-deionized water, collecting the rinsings in the impinger. The 
impinger is then sealed with a nonreactive stopper, such as Teflon. Do not 
use a rubber stopper. If it is preferred to store or ship the impinger with 
the stem in, the openings should be sealed with an inert film or other 
nonrubber cover, and the ground glass joint should be taped securely. Care 
should be taken to minimize spillage or loss by evaporation at all times.
(c) A "blank" impinger should be handled in the same manner as the 
samples (ie, fill, seal, transport, and analyze) except that no air is sampled 
through it.
(d) Where a prefilter has been used, the filter cassettes are capped and
appropriately identified. The prefilter, along with blank filters, is 
analyzed for particulate antimony and antimony compounds.
(e) Samples should be collected so as to contain at least 2,5 /¿g Sb if
analysis is to be by the flameless method. If the flame method is used, at
least 50 ¿ig Sb should be collected.
104
Calibration of Equipment
Since the accuracy of an analysis can be no greater than the accuracy with 
which the volume of air is measured, the accurate calibration of the sampling 
pump is essential. The frequency of calibration required depends on the use, 
care, and handling to which the pump is subjected. Pumps should be calibrated 
initially and recalibrated if they have been abused or repaired. Regardless 
of use, maintenance and calibration should be performed on a routine schedule, 
and records of these should be kept.
The accuracy of calibration depends on the type of instrument used for 
calibration. The choice of instrument will depend largely on where the 
calibration is to be performed. For laboratory testing, a spirometer or 
soapbubble meter is recommended, although other calibration instruments, such 
as a wet test meter, dry gas meter, or rotameter can be used. For field 
testing, calibration as necessary using a rotameter is recommended. Since the 
flowrate given by a pump depends on the pressure drop across the sampling 
device, the pump must be calibrated while operating with a representative 
filter in line.
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X. APPENDIX II
ANALYTICAL METHODS FOR ANTIMONY
Method for Particulates
A known volume of air is drawn through a membrane filter to collect 
particulate matter. The residue obtained from digesting the collected 
particulate matter in a mixture of nitric, perchloric, and sulfuric acids is 
diluted with distilled water; aliquots are analyzed for antimony at 217.6 nm 
by flameless atomic absorption. If lead is present in the sample, the 231,2- 
nm resonance line is used.
Method for Volatile Antimony Compounds
Air samples collected in impinger solutions are analyzed directly by 
flameless atomic absorption.
Range and Sensitivity
The analytical range is 0.05-1.0 mg of antimony/cu m for a 50-liter air 
sample diluted to 50 ml for particulates and 25 ml for volatile compounds; a 
25-jul aliquot is used for analysis. This range corresponds to 2.5-50 jug Sb in 
the collected sample. The analytical range may be extended by altering the 
dilution volume or the size of the analytical aliquot.
Sensitivity varies with different instruments, graphite tubes, and sample 
matrices. NIOSH has found a sensitivity of 125 pg Sb/1% absorbance in ashed 
filter solutions and 250 pg Sb/1% absorbance in 5% HgC12/6fJ HC1. Sensitivity 
may be increased 5-fold over these values by using the purge-gas interrupt 
mode.
Interferences
(a) Lead in the sample will absorb at 217.0 nm and may interfere at 217.6 
nm if the reading power of the instrument is not adequate.
(b) Flameless atomic absorption is prone to matrix effects; standard 
addition methods can be used to evaluate such interferences.
Precision and Accuracy
The performance characteristics of the method as found by NIOSH are 
discussed in subsections (a) and (b).
(a) The pooled coefficient of variation for the analysis of five 
calibration solutions (10 determinations each) covering the range (0.05-1.0 
Mg/ml) was 0.038.
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(b) The recoveries of antimony from filters spiked with 5.0, 12,5, and 
25.0 tig Sb/filter were 100 +3.9%, 99.3 +2.9%, and 98,7 +3.2%, respectively.
The pooled coefficient of variation was 0.034.
Advantages of the Flameless Method
(a) It is approximately 50-100 times more sensitive than conventional 
flame atomic absorption.
(b) It requires fewer operations on the sample and has a lower 
coefficient of variation than hydride generation techniques.
Disadvantages of the Flameless Method
Matrix effects are more prevalent than with conventional flame atomic 
absorption.
Apparatus
(a) Atomic absorption spectrophotometer with graphite atomizer and 
deuterium or hydrogen continuum correction.
(b) Hollow cathode or electrodeless discharge lamp for antimony 
(wavelength, 217.6 nm).
(c) Argon, high purity, in a cylinder equipped with a two-stage pressure 
regulator and appropriate hose connections.
(d) Variable temperature hotplate capable of reaching 350 C.
(e) Perchloric acid fume hood.
(f) Borosilicate glassware, including:
(1) Phillips beakers with watchglass covers (125 ml);
(2) Volumetric flasks, (50 and 100 ml);
(3) Volumetric pipets, (1, 5, and 10 ml);
(4) Micro-pipets, (10, 25, 50 and 100 /il;
(5) Small test tubes (10 ml).
Reagents
(a) Double distilled or deionized water.
(b) Nitric acid, concentrated, analytic reagent grade, redistilled in 
glass.
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(c) Perchloric acid, 70%, analytic reagent grade.
(d) Sulfuric acid, 98%, analytic reagent grade.
(e) Ashing acid, (3:1:1, nitric:perchloric:sulfuric).
(f) Antimony stock solution containing antimony at 1,000 Mg/ml*
(g) Mercuric chloride (HgC12).
(h) Hydrochloric acid, 6N, redistilled (constant-boiling HC1 is 
approximately 6N).
Procedure
(a) Cleaning of Equipment
(1) Before first use, clean all glassware with a detergent solution, 
followed in order by rinsing with water, rinsing with distilled water, soaking 
30 minutes in concentrated nitric acid, and thorough rinsing in distilled 
water.
(2) Glassware used exclusively for antimony analysis may be cleaned 
by soaking for 30 minutes in dilute nitric acid followed by thorough rinsing 
in distilled water.
(b) Analysis of Samples
(1) Place sample filters and blank filters in 125-ml Phillips
beakers, add 5 ml of ashing acid, cover with a watchglass and heat at 140 C on
a hotplate for 2 hours. Increase the temperature to 200 C and reduce the
volume of solution to approximately 2 ml. Complete digestion is indicated by
a nearly colorless residual solution. Additional small amounts (1 ml) of 
nitric acid may be added and evaporated to complete digestion. Remove the 
watchglass and raise the temperature to 350 C until the evolution of sulfur 
trioxide is complete and the residual volume is reduced to 0.5 ml. Do not 
allow the solution to evaporate to dryness. Cool, then add 1 ml of H2S04, 
transfer quantitatively to a volumetric flask, and dilute to volume with 
distilled water.
(2) For impinger samples, quantitatively transfer the contents of 
the impinger to a 25-ml volumetric flask. Dilute to volume with distilled 
wat er.
(3) Analyze triplicate aliquots of sample solution for antimony by 
flameless atomic absorption using the manufacturer's recommended operating 
conditions except for drying, charring, and atomizing times and temperatures. 
For these, use the following:
(A) Dry for 30 seconds at 110 C;
(B) Char for 20 seconds at 700 C; and
(C) Atomize for 8 seconds at 2,700 C.
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(4) Analyze triplicate aliquots of standard solutions, at least one 
standard analysis for three sample analyses.
(c) Determine the concentration of antimony present in the sample from a 
standard curve or by standard addition, as indicated below.
(1) Standard Curve
(A) For analysis of particulate samples, prepare at least five 
standard solutions containing a series of concentrations of antimony within 
the analytical range of the method. Prepare the final dilutions by 
transferring the required aliquot to 3 ml of sulfuric acid and diluting to 100 
ml with distilled water.
(B) For analysis of volatile compounds, prepare at least five 
standard solutions containing a series of concentrations of antimony within 
the analytical range of the method. The concentration of the C12 and HC1 in 
the standards should be made identical to those in the samples by diluting 10 
ml of 5% HgC12 in 6N_ HC1 to 25 ml with distilled water after adding an 
appropriate amount of antimony stock solution. Prepare a blank solution by 
diluting 10 ml of 5% HgCl2/6iJ HC1 to 25 ml with distilled water,
(C) Determine absorbance of the standard solutions and subtract 
the absorbance of the blank solution from each.
(D) Prepare a calibration curve by plotting absorbance vs 
concentration of antimony in n g / m l ,
(E) From the peak absorbance of the samples, subtract the 
absorbance of the filter blank to determine the corrected sample absorbance. 
Compare the corrected sample absorbance with the calibration curve to 
determine the amount of antimony, in mg/ml, in the sample solution.
The concentration of antimony in air is calculated as follows:
C - /ig Sb/ml x V_
Vs
where:
C = Concentration of antimony (mg Sb/cu m)
Mg Sb/ml * Concentration determined from the calibration curve
V - Volume of diluted solution (ml)
Vs ■ Volume of air samples (liters)
(2) Standard Addition
(A) To a series of at least three test tubes containing equal 
aliquots (5 ml) of the sample solution, add, to all but one, aliquots of a 
standard antimony solution graded to contain multiples, such as 0.5, 1, 2, and 
3, of the amount of antimony estimated to be present in the sample aliquots. 
Make the final volume in all test tubes equal by adding distilled water. 
Prepare a similar set of test tubes starting with equal aliquots (5 ml) of the
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filter blank solution. All concentrations of antimony must fall within the 
linear portion of the standard curve; otherwise the standard addition is 
invalid.
(B) Analyze triplicate aliquots of each of these sample and 
blank solutions.
(C) Plot the absorbance values for the sample solutions and the 
spiked sample solutions against an abscissa labeled "/ug of Sb added/N ml." 
Draw the best straight line through the points. The intercept of this line on
the negative abscissa (0.0 absorbance units) is read as the concentration in
/ug/N ml of antimony in the sample solution. The concentration is converted to 
Mg/ml by multiplying by N. Subtract the concentration, if any, in n g / m l for
the blank from the samples. Convert to mg Sb/cu m.
If the result of this determination is not within 10% of the values 
obtained from the standard curve, an interference is indicated and standard 
addition techniques should be utilized for sample analysis.
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XI. APPENDIX III
MATERIAL SAFETY DATA SHEET
General instructions for preparing a Material Safety Data Sheet (MSDS) are 
presented in this appendix. The examples used in the text are for 
illustrative purposes and are not intended to apply to any specific compound 
or product. Applicable information about a specific product or material shall 
be supplied in the appropriate block of the MSDS.
The product designation is inserted in the block in the upper left corner
of the first page to facilitate filing and retrieval. Print in upper case
letters as large as possible. It should be printed to read upright with the
sheet turned sideways. The product designation is that name or code 
designation which appears on the label, or by which the product is sold or 
known by employees. The relative numerical hazard ratings and key statements 
are those determined by the guidelines in Chapter V, Part B, of the NIOSH 
publication, An Identification System for Occupationally Hazardous Materials.
The company identification may be printed in the upper right corner if 
desired.
(a) Section I. Product Identification
The manufacturer's name, address, and regular and emergency telephone 
numbers (including area code) are inserted in the appropriate blocks of 
Section I. The company listed should be a source of detailed backup
information on the hazards of the material(s) covered by the MSDS. The 
listing of suppliers or wholesale distributors is discouraged. The trade name 
should be the product designation or common name associated with the material. 
The synonyms are those commonly used for the product, especially formal 
chemical nomenclature. Every known chemical designation or competitor's trade 
name need not be listed.
(b) Section II. Hazardous Ingredients
The "materials" listed in Section II shall be those substances which are 
part of the hazardous product covered by the MSDS and individually meet any of 
the criteria defining a hazardous material. Thus, one component of a
multicomponent product might be listed because of its toxicity, another 
component because of its flammability, while a third component could be 
included both for its toxicity and its reactivity. Note that a MSDS for a 
single component product must have the name of the material repeated in this
section to avoid giving the impression that there are no hazardous
ingredients.
Chemical substances should be listed according to their complete name 
derived from a recognized system of nomenclature. Where possible, avoid using 
common names and general class names such as "aromatic amine," "safety 
solvent," or "aliphatic hydrocarbon" when the specific name is known.
The may be the approximate percentage by weight or volume (indicate
basis) which each hazardous ingredient of the mixture bears to the whole
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mixture. This may be indicated as a range or maximum amount, ie, "10-40% vol" 
or "10% max wt" to avoid disclosure of trade secrets.
Toxic hazard data shall be stated in terms of concentration, mode of 
exposure or test, and animal used, eg, "100 ppm LC50-rat," "25 mg/kg LD50- 
skin-rabbit," "75 ppm LC man," or "permissible exposure from 29 CFR 
1910,1000," or, if not available, from other sources of publications such as 
the American Conference of Governmental Industrial Hygienists or the American 
National Standards Institute Inc. Flashpoint, shock sensitivity or similar 
descriptive data may be used to indicate flammability, reactivity, or similar 
hazardous properties of the material.
(c) Section III. Physical Data
The data in Section III should be for the total mixture and should include 
the boiling point and melting point in degrees Fahrenheit (Celsius in 
parentheses); vapor pressure, in conventional millimeters of mercury (mmHg); 
vapor density of gas or vapor (air = 1); solubility in water, in parts/hundred
parts of water by weight; specific gravity (water ■ 1); percent volatiles
(indicate if by weight or volume) at 70 F (21.1 C) ; evaporation rate for 
liquids or sublimable solids, relative to butyl acetate; and appearance and 
odor. These data are useful for the control of toxic substances. Boiling 
point, vapor density, percent volatiles, vapor pressure, and evaporation are 
useful for designing proper ventilation equipment. This information is also
useful for design and deployment of adequate fire and spill containment
equipment. The appearance and odor may facilitate identification of 
substances stored in improperly marked containers, or when spilled.
(d) Section IV. Fire and Explosion Data
Section IV should contain complete fire and explosion data for the 
product, including flashpoint and autoignition temperature in degrees
Fahrenheit (Celsius in parentheses); flammable limits, in percent by volume in 
air; suitable extinguishing media or materials; special firefighting 
procedures; and unusual fire and explosion hazard information. If the product 
presents no fire hazard, insert "NO FIRE HAZARD" on the line labeled 
"Extinguishing Media."
(e) Section V. Health Hazard Information
The "Health Hazard Data" should be a combined estimate of the hazard of 
the total product. This can be expressed as a TWA concentration, as a
permissible exposure, or by some other indication of an acceptable limit. 
Other data are acceptable, such as lowest LD50, if multiple components are 
involved.
Under "Routes of Exposure," comments in each category should reflect the 
potential hazard from absorption by the route in question. Comments should 
indicate the severity of the effect and the basis for the statement, if 
possible. The basis might be animal studies, analogy with similar products, 
or human experiences. Comments such as "yes" or "possible" are not helpful. 
Typical comments might be:
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Skin Contact— single short contact, no adverse effects likely; 
prolonged or repeated contact, irritation, and cracking.
Eye Contact— some pain and mild transient irritation; no corneal
scarring.
"Emergency and First Aid Procedures" should be written in lay language and 
should primarily represent first-aid treatment that could be provided by 
paramedical personnel or individuals trained in first aid.
Information in the "Notes to Physician" section should include any special 
medical information which would be of assistance to an attending physician 
including required or recommended preplacement and periodic medical 
examinations, diagnostic procedures, and medical management of overexposed 
workers.
(f) Section VI. Reactivity Data
The comments in Section VI relate to safe storage and handling of 
hazardous, unstable substances. It is particularly important to highlight 
instability or incompatibility to common substances or circumstances such as 
water, direct sunlight, steel or copper piping, acids, alkalies, etc. 
"Hazardous Decomposition Products" shall include those products released under 
fire conditions. It must also include dangerous products produced by aging, 
such as peroxides in the case of some ethers. Where applicable, shelf life 
should also be indicated.
(g) Section VII. Spill or Leak Procedures
Detailed procedures for cleanup and disposal should be listed with 
emphasis on precautions to be taken to protect workers assigned to cleanup 
detail. Specific neutralizing chemicals or procedures should be described in 
detail. Disposal methods should be explicit including proper labeling of
containers holding residues and ultimate disposal methods such as "sanitary 
landfill," or "incineration." Warnings such as "comply with local, state, and 
Federal antipollution ordinances" are proper but not sufficient. Specific
procedures should be identified.
(h) Section VIII, Special Protection Information
Section VIII requires specific information. Statements such as "Yest" 
"No," or "If Necessary" are not informative. Ventilation requirements should 
be specific as to type and preferred methods. Specify respirators as to type 
and NIOSH or US Mine Safety and Health Administration approval class, ie, 
"Supplied air," "Organic vapor canister," "Suitable for dusts not more toxic 
than lead," etc. Protective equipment must be specified as to type and 
materials of construction.
(i) Section IX. Special Precautions
"Precautionary Statements" shall consist of the label statements selected 
for use on the container or placard. Additional information on any aspect of 
safety or health not covered in other sections should be inserted in Section
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IX. The lower block, can contain references to published guides or in-house 
procedures for handling and storage. Department of Transportation markings 
and classifications and other freight, handling, or storage requirements and 
environmental controls can be noted.
(j) Signature and Filing
Finally, the name and address of the responsible person who completed the 
MSDS and the date of completion are entered. This will facilitate correction 
of errors and identify a source of additional information.
The MSDS shall be filed in a location readily accessible to workers 
potentially exposed to the hazardous material. The MSDS can be used as a 
training aid and basis for discussion during safety meetings and training of 
new employees. It should assist management by directing attention to the need 
for specific control engineering, work practices, and protective measures to 
ensure safe handling and use of the material. It will aid the safety and 
health staff in planning a safe and healthful work environment and in 
suggesting appropriate emergency procedures and sources of help In the event 
of harmful exposure of employees.
114
MATERIAL SAFETY DATA SHEET
1 PRODUCT IDENTIFICATION
M A N U F A C T U R E R ' S  N A M E R E G U L A R  T E L E P H O N E  N O  E M E R G E N C Y  T E L E P H O N E  N O
A D D R E S S
TRADE NAME
SYNO NYM S
II HAZARDOUS INGRED IENTS
m a t e r i a l  o r  c o m p o n e n t % H A Z A R D  D A T A
III PHYSICAL DATA
B O I L I N G  PO INT .  760 M M  H.G M E L T I N G  P O IN T
S P E C I F I C  G R A V I T Y  (H 20 = 1 l V A P O R  P R E S S U R E
V A P O R  D E N S I T Y  I A I R - 1 ) S O L U B I L I T Y  IN  H jO .  %  B Y  WT
\ V O L A T l L E S  B Y  V O L E V A P O R A T I O N  R A T E I B U T Y I  A C E T A T E  1)
A P P E A R A N C E  A N D  O D O R
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IV FIRE AND EXPLOSION DATA
F L A S H  P O IN T  
(TEST  M E T H O D !
A U T O I G N I T I O N
T E M P E R A T U R E
F L A M M A B L E  L IM I T S  i n  A IR ,  %  B Y  VOL. U P P E R
E X T I N G U I S H I N G
M E D I A
S P E C I A L  F I R E
F IG H T IN G
P R O C E D U R E S
U N U S U A L  F IR E  
A N D  E X P L O S I O N  
H A Z A R D
V HEALTH HAZARD INFORMATION
H E A L T H  H A Z A R D  D A T A
R O U T E S  O F  E X P O S U R E  
I N H A L A T I O N
S K I N  C O N T A C T
S K I N  A B S O R P T I O N
E Y E  C O N T A C T
IN G E S T IO N
E F F E C T S  O F  O V E R E X P O S U R E  
A C U T E  O V E R E X P O S U R E
C H R O N I C  O V E R E X P O S U R E
E M E R G E N C Y  A N D  F IR S T  A I D  P R O C E D U R E S  
E Y E S
S K IN
I N H A L A T I O N
IN G E S T IO N
N O T E S  TO  P H Y S I C I A N
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VI REACTIVITY DATA
C O N D IT I O N S  C O N T R I B U T I N G  T O  I N S T A B I L I T Y
I N C O M P A 1  i B I U T Y
H A Z A R D O U S  D E C O M P O S IT I O N  P R O D U C T S
C O N D I T I O N S  C O N T R I B U T I N G  T O  H A Z A R D O U S  P O L Y M E R I Z A T I O N
VII SP ILL OR LEAK PRO CEDURES
S T E P S  T O  BE  T A K E N  IF M A T É R I A L  IS R E L E A S E D  O R  S P I L L E D  
N E U T R A L I Z I N G  C H E M I C A L S
W A S T E  D I S P O S A L  M E T H O D
VIII SPEC IAL  PROTECTION INFORMATION
V E N T I L A T I O N  R E Q U I R E M E N T S
S P E C I F I C  P E R S O N A L  P R O T E C T I V E  E Q U IP M E N T  
R E S P I R A T O R Y  ( S P E C IF Y  IN  D E T A I L )
E Y E
G L O V E S
O T H E R  C L O T H I N G  A N O  E Q U IP M E N T
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P R E C A U T I O N A R Y
S T A T E M E N T S
IX SPEC IA L  PRECAUTIONS
O T H E R  H A N D L I N G  A N D  
S T O R A G E  R E Q U I R E M E N T S
P R E P A R E D  B Y
A D D R E S S
O A T E
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XII. TABLES
TABLE XII-1
PHYSICAL AND CHEMICAL PROPERTIES OF ANTIMONY AND SOME OF ITS INORGANIC COMPOUNDS
Temperature 
for 1 mm Hg
Substance
Formula
Weight SG*
Melting 
Point C
Boiling 
Point C
Vapor
Pressure
Solubility Data, 
Solvent and Degree**
Solids at STP
Antimony
(Sb)
121.76 6.68 630 1,380 886 C Hot conc. H2S04 s 
Aqua regia s 
Dilute acids 1
Antimony
trioxlde
(Sb203)
291.52 5.2 656 1,550 574 C Hot water 
Conc. HC1 
Conc. H2S04 
KOH
Sl 8
s
s
Antimony
pentoxide
(Sb205)
323.5 3.78 loses 0 
at 380 C 
loses 02 
at 930 C
Hot water
Cold water
Conc. HC1 
KOH
i
1
s
s
Antimony 
trisulfide 
(Sb2S3)
339.7 4.64 550 1,150 Water 
Hot water 
Alkali 
Conc. HC1 
Sulfide solns
i
d
s
8
8
Antimony
pentasulfide
(Sb2S5)
403.82 4.12 75 d** Hot water 
Alkali
1
S
TABLE XII-1 (CONTINUED)
PHYSICAL AND CHEMICAL PROPERTIES OF ANTIMONY AND SOME OF ITS INORGANIC COMPOUNDS
Substance
Formula
Weight SG*
Melting 
Point C
Boiling 
Point C
Temperature 
for 1 mm Hg 
Vapor 
Pressure
Solubility Data, 
Solvent and Degree**
Antimony 228.13 3.14 73.4 . 283 49.2 C Alcohol i
trichloride (sub­ Acetone 8
(SbC13) limes) Acids 8
Antimony 178.8 4.38 292 319 Cold water 385
triflouride (Sub­ Hot water 5.6
(SbF3) limes) NH3 i
Liquids at STP
Antimony 299.05 2.34 2.8 79 22.7 C Excess water d
pentachloride (at 22 HC1 s
(SbC15) mm Hg) Chloroform s
Antimony 216.76 2.99 7 149.5 Cold water 8
pentaflouride KF S
(SbF5)
Gas at STP
Antimony 124.78 4.34 -88 -17 Cold water 500
hydride (15 C,
(SbH3) air=l) Water 100 C 250
*SG-specific gravity
**s-8oluble, si s-slightly solubl-e, i-insoluble, d-decomposes; numerical values in g/100 ml
Adapted from references 131,224-26
TABLE XII-2
US INDUSTRIAL CONSUMPTION OF PRIMARY ANTIMONY IN 1976 
BY CLASS OF MATERIAL PRODUCED
Product Antimony Content 
(Short Tons)
Metal products
Ammunition 63
Antlmonlal lead 3,861
Bearing metal and bearings 405
Cable covering 19
Castings 24
Collapsible tubes and foil 23
Sheet and pipe 74
Solder 188
Type metal 79
Other 164
Subtotal 4,900
Nonmetal products (excluding flame retardants)
Ammunition primers 13
Fireworks 12
Ceramics and glass 1,260
Pigments 415
Plastics 1,277
Rubber products 578
Other 1,330
Subtotal 4,885
Flame retardants
Plastics 3,777
Pigments 183
Rubber 199
Adhesives 141
Textiles 1,055
Paper 197
Subtotal 5,552
Total 15,337
Adapted from reference 2
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TABLE XII-3
US INDUSTRIAL CONSUMPTION OF ANTIMONY IN 1976 
BY CLASS OF MATERIAL CONSUMED
Material
Consumed
Antimony Content 
(Short Tons)
End Use
Primary Antimony:
Metal
Ore and concentrate
3,375
640
Solder, type metal, ammunition, 
storage batteries, power trans­
mission and communication equip­
ment
Oxide 10,397 Glass products, rubber and 
plastics, textiles, chemicals, 
metalware
Sulfide 37 Pigments, plastics, ammunition, 
visual signaling, vulcanizing 
agent
Byproduct antimonial 
lead 
Residues
697
191
Storage batteries, cable cover­
ing, printing and publishing, 
communications, ammunition
Secondary Antimony:
Antimonial lead and 
other alloys
19,799 Storage batteries, cable cover­
ing, printing and publishing, 
communications, ammunition
Adapted from references 1 and 2
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TABLE XII-4
POTENTIALLY HAZARDOUS ANTIMONY COMPOUNDS
Chemical Name Synonym
Antimony
Antimony arsenate 
Antimony arsenite 
Antimony dioxysulfate 
Antimony ethoxide 
Antimony hydride
Antimony lactate 
Antimony a-mercaptoacetamide 
Antimony pyrogaliol 
Antimony oxychloride
Antimony oxysulfide
Antimony pentachloride
Antimony pentafluoride 
Antimony pentaiodide 
Antimony pentasulfide
Antimony pentoxide
Antimony potassium dimethyl- 
cysteino tartrate 
Antimony potassium oxalate
Antimony sodium dimethylcysteino 
tartrate 
Antimony sodium gluconate
Antimony sodium tartrate 
Antimony sodium thioglycollate 
Antimony sulfate 
Antimony tetroxide
Regulus of antimony, antimony 
regulus, stibium
Triethyl antimonite 
Stibine, antimonous hydride hydrogen 
antlmonide
Antimonine, antimony salt of lactic acid 
Antimony thioglycolamide
Algaroth powder, antimonyl chloride,
antimony chloride oxide, basic antimony 
chloride, mercurius vitae 
Cathusian powder, kermes mineral, ker- 
mesite, pyrostibonite antimony blend, 
sulfurated antimony 
Antimony perchloride, butter of antimony, 
antimonic chloride 
Antimony fluoride 
Antimony iodide
Antimony red, antimony sulfide, 
antimonial saffron, antimony 
persulfide, golden antimony sulfide 
Antimonic anhydride, antimonic oxide, 
antimonic acid, antimonic pentoxide, 
stibic anhydride
Potassium-antimony oxalate, potassium 
oxalatoantimonate
Antimony gluconate complex sodium salt, 
antimony gluconate sodium, gluconic 
acid, antimony sodium derivative, sod­
ium antimony gluconate, sodium 
stibogluconate, triostam, T.S.A.G. 
Antimony sodium oxide L-tartrate, Emeto- 
Na, sodium antimonyl tartrate, stibunal 
Antimony sodium thioacetate, mercaptoa- 
cetic acid 
Antimony salt of sulfuric acid, anti­
monous sulfate, antimony trisulfate 
Antimony oxide
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TABLE XII-4 (CONTINUED)
POTENTIALLY HAZARDOUS ANTIMONY COMPOUNDS
Chemical Name Synonym
Antimony tribromide 
Antimony trichloride
Antimony trichloride solution
Antimony trifluoride 
Antimony trioxide
Antimony triiodide 
Antimony triselenide 
Antimony trisulfide
Antimony tritelluride 
Emetine antimony iodide 
Lead antimonate 
Oxo(tartrato)antimonate 
(1-)aniline 
Sodium antimonate 
Sodium antimonyl adonitol 
Sodium antimonyl D-arabitol 
Sodium antimonyl biscatechol 
Sodium antimonyl tert-butyl 
catechol 
Sodium antimonyl catechol 
thiosalicylate 
Sodium antimonyl citrate 
Sodium antimonyl erythritol 
Sodium antimonyl D-funcitol 
Sodium antimonyl gluco- 
guloheptitol 
Sodium antimonyl glycerol 
Sodium antimonyl 2,5-methylene 
D-mannitol 
Sodium antimonyl 2,.4-methylene 
D-sorbitol 
Sodium antimonyl xylitol
Antimonous bromide, antimony bromide 
Antimonous chloride, butter of 
antimony, caustic antimony, 
mineral butter 
Antimony chloride solution, liquid butter 
of antimony 
Antimonous fluoride, antimony fluoride 
Antimony white, flowers of antimony, 
antimony bloom, antimony oxide, 
black antimony, weisspiess-glanz 
Antimonous iodide, antimony iodide
Sulfuret of antimony, antimony orange, 
black antimony, antimony needles, 
antimonous sulfide, antimony 
glance, crimson antimony, gray 
antimony 
Antimony telluride 
Antimony emetine iodide 
Antimony yellow, Naples yellow 
Aniline antimonyl tartrate, antimonyl 
aniline tartrate 
Antimony sodiate
Sodium antimonous-3-catechol 
thiosalicylate, stibsol
Adapted from reference 226
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TABLE XII-5
OCCUPATIONS WITH POTENTIAL EXPOSURE TO ANTIMONY
Antimony ore smeltera Metal bronzers
Antimony workers Miners
Babbitt metal workers Monotypers
Battery workers, storage Mordanters
Brass founders Organic chemical synthesizers
Britannia metal workers Paint makers
Bronzers Painters
Burnishers Perfume makers
Cable splicers Pewter workers
Ceramic makers Pharmaceutical workers
Compositors Phosphor makers
Copper refiners Pigment makers
Dye makers Plaster cast bronzers
Electroplaters Porcelain workers
Explosives makers Pottery workers
Fireworks makers Printers
Flame retardant workers Pyrotechnics workers
Foundry workers Rubber makers
Glass makers Semiconductor workers
Glaze dippers, pottery Solder makers
Gold refiners Stereotypers
Insecticide makers Stibnite miners
Insulators, wire Textile dryers
Lake color makers Textile flame-retardant workers
Lead burners Textile printers
Lead hardeners Type metal workers
Lead shot workers Typesetters
Linotypers Vulcanizers
Match makers Zinc refiners
Adapted from reference 226
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